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This thesis tests the hypothesis that certain mediators (purines, catecholamines and
bradykinin), which are known to be involved in inflammation, contribute to the
sensitisation of peripheral nociceptors that occurs in chronic inflammation and
hyperalgesia associated with arthritis. The major part of the studies determined the
role of these substances and their pharmacological receptors in modulating discharge
recorded from high threshold C-fibre mechanonociceptors (on-going or
'spontaneous', and mechanically-evoked) in normal ankle joints and in those with a
monoarthritis induced by Freunds complete adjuvant (FCA). Some of the in-vivo
neuropharmacological investigations were complemented by behavioural studies on
intact normal and arthritic rats. Related in-vitro experiments were performed
involving a) extracellular 'grease gap' recordings from various peripheral nerves and
b) contractile responses of the electrically-stimulated rat vas deferens.
Recordings from C-fibres in arthritic joints revealed an enhanced resting discharge,
a greater number of receptive fields and lower mechanical activation thresholds
(sensitisation) of mechanonociceptors as compared to untreated joints. Indomethacin
significantly attenuated, but did not abolish, either the elevated resting discharges
recorded from C-fibres in arthritic joints or the swelling, mechanical hyperalgesia and
inflammation associated with functional studies in monoarthritic rats. These results
with indomethacin indicate that although prostanoids are important mediators in FCA-
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induced arthritis, other mediators are also likely to be responsible for the observed
neuropharmacological and behavioural changes seen in this model of arthritis.
Close intra-arterial injection of adenosine Ai and A2 receptor agonists and
antagonists had no effect on either spontaneous or mechanically-evoked discharge
recorded from articular C-fibres in either normal or arthritic joints. Preliminary studies
provided no evidence for the involvement of P2 purinoceptors in modulating afferent
articular neural discharge from either normal or arthritic joints.
Selective [^-adrenoceptor agonists (salbutamol and salmeterol) and antagonists
(ICI 118551) did not affect neural discharge recorded from mechanonociceptors in
either normal or arthritic rat ankle joints. In line with these neuropharmacological
experiments, functional studies involving chronic dosage treatment of animals with
salmeterol or propranolol had no effect on the swelling, mechanical hyperalgesia or
inflammation associated with arthritic rat ankle joints; dexamethasone significantly
reduced joint swelling, inflammation and mechanical hyperalgesia.
Although adrenaline and noradrenaline did not affect neural discharge from
mechanonociceptors in normal joints, these catecholamines did enhance both
spontaneous and mechanically-evoked discharge in approximately 50% of
mechanonociceptors recorded from arthritic joints. Since these effects were not
affected by the (3-adrenoceptor antagonist, propranolol, this suggests that the
catecholamines were likely to be acting at a-adrenoceptors. Further studies, which
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were not possible in the present investigation, using selective a-adrenoceptor agonists
and antagonists are needed to confirm this suggestion.
Close intra-arterial injection of bradykinin caused a dose-dependent increase in
spontaneous and mechanically-evoked discharge recorded from mechanonociceptors
both in normal and arthritic joints; responses to bradykinin were of lower magnitude
in arthritic joints. The bradykinin B2 receptor antagonist, Hoe 140, differentially
antagonised these responses to bradykinin: there was surmountable antagonism of
bradykinin-evoked increase in the responsiveness to the standard mechanical stimulus,
whereas there was insurmountable antagonism of bradykinin-induced excitation.
These differential effects of Hoe 140 may reflect subtypes of the bradykinin B2
receptor. Agonists and antagonists selective for the bradykinin Bi receptor had no
effect on afferent neural discharge (spontaneous or mechanically-evoked) from
mechanonociceptors in either normal or arthritic joints. A more detailed study of
bradykinin and Hoe 140 was performed in-vitro. Changes in membrane potential were
recorded from various isolated nerves (vagus, tibial, tibialis, sciatic and saphenous)
using the 'grease-gap' technique. However, in this model bradykinin had no effect on
the membrane potential of any of the nerves examined, so this technique was
abandoned, An alternative preparation, the electrically-stimulated rat vas deferens,
was used and responded to bradykinin with two distinct effects; an enhancement in
the electrically-evoked twitch (neurogenic response) and an increase in the baseline
muscle tension (musculolropic response). Hoel40 differentially antagonised these
responses to bradykinin; there was surmountable antagonism of the bradykinin-
v
induced neurogenic response, but insurmountable antagonism of the musculotropic
response. In addition, certain B2 receptor agonists and antagonists had differential
actions on the neurogenic and musculotropic responses, indicating that subtypes of
the B2 receptor may be present. Bradykinin Bi receptor agonists and antagonists were
ineffective in the electrically-stimulated rat vas deferens.
In conclusion, the results show that C-fibre afferent discharge from articular
mechanonociceptors in the normal and chronically-inflamed (adjuvant-arthritic) rat
ankle joint is modulated by bradykinin (excitation and sensitisation). Catecholamines
can also cause excitation and sensitisation of arthritic joints, but purines appear to
have no effect on the activity of these sensory receptors. Bradykinin, acting via
bradykinin B2 receptors plays an important role in altering neural excitability in the
rat, and different subtypes of B2 receptor may be involved. Overall, the present results
add further to our knowledge and understanding of the peripheral mechanisms
involved in nociception in the normal state and in chronic inflammation.
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1.1 Pain, nociception and sensitisation
Early observations from the work of Blix (1884) and Von Frey (1895) provided
evidence for the existence of specialised sensory organs which were responsible for
the signalling of noxious stimuli. These specialised sensory organs were termed as
nociceptors by Sherrington (1906). Under normal physiological conditions, intense or
potentially damaging noxious stimuli activate nociceptors ('pain receptors' / high
threshold sensory receptors) with the resulting pain being highly localised in nature
and, if no tissue damage has occurred, usually of short duration (see Wooll", 1991).
The function of this physiological pain is to inform of and protect the body from
potential injury, which is why it is highly correlated with the initiation of the flexion
withdrawal reflex (Wilier 1979; Woolf, 1991). The amplitude of physiological pain is
closely related to the intensity of the stimulus and has distinct mechanical, thermal and
chemical activation thresholds. Thus, physiological pain can be considered to involve
nociceptor-mediated pain. In contrast, pathological pain can arise following tissue
damage and inflammation, and under this circumstance pain can occur in the absence
of a clear stimulus, in response to innocuous stimuli, and in an enhanced and
prolonged fashion following noxious stimuli. These features, which represent an
increase in the sensitivity of the nociceptive sensory system, have been termed as
sensitisation. Such sensitisation results from changes in the properties of peripheral
terminals of primary afferent nociceptors (peripheral sensitisation) and from changes
in the properties of spinal cord or supraspinal neurones (central sensitisation).
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Although pathological or inflammatory pain in its acute form has a physiological role
(contact to stimuli, whether noxious or innocuous, is avoided thus preventing any
further damage and allowing tissue repair), in its chronic form it no longer has an
adaptive function. In chronic pain there appears to be little correlation with the
amplitude of a given stimulus, and indeed pain can outlast the original tissue
inflammation (Woolf, 1991).
It is thus clear that, if new drugs are to be developed to treat the pain associated
with chronic inflammatory conditions such as rheumatoid arthritis, it is necessary to
obtain a detailed understanding of the changes in sensory receptor sensitivity that take
place during inflammation.
1.2 Articular sensory receptors
Although there is a large body of work which has investigated sensory receptors in
many tissues (particularly skin), only joint sensory receptors are described here
because of their particular relevance to the present experimental work.
1.2.1 Anatomy and histology of articular sensory receptors
Joints are supplied by articular branches descending from main nerve trunks or by
their muscular, cutaneous and periosteal branches (see Polacek, 1966). Articular
nerves contain myelinated and unmyelinated sensory afferent fibres and unmyelinated
efferent sympathetic postganglionic fibres (Skoglund, 1956; Polacek, 1966; Freeman
& Wyke, 1967; Langford & Schmidt, 1983; Guilbaud et al., 1985). Morphological
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studies in animals (Andrew & Dodt, 1953; Hromda & Polacek, 1958; Polacek,1966)
have enabled the classification of articular sensory endings into four main types
(Freeman & Wyke, 1967), namely:
1) Ruffini-type corpuscles: these are clusters (3 - 6) of encapsulated nerve endings
emanating from one small-diameter myelinated axon. This type of nerve ending is
found predominantly in the fibrous layer of the joint capsule, although a small number
are located on extrinsic ligaments, para-articular periosteum, and related tendons.
2) Pacinian-type corpuscles: these are of elongated cylindrical shape (thick laminated
capsule) and are found individually or in clusters of 2 - 3 and are innervated by
branches from a single myelinated axon. They are found mostly in the deeper capsular
tissues with a small number in the articular fat pads (where attached to joint capsule).
They are more likely to be found on the lateral aspect of the joint.
3) Golgi-tendon (fusiform) corpuscles: these have a structure which is similar to the
Ruffini-type corpuscle. They are innervated by a single large myelinated axon and are
found only in joint ligaments and tendons.
4) Free nerve endings: these are non-corpuscular terminations composed of
unmyelinated nerve filaments and are associated with unmyelinated or Finely
myelinated axons. Sensory axons consist of a series of spindle-shaped 'beads' which
are connected by thinner segments without Schwann cell processes (Heppelmann et
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al., 1990). These beads and the end bulb contain numerous vesicles, glycogen
particles and mitochondria and, are assumed to represent multiple receptive sites
(Heppelmann et al., 1990). Free nerve endings provide the majority of joint afferent
innervation and are found distributed throughout the fibrous capsule, adjacent
periosteum, articular fat pads, tendons, ligaments and in the advential sheaths of
articular blood vessels. There is also evidence that free nerve endings are found in the
synovial membrane (Halata & Grolh, 1976; Halata et al., 1984).
Although the above classification of articular sensory receptors is from cats and rats,
human joints also appear to contain similar articular sensory receptors (Schultz et al.,
1984; Schutte et al., 1987; Zimny, 1988; De Avila et al., 1989).
1.2.2 Electrophysiological studies of joint sensory receptors
Electrophysiological studies, mainly in rats, cats and monkeys, were initially focused
on examining the response properties of those receptors (i.e. Ruffini-, Pacinian- and
Golgi-type) that are associated with myelinated fast-conducting afferent fibres (see
review by Schaible & Grubb, 1993). Ruffini corpuscles are excited by flexion,
extension, and the application of direct pressure (low mechanical activation
threshold). These endings show a slowly adapting discharge in response to maintained
stretch of the capsule (Boyd, 1954; Eklund & Skoglund, 1960; Burgess & Clark,
1969; Grigg & Hoffman, 1982). Pacinian corpuscles show a rapidly adapting response
to low threshold stimulation (Burgess & Clark, 1969). Sensory endings of the Golgi-
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type are excited by flexion or the application of light pressure to ligaments and show a
slowly-adapting response (Burgess & Clark, 1969; Grigg & Hoffman, 1982).
In more recent years electrophysiological recordings have been made from
unmyelinated or finely myelinated afferent articular fibres that are associated with free
nerve endings (see review by Schaible & Grubb, 1993). Unmyelinated afferent fibres
(also termed C- or Group IV fibre afferents) have conduction velocities < 2.5ms"1,
whereas thin myelinated afferent fibres (termed A5 or Group III afferents) have
conduction velocities of between 2.5 - 20ms 1 (see Schaible & Schmidt, 1983a,b;
Heppelmann et al., 1988; Hildebrand et al., 1991; Schaible & Grubb, 1993). Various
investigations demonstrated that C- or A8-fibre afferent units were only activated by
joint movements outside the normal physiological range (e. g. extreme rotation), had
high mechanical activation thresholds, and were excited by algogens (Coggeshall et
al., 1983; Schaible & Schmidt, 1983a; Guilbaud & Iggo, 1985; Guilbaud et al., 1985;
Kanaka et al., 1985; Grigg et al., 1986; Heppelmann et al., 1986; Russell et al., 1987;
Neugebauer et al., 1989; He et al., 1990; Birrell et al., 1990; Grubb et al., 1991;
Schepelmann et al., 1992; Schaible & Grubb, 1993). These observations suggested
that C- and AS- fibres are associated with articular nociceptors which are likely to be
involved in the signalling of joint pain. Furthermore, the sensitivity of articular
nociceptors can be altered under inflammatory conditions. Thus, following acute
inflammation of the knee joint, evoked by an intra-articular injection of kaolin and
carrageenan, high-threshold afferents had reduced mechanical thresholds
(sensitisation) such that they were now activated by innocuous flexion and extension
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and some afferents developed on-going discharges (Coggeshall et al., 1983; Schaible
& Schimdt, 1985; Grigg et al., 1986). A lowering of the mechanical activation
threshold and the presence of on-going discharges has also been found for
mechanonociceptors in chronically-inflamed (arthritic) rat ankle joints (Guilbaud et
al., 1985; Grubb et al., 1991). The possible involvement of various inflammatory
chemicals in mediating the altered sensitivity of nociceptors under inflammatory
conditions is discussed below (see Section 1.3).
1.3 Inflammatory mediators in pain and nociception
The response to tissue injury is complex and involves the release of numerous
chemicals that mediate and/or facilitate the inflammatory process. Inflammatory
mediators originate from both non-neural and neural sources. The former includes
various inflammatory cells such as mast cells, macrophages, lymphocytes and
polymorphonuclear leukocytes, and the latter, somatosensory afferent and
postganglionic sympathetic efferent nerve terminals (see Woolf, 1991).
A large number of endogenous mediators have been shown to have a role in the
inflammatory process, including: prostanoids, bradykinin, purines, adrenergic agents,
protons, 5-hydroxytryptamine, substance P, histamine & leukotrienes (see Higashi,
1986; Doherty & Wong, 1988; Rang et al., 1991; Schaible & Grubb, 1993; Dray et
al., 1994). Furthermore, a number of putative endogenous inflammatory mediators
such as nitric oxide, nerve growth factor and the cytokines are currently being
evaluated (see Dray et al., 1994). One important factor in the study of inflammatory
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mechanisms is that although inflammatory mediators may act independently, they are
more likely to act synergistically (i.e. wherehy the action of one mediator is dependent
/ enhanced by the action of another).
Two important effects of inflammatory mediators on sensory afferent neurones of
particular relevance to the work presented in this thesis are excitation and sensitisation
of nociceptors. Excitation is an induction or increase of afferent neural firing
following the application of a stimulus (e.g. chemical, mechanical, thermal or
electrical). Nociceptor sensistisation or hyperalgesia is characterised by 1) a decreased
threshold for nociceptor activation and 2) an increased responsiveness to stimuli (e.g.
chemical, mechanical, thermal or electrical). Inflammatory mediators vary in the
extent to which they can cause excitation and/ or sensitisation of nociceptors. For
example, bradykinin causes excitation, and increases responsiveness to mechanical
stimuli, of high threshold mechanonociceptors in the rat ankle joint (Grubb et al.,
1991). In contrast, the same study also showed that, although PGE2 does not excite
or cause sensitisation to mechanical stimuli, it does potentiate the excitatory action of
bradykinin and enhances its sensitising effect on mechanical stimuli.
Although there are many inflammatory mediators that are involved, or are currently
being investigated in chronic pain and hyperalgesia, the experimental work presented




1.3.1.1 Biosynthesis and inactivation of bradykinin
Kinins are polypeptides that include bradykinin, lysine-bradykinin and methionine-
lysine-bradykinin (see Figure 1.1 for amino acid sequences) which are generated in
plasma or tissue following the breakdown of precursors called kininogens by the
proteolytic action of plasma or tissue kallikrein (see Figure 1.2 and Marceau et al.,
1980; Proud & Kaplan, 1988; Shanna, 1991).
The kininogens are multifunctional proteins that are mainly derived from a2-globulin
having the kinin sequence in their molecules, and are synthesised in the liver and
circulate in plasma and other body fluids (Shanna, 1991). In mammals three types of
kininogens have been described ,namely: (i) a high molecular weight kininogen
(HMWK) in the blood, (ii) a low molecular weight kininogen (LMWK) in both blood
and body tissues, and (iii) an acute phase protein called T-kininogen that occurs only
in the rat (Bhoola et al., 1992) - the mode of T-kininogen formation in the rat plasma
and inflammatory fluid is summarised in Figure 1.3. In animals, increased levels of
plasma kininogen have been reported following various inflammatory reactions,
including adjuvant-induced arthritis (VanArman & Nuss, 1969; Borges & Gorden,
1976; Reis et al., 1982; Sharma, 1991). T-kininogen has been found to be raised in
rats with adjuvant-induced arthritis (Greenbaum, 1984) or carrageenan-induced





position 12 345678 9
(b) Lysine-bradykinin (Kallidin or Lys-bradykinin)
amino acids Lys-Arg-Pro-Pro-GIy-Phe-Ser-Pro-Phe-Arg




Figure 1.1 Amino acid sequence of (a) bradykinin, (b) Lys-bradykinin and (c) Met-
Lys-bradykinin. Phe = Phenylalanine, Pro = Proline, Gly = Glycine, Ser = Serine, Arg

















Figure 1.2 Schematic diagram showing the generation and breakdown of bradykinin.








Figure 1.3 The mechanism of T-kinin formation in the rat.
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Kallikreins are trypsin-like serine proteases which cause the breakdown of the
kininogens to bradykinin or lysine-bradykinin (see Figure 1.2). There are two main
kallikrein enzymes, namely plasma kallikrein and tissue kallikrein. These two kinin-
forming enzymes differ from each other in molecular weight, action on kininogen
substrates and the kinin formed (see Table 1.1 and Figure 1.2). The transformation of
prekallikrein to kallikrein occurs in response to various activators (e.g. Flagemans
factor, nerve stimulation, plasmin, trypsin and immunoglobulin E) which arise as a
result of tissue damage or inflammation. It has been demonstrated that synovial tissue
kallikrein is increased in rheumatic patients as compared to healthy subjects (Sharma
et al., 1983; Al-Haboubi et al., 1986).
Bradykinin and related kinins are inactivated by peptidases called kininases that are
found in plasma, endothelial cells and tissues. There are two main types of kininases,
termed Kininase I and Kininase II. Kininase I enzymes include plasma
carboxypeptidase N and the cell membrane enzyme, carboxypeptidase M, both of
which remove the C-terminal arginine from bradykinin to form des-Arg9-BK. The
Kininase 13 group of enzymes, angiotensin converting enzyme and neutral
endopeptidase remove the two C-terminal amino acids (Phe-Arg) from bradykinin
(Bhoola et al., 1992). Kininase II further degrades the remaining C-terminus by
cleaving the dipeptide serine-proline. Although the concentration of kininase is always
lower in synovial fluid as compared to blood, higher levels of kininase I are seen in
rheumatoid or psoriatic arthritis (see Bhoola et al., 1992). Neutral endopeptidase has
been indentified on the cell surface of human synovial cells, whereas no significant
13


















angiotensin converting enzyme or carboxypeptidase N activities were found (see
Bhoola et al., 1992). In joints, the degradation of bradykinin by synovial cells has been
attributed entirely to neutral endopeptidase (see Bhoola et al., 1992).
1.3.1.2 Bradykinin in pain and inflammation
Bradykinin is one of the most potent endogenously occurring algogenic agents and
causes many pro-inflammatory effects including: vasodilation, tissue oedema and
increased vascular permeability, release of histamine and eicosanoids, and stimulation
of cell growth (for reviews see Marceau et al., 1983; Proud & Kaplan, 1988; Taylor
et al., 1989; Bathon & Proud, 1991; Steranka & Burch, 1991; Bhoola et al., 1992).
Endogenous bradykinin is implicated as an important inflammatory mediator in
disorders such as rheumatoid arthritis, rhinitis, or asthma (see Proud & Kaplan, 1988;
Bhoola et al., 1992). In man, bradykinin produces pain when applied to the
cantharadin-induced blister base on the forearm (Keele & Armstrong, 1964; Whalley
et al., 1987), or when it is injected intra-arterially (Coffman, 1966), intra-abdominally
(Lim et al., 1967), sub-dermally (Ferreira, 1972), intra-muscularly (Jensen et al.,
1990a) or intra-dermally (Jensen et al., 1990b). In animal studies, pseudoaffective
responses (e.g. vocalisation, dextrorotation, biting, scratching, licking and reflex
increase in blood pressure) indicative of pain are obtained following injection of
bradykinin intra-arterially (Guzman et al., 1962; Guzman et al., 1964; Hashimoto et
al., 1964), subdermally (Collier & Lee, 1963) or intra-articularly (Melmon et al.,
1967; Moncada et al., 1975). In animal models of inflammation such as those induced
by formalin (Correa & Calixto, 1993), carrageenan (Costello & Hargreaves, 1989),
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collagenase (Legat et al., 1994) or Porphyromonas gingivalis (Griesbacher et al.,
1994), endogenous bradykinin has been shown to be an important inflammatory
mediator.
1.3.1.3 Bradykinin and sensory afferent neural recordings
In electrophysiological recordings from C- or A5 afferent fibres, bradykinin has been
shown to excite nociceptors in skin (Fjallbrant & Iggo, 1961; Beck & Handwerker,
1974; Szolcsanyi, 1987; Lang et al., 1990; Dray et al., 1992), viscera (Haupt et al.,
1983; Mizumura et al., 1990; 1992), skeletal muscle (Mense & Schimdt, 1974; Franz
& Mense, 1975; Kumazawa & Mizumura, 1976; Mense, 1981; 1982), trachea (Fox et
al., 1993) and joints (Kanaka et al., 1985; Schepelmann et al., 1992). It has also been
demonstrated that bradykinin can sensitise to mechanical (Mense & Meyer, 1987;
Neugebauer et al., 1989; Grubb et al., 1991; Birrell et al., 1993) and thermal
(Koltzenburg et al., 1992) stimuli. Evidence consistent with a role of bradykinin as a
physiological mediator of pain has been provided by autoradiographic studies, where
bradykinin receptors were shown to be localised to sensory neurons (Steranka et al.,
1988).
Tachyphylaxis of bradykinin-induced increases in afferent neural discharge has been
reported in many tissues such as the cat knee joint (Kanaka et al., 1985), dog testis
(Kumazawa et al., 1987) and rat skin (Lang et al., 1990). In contrast, no
tachyphylaxis to bradykinin was observed in afferents from dog viscera (Guzman et
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al., 1962), cat muscle (Hiss & Mense, 1976; Mense et al., 1982) and cat cornea
(Belmonte et al., 1994).
In general, the excitatory actions of bradykinin on nociceptors are found to be
enhanced in the presence of other inflammatory mediators such as prostaglandins
(Chahl & Iggo, 1977; Mense, 1981; Grubb et al., 1991; Birrell et al., 1993; Birrell &
McQueen, 1993) or 5-HT (Mense, 1981). Consistent with this, bradykinin-induced
excitation of muscle, visceral and cutaneous nociceptors were reduced by aspirin,
paracetamol or indomethacin (Kumazawa & Mizumura, 1980; Mense, 1982; Dray et
al., 1992). In contrast, it has been shown by Fox et al (1993) that bradykinin-evoked
discharges, recorded from vagal aflerents innervating the guinea-pig trachea, were not
affected by ibuprofen, suggesting that bradykinin-induced responses were not
dependent on, or influenced by endogenous prostaglandin production in this
preparation.
1.3.1.4 Bradykinin receptors
Bradykinin receptors were originally classified by Regoli & Barabd (1980) on the
basis of relative potencies of agonists on isolated vascular smooth muscle
preparations, and subdivided into two classes, Bj and B2. Thus, for example, Bi
receptors as found in rabbit aorta respond to kinin agonists with the following rank
order of potency (see also Table 1.2):
des-Arg9-bradykinin > Lys-bradykinin > bradykinin
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Table 1.2 Activities of kinins on the rabbit aorta (Bj receptor) and jugular
vein (B2 receptor)
Rabbit aorta Rabbit Jugular vein
pD2 R.A. pD2 R.A.
Bradykinin 6.22 100 8.48 100
Lys-Bradykinin 7.27 1122 8.63 141
Des-Arg9- 7.29 1175 <0.01
Bradykinin
pD2: negative log of the concentration that produces 50% of the maximum effect.
R.A.: Relative Affinity in percent of bradykinin. See also Regoli et ah, 1990.
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In contrast, B2 receptors as found in rabbit jugular vein exhibit almost the opposite
rank order of potency to kinin agonists (see also Table 1.2):
Lys-BK > bradykinin > des-Arg9-bradykinin
On examination of the rank orders of potency from a vast number of different tissues,
it is clear that bradykinin exhibits a much greater affinity for B2 receptors than its
carboxypeptidase N metabolite, des-Arg9-bradykinin, and conversely, Bi receptors are
more sensitive to des-Arg9-bradykinin than to bradykinin (Vavrek & Stewart, 1985;
Taylor et al., 1989; Bathon & Proud, 1991; Rhaleb et al., 1991; Farmer & Burch,
1992). As a result, the relative potencies of des-Arg9-bradykinin and bradykinin are
used conventionally to classify a particular response as Bj or B2 mediated.
1.3.1.4.1 Bradykinin Bj receptors
In general, Bi receptors have a limited distribution, with the main location studied
being the rabbit aorta (Regoli et ah, 1978; Bouthillier et ah, 1987; DeBlois et ah,
1988; Farmer et ah, 1991a). Interestingly, in this tissue Bi receptors are generated de
novo in a time-dependent manner during in-vitro incubations, as shown by the
increased responsiveness to the Bj agonist, des-Arg9-bradykinin (Bouthillier et ah,
1987; DeBlois et ah, 1988). Such an induction of Bi receptors has also been
demonstrated in-vitro in the mesenteric (Churchill & Ward, 1986; DeBlois &
Marceau, 1987), coeliac (Ritter et ah, 1989) and basilar (Whalley et ah, 1983) arteries
of the rabbit. Cytokines have been implicated in the induction of Bi receptors. For
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example, IL-1 is potent in its stimulation of responses to des-Arg9-bradykinin in the
rabbit aorta (see Bureh & Kyle, 1992; Fanner & Burch, 1992). That IL-1 may be
important in induction of aortic responses to des-Arg9-bradykinin was evidenced by
the observation that glucocorticoid treatment (inhibits IL-1 synthesis) inhibited the
development of Bi responsiveness (DeBlois et al., 1988).
The development of responsiveness to des-Arg9-bradykinin during in vitro
incubations has lead investigators to propose that noxious stimuli from tissue damage
or inflammation may lead to Bi receptor induction. In support of this concept are
studies showing induced responses to des-Arg9-bradykinin in rabbits with antigen-
arthritis (Farmer et al., 1991a) or rabbits pretreated with either lipopolysaccharide
(Regoli et al., 1981) or Triton X-100 (Marceau et al., 1980). Recently, the importance
of Bi receptors in chronic pain, hyperalgesia and inflammation has been demonstrated
in rat models of persistent inflammatory thermal (Perkins & Kelly, 1993) or
mechanical (Davis & Perkins, 1994) hyperalgesia. There is also evidence that Bi
receptors participate in both phases of the formalin-induced inflammation in the
mouse (Correa & Calixto, 1993).
Bradykinin Bi receptor antagonists arose from the observation that the agonist
action of des-Arg9-bradykinin is dependent upon the presence of phenylalanine at
position 8 of the bradykinin sequence (Figure 1.1). Replacement of this phenylalanine
with aliphatic amino acids was found to confer selective competitive Bi receptor
antagonist activity (Regoli et al., 1977). The most widely used potent, selective and
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competitive Bi receptor antagonists are des-Arg9-Leu8-bradykinin and its related
analog, des-Arg'°-Leu8-Lys-bradykinin (for review see Taylor et al., 1989; Bathon &
Proud, 1991; Farmer & Burch, 1992). Recently, more potent and stable bradykinin Bi
receptor antagonists, such as des-Arg10-Hoel4(), have been developed (Wirth et al.,
1991a).
The signal-transduction pathways activated by Bi receptor stimulation are presently
very poorly understood. Several workers have shown that des-Arg9-bradykinin does
not stimulate eicosanoid synthesis in rabbit smooth muscle (Regoli & Barabe, 1980),
murine macrophages (Tiffany & Burch, 1989) or in human fibroblasts (Goldstein &
Wall, 1984). In contrast, it has also been reported that Bi receptor agonists do
stimulate eicosanoid production in endothelial cells (Cahill et al., 1988; Conklin et al.,
1988).
1.3.1.4.2 Bradykinin B2 receptors
In contrast to Bi receptors (see Section 1.3.1.4.1), B2 receptors show a widespread
distribution being particularly evident in peripheral and central neurones, vascular
smooth muscle, epithelium and various inflammatory cells (for review see Taylor et
al., 1989; Bathon & Proud, 1991; Farmer & Burch, 1992). The vast majority of the
effects of bradykinin such as pain, hyperalgesia, smooth muscle contraction or
relaxation, increase in vascular permeability, reduction in blood pressure and release
of inflammatory mediators are mediated by its activation of B2 receptors (Taylor et
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al., 1989; Bathon & Proud, 1991; Steranka & Burch, 1991; Bhoola et al., 1992;
Burch & Kyle, 1992; Fanner & Burch, 1992).
The substitution of the proline residue at position 7 with D-phenylalanine in the
bradykinin sequence (Figure 1.1) was perhaps the most important step in the
development of bradykinin B2 receptor antagonists (Vavrek & Stewart, 1985).
Subsequently, a vast number of B2 antagonists based on DPhe7-bradykinin were
synthesised and studied in a range of tissues (see Steranka et al., 1989; Burch et al.,
1990; Regoli et al., 1990; Stewart & Vavrek, 1990; Rhaleb et al., 1991). Although
these early bradykinin B2 receptor antagonists made a remarkable contribution to the
understanding of bradykinin-receptor pharmacology, they were of weak affinity and
potency (pKB 5 - 7) and susceptibile to rapid enzymatic degradation (Griesbacher et
al., 1989; Steranka et al., 1989; Burch et al., 1990). Recently, new bradykinin B2
receptor antagonists, based on modified amino acids in positions 7 and 8 of
bradykinin's primary sequence, have been synthesised and shown to be long-acting,
with potencies two or three orders of magnitude greater than the earlier antagonists
(Baoet al., 1991; Hock et al., 1991; Kyle et al., 1991; Lembeck et al., 1991; Burch &
Kyle, 1992). D-Arg-[Hyp3, Thi5, D-Tic7, Oic8]-bradykinin (Hoe 140) is one such potent
B2 receptor antagonist, and has recently been evaluated in various smooth muscle
preparations (Hock et al., 1991; Lembeck et al., 1991; Field et al., 1992; Rhaleb et al.,
1992; Griesbacher & Lembeck, 1992; Liebmann et al., 1993; Feldtou et al., 1994) or
in various models of acute and chronic inflammation (Wirth et al., 1991; Damas &
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Remade-Volon, 1992; Correa & Calixto, 1993; Heapy et al., 1993; Griesbacher et al.,
1993; Griesbacher et al., 1994).
The observed differences in the responsiveness to a series of receptor agonists and
antagonists is generally taken as evidence to suggest the existence of subclasses of
receptor (Kenakin, 1984). Such a proposed subclassification is then, ideally,
confirmed by radioligand binding studies, in which the potencies of ligands are
correlated with their binding affinities (Weiland & Molinoff, 1981). There have been
no studies in the bradykinin field to date which have rigorously satisfied all the criteria
for subclassification of the bradykinin B2 receptor. Nevertheless, evidence that there
may be different subtypes of the B2 receptor has been provided by various studies,
such as those in rat myometrial membranes (Liebmann, 1991), rat uterus, guinea-pig
ileum and trachea (Plevin, 1988), murine neuroblastoma cells (Braas et al., 1988) and
in the electrically-stimulated rat vas deferens (Huidobro-Toro et al., 1986; Llona et
al., 1987; Rifo et al., 1987).
Activation of B2 receptors has been reported to cause stimulation of a variety of
intracellular events. For example, phospholipase C is activated and causes the
formation of inositol phosphates, which cause a rise in intracellular calcium and in
diacylglycerol which activates protein kinase C (Higashida & Brown, 1988; Portilla et
al., 1988; Chuang, 1989; Kaya et a., 1989; Perney & Miller, 1989; Burch et al.,
1990). Protein kinase C has been shown to be an important second messenger in the
action of bradykinin in various rat sensory neurons including skin C-fibre afferents
23
(Dray et al., 1988; Dray et. al., 1992) and dorsal root ganglion neurons (Burgess et
al., 1989; Boland et al., 1991; McGuirk & Dolphin, 1992). An increase in
conductance to Na+ (depolarisation / excitation) is postulated to arise following
protein kinase C activation by bradykinin (Burgess et al., 1989; Boland et al., 1991).
This depolarisation caused by bradykinin appears to be sufficient to induce the
opening of the high-threshold, dihydropyridine-sensitive, L-type calcium channels as
bradykinin-induced influx of radiolabelled calcium is markedly reduced by nifedipine
(Burgess et al., 1989; Boland et al., 1991). Activation of B2 receptors has also been
reported to cause stimulation of other intracellular events, including: stimulation of
eicosanoid production probably as a result of phospholipase A2 activation (see Bathon
& Proud, 1991; Farmer & Burch 1992); accumulation of cyclic AMP (Smith et al.,
1990; Farmer & Burch, 1992) and GMP (Schini et al., 1990) which is frequently due
to an indirect stimulation of the biosynthesis of eicosanoids (Smith et al., 1990). Since
bradykinin can cause inhibition of a slow after-hyperpolarisation, an effect mediated
by cyclic-AMP, this may be one of the mechanisms underlying bradykinin-induced
sensitisation (Weinreich,1986; Weinreich & Wonderlin, 1987).
Many studies have provided indirect evidence which suggests that B2 receptors are
coupled to G proteins (Higashida et al., 1986; Burch & Axelrod, 1987; Murayama &
Ui, 1987). This hypothesis has been confirmed by the recent cloning of a B2 receptor
from the rat uterus (McEachern et al., 1991) and from a human lung fibroblast cell
line (Hess et al., 1992), where the amino-acid sequences predict a protein which has
characteristics of a seven transmembrane G protein-coupled receptor.
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1.3.1.4.3 Other bradykinin receptor subdivisions
Since bradykinin B, and B2 receptor antagonists did not inhibit bradykinin binding,
bradykinin-induced tracheal contractions or bradykinin-induced bronchoconstriction
in the guinea-pig, this led to the proposed existence of the airway bradykinin B3
receptor (Farmer et al., 1989; Farmer et ah, 1991b; Fanner & DeSiato, 1994).
Bradykinin B3 receptors have also been proposed in the guinea-pig taenia caeci (Field
et ah, 1992). There is also evidence from studies on the opossum lower oesophageal
sphincter muscle preparation, that bradykinin B4 (mediate relaxtion) and B5 (mediate
contraction) receptors may exist (Saha et ah, 1990; 1991). All of these proposed new
bradykinin receptor subdivisions will need confirmation using molecular cloning
techniques and the development of selective and potent receptor antagonists.
1.3.2 Adenosine
1.3.2.1 Release of adenosine
In hypoxic or ischaemic tissue, as found in inflammatory lesions, it has been reported
that adenosine is generated in large amounts (Edlund et ah, 1983; Church &
Holgate, 1986; Fredholm & Sollevi, 1986). In human inflammatory conditions, such
as asthma, the release of adenosine has been demonstrated following allergen
challenge in asthmatics (Mann et ah, 1983; Church & Holgate, 1986). This evoked
release of adenosine originated from mast cells as well as other inflammatory cells in
the airways following antigen challenge, and from muscle contraction or regional
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hypoxia within the lungs (Mann et al., 1983; Church & Holgate, 1986). Adenosine
release, evoked hy an elevated potassium concentration, has been shown to originate
from small diameter primary afferent neurons because it is reduced by pre-treating rats
(neonatal or adult) with the selective C-fibre neurotoxin, capsaicin (Sweeney et al.,
1989). Electrical stimulation of rabbit un-myelinated nerve fibres has been
demonstrated to induce adenosine realease (Maire et al., 1984). Release of
endogenous adenosine has been demonstrated from synaptosomes (prepared from
spinal cord) in response to capsaicin or an elevated potassium concentration (Sweeney
et al., 1987; Sweeney et al., 1989). Adenosine release evoked by elevated potassium
or electrical stimulation has also been extensively reported in brain synaptosomes or
slices (for review see Stone, 1981; Phillis & Wu, 1981).
1.3.2.2 Adenosine in pain and inflammation
Observations by Bleehen & Keele (1977) have shown that pain results from the
application of adenosine to a cantharadin-induced blister base on the human forearm.
Pain can also be evoked in humans when adenosine is injected into the coronary (Crea
et al., 1990; Lagerqvist et al., 1990a), brachial (Sylvan et al., 1988b) and
iliac (Lagerqvist et al., 1990a) arteries, or when it is injected intravenously
(Conradsson et al., 1987; Sylven et al., 1988a; Crea et al., 1990; Lagerqvist et al.,
1990b), or into the abdominal aorta (Lagerqvist et al., 1990a). In contrast, injection of
adenosine into hand veins does not evoke pain from venous and paravascular
nociceptors (Klement & Arndt, 1992).
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Behavioural studies (paw withdrawal in response to increasing pressure) in rats have
shown that intradermal injection of adenosine causes direct cutaneous hyperalgesia
(Taiwo & Levine, 1990). Paradoxically, it has been reported that adenosine also has
antinociceptive or anti-inflammatory actions in various animal models including
carrageenan-induced pleurisy (Schrier et al., 1990; Lesch et al., 1991) or paw
inflammation (Firestein et al., 1993) and tail flick (Holmgren et al, 1983) or hot plate
(Holmgren et al., 1986) tests in rats, and acetylcholine-induced writhing (Herrick-
Davis et al., 1989) or substance P or N-Methyl-D-aspartate-induced nociceptive
behaviour (Delander & Wahl, 1988) in mice.
1.3.2.3. Adenosine and sensory afferents
Intra-arterial injection of adenosine into the brachial arteries of human volunteers has
been suggested to cause activation of forearm afferent fibres, as determined indirectly
by measuring reflex sympathetic stimulation (Costa & Biaggioni, 1993). In animal
studies, adenosine has been reported to excite cat carotid body (McQueen & Ribeiro,
1981; Moteiro & Ribeiro, 1987), rat vagal pulmonary (Cherniack et al., 1987; Runold
et al., 1987) and rat renal pelvis (Katholi et al., 1985) afferents. Adenosine has also
been reported to evoke depolarisations in the isolated rat vagus, although such
reductions in membrane potential were small (Trezise et al., 1993)
1.3.2.4 Adenosine receptors
Purine receptors are classified into Pi (adenosine receptors) and P2 (ATP receptors)
subtypes. The role of P2 purinoceptors in pain and inflammation is discussed later (see
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Section 1.3.3). The first proposal that cell membrane adenosine receptors could be
subdivided into A! and A2 subtypes was made by Van Calker et al. (1979), based on
the observation that adenosine could either inhibit (via the A| subtype) or stimulate
(via the A2 subtype) adenylate cyclase. There is increasing evidence that subtypes of
adenosine At (Aia, A!b, Aic) and A2 (A2a, A2b) receptors may exist, as well as an A3
receptor (Linden, 1991; Collis & Hourani, 1993).
Selective adenosine A, or A2 receptor agonists cause nociception or antinociception
depending on which particular model of inflammation and route of administration is
used. Thus, for example, intra-dermal injection of the selective adenosine A2 receptor
agonist, CV1808, causes direct cutaneous mechanical hyperalgesia in the rat (Taiwo
& Levine, 1990) whereas, when At and/or A2 selective agonists are injected
intracerebroventrically (Herrick-Davis et al., 1989) or inlrathecally (Holmgren et al.,
1986; Sawynok el al., 1986) antinociception (tail flick, hot plate or acetylcholine-
induced writhing tests), rather than nociception, results. The nociceptive,
inflammatory, or antinociceptive actions of adenosine and adenosine receptor agonists
are blocked by nonselective (e.g. theophylline, 8-phenyltheophylline), Ai selective
(e.g. DPCPX) or A2 selective (e.g. CP-66713) adenosine receptor antagonists (see




Adenosine 5v-triphosphate (ATP) is a ubiquitous component of cells that is present
at millimolar levels (see Rang et al., 1991). Thus, tissue injury or damage is likely to
release large amounts in the vicinity of sensory nerve endings (see Rang et al., 1991).
ATP could be released from various sources including C-fibre terminals, sympathetic
efferents, endothelial cells and platelets (see Sawynok & Sweeney, 1989; Hoyle &
Burnstock, 1991). ATP has been shown to release mediators that are involved in
inflammation such as nitric oxide from endothelial cells (see Hoyle & Burmnstock,
1991). In synaptosomal preparations of nerve terminals from the dorsal horn of the
spinal cord, from rats and guinea-pigs, ATP is released in response to depolarising
stimuli or by the sensory neurotoxin, capsaicin (White et al., 1985; Sweeney et al.,
1989). ATP is also liberated from peripheral endings of un-myelinated sensory nerve
fibres in the rabbit ear following antidromic electrical stimulation (Holton & Holton,
1954).
1.3.3.2 ATP in pain and inflammation
In humans, application of ATP to the cantharadin-induced blister base in the forearm
has been reported to cause pain (Bleehen & Keele, 1977). Although no pain is caused
by the application of intact erythrocytes to the human blister base, pain is produced
after lysis (see Keele et al., 1982). Such pain is partly due to the high concentration of
ATP, although other adenosine phosphates such as adenosine monophosphate and
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adenosine diphosphate are also likely to be involved (Keele et al., 1982). In animal
studies, ATP and ATP analogues cause activation of cat or rat sensory neurons
(Krishtal et al., 1988; Burnstock, 1990; Hies & Norenberg, 1993). ATP has also been
reported to cause depolarisation of the rat isolated vagus nerve (Trezise et al., 1993).
ATP can also cause the induction / release of other inflammatory mediators such as
prostanoids from various organs (e.g. lung, liver and kidney: see Needleman et al.,
1974) or cytokines from macrophages (see Rang et al., 1991). These inflammtory
mediators can in turn excite or sensitise sensory neurones (see Rang et al., 1991).
1.3.3.3 ATP receptors
ATP interacts at purinoceptors of the P2 subtype (Burnstock & Kennedy, 1985;
Burnstock, 1990; Hoyle & Burnstock, 1991). The P2 receptor has been subclassified
into two subtypes, P2x and P2y, on the basis of the effects of structural analogues of
ATP using classical pharmacological methods (O'Conner et al., 1991; O'Conner,
1992; Illes & Norenberg, 1993). In addition, there is also evidence for two further P2
receptor subtypes, namely P2t and P2z, which have been characterised in studies on
platelets and mast cells, respectively (Gordon, 1986; Pintor et al., 1993).
Electrophysiological experiments using peripheral neurones (various sensory ganglia
of rats and cats) indicate the presence of P2y-like purinoceptors (see Illes &
Norenberg, 1993), although other investigators report a mixed population of P2x and
P2y receptors in the isolated cervical vagus nerve (Trezise et al., 1993) or centrally in
the locus coeruleus (Harms et al., 1992; Tschopl et al., 1992).
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1.3.3.4 ATP receptor antagonists
The few purine P2 receptor antagonists that are presently available all have problems
of receptor selectivity. Nevertheless, suramin and arylazidoaminopropionyl-ATP are
two non-selective purine P2 receptor antagonists that have been used widely to
antagonise the effects of ATP and ATP analogs in various neuronal and smooth
muscle preparations (Sneddon & Burnstock, 1984; Dunn & Blakeley, 1988; Leff et
al., 1990; Trezise et ah, 1993).
Receptor desensitisation has also been used as a method for blocking purine
receptors. Thus, for example, although the purine P2x receptor agonist, a,(3-
methylene-ATP, initially causes a response (smooth muscle contraction or
depolarisation) there is full desensitisation upon subsequent exposures. Indeed, such a
desensitisation by a,P-methylene-ATP is a recognised identification criterion for P2x
receptors (Burnstock & Kennedy, 1985; O'Conner et ah, 1990; O'Conner, 1992)
1.3.4. Adrenoceptors
1.3.4.1. Inflammation and adrenoceptors
The observations of Wall & Gutnick (1974) that many unmyelinated and myelinated
afferent fibres innervating a rat neuroma were excited by adrenaline or noradrenaline,
raised the possibility that damaged fibres expressed and/or up-regulated
adrenoceptors or that they became fuctional. A great deal of subsequent work by
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various workers has confirmed that an appreciable number of damaged fibres in a
variety of species show sensitivity to noradrenaline or adrenaline (see below, and
review by Devor, 1991).
Adrenoceptors are classifed into two main divisions namely, a- and P-
adrenoceptors. a-adrenoceptors are further subclassified into ai and a2-subtypes, and
^-adrenoceptors into the Pi, p2 and p3 subtypes (see Bowman & Rand, 1980; Rang
and Dale, 1987). Subdivisions of both oti and a2-adrenoceptors also exist (see Watson
& Girdlestone, 1994). Although noradrenaline and adrenaline act at both a- and P-
adrenoceptors, noradrenaline has greater affinity (receptor specificity) for a-
adrenoceptors (ai and a2), whereas adrenaline has a greater affinity for P-
adrenoceptors (Pi and p2) (see Bowman & Rand, 1980; Rang and Dale, 1987;
Watson & Girdlestone, 1994).
1.3.4.2 Adrenoceptors in pain and inflammation
Adrenoceptors have been implicated in chronic inflammatory conditions in man,
such as reflex sympathetic dystrophy (Schott, 1986; Schwartzman & McLellan, 1987)
and rheumatoid arthritis (Kaplan et al., 1980; Levine et al., 1986a; Hannington-Kiff,
1990). In these disorders a reduction in pain and inflammation can be achieved by the
use of adrenergic neurone blocking drugs, such as guanethidine, which cause
catecholamine depletion (Loh & Nathan, 1978; Bonica, 1979; Levine et al., 1986a;
Hannington-Kiff, 1990).
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A contribution of adrenoceptors, particularly p2-adrenoceptors, has been suggested
from the results of behavioural studies of chronic pain and inflammation associated
with arthritis (see Fitzgerald, 1989). For example, treatment with the non-selective P-
adrenoceptor antagonist, propranolol, was found to decrease the signs and symptoms
of inflammation in patients with rheumatoid arthritis (Kaplan et al., 1980). Similarly,
in rats with adjuvant-induced arthritis, treatment with propranolol was shown to
reduce the severity of joint injury (Levine et al., 1988). Moreover, in this model of
arthritis, ai, a2 or pt-adrenoceptor antagonists were without effects, whereas the p2-
adrenoceptor antagonists, butoxamine or ICI 118551, were found to decrease the
degree of joint severity (Levine et al., 1988). It has also been demonstrated that the
p2-adrenoceptor agonist, salbutamol, or the catecholamine, adrenaline (acting at p2-
adrenoceptors), exacerbate adjuvant-induced arthritis (Coderre et al., 1990; Coderre
et al., 1991). In another model of inflammation, carrageenan-induced mechanical
hyperalgesia, the p-adrenoceptor antagonist, propranolol, partially blocked the
reduced nociceptive threshold to pressure on the hind paw of the rat (Nakamura &
Ferreira, 1987). The a-adrenoceptor antagonist, phentolamine, had no effect in this
model of inflammation. Paradoxically, in other studies, p2-adrenoceptor agonists have
been reported to have anti-inflammatory actions. For example, p2-adrenoceptor
agonists such as salbutamol and, in particular the longer-duration p2-adrenoceptor
agonist, salmeterol (Ball et al., 1991), are inhibitors of mediator (histamine,
leukotrienes and prostaglandins) release (Butchers et al., 1979; Butchers et al., 1991),
bradykinin-induced plasma protein extravasation (Whelan et al., 1993), vascular
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permeability & granuloeyte accumulation (Whelan & Johnson, 1992) and
carrageenan-induced oedema (Green, 1972).
1.3.4.3. Effects of adrenaline and noradrenaline on afferent nerves
Electrophysiological recordings from C- or A8-fibres have shown that adrenaline
and noradrenaline cause excitation only in inflamed tissues. For example, afferent
neural recordings from C- fibres in rabbit ears have shown that, although
noradrenaline did not excite C-polymodal nociceptors in undamaged ears,
approximately 60% of C-fibre nociceptors were excited by this catecholamine in ears
with damaged auricular nerves (Sato & Perl, 1991). This noradrenaline-induced
excitation was blocked by a2 (predominantly) and oti-adrenoceptor antagonists; the
effects of P-adrenoceptor antagonists were not examined. In chronically lesioned
nerves (neuromas) in the cat, adrenaline was shown to excite 40% of unmyelinated
skin afferents (Habler et al., 1987), although which adrenoceptor mediated this action
was not studied. In the investigation by Sanjue & Jun (1989), rat skin nociceptors
showed no responses to noradrenaline, although when there was a sustained neural
discharge, induced by a compound algogenic substance (mixture of 5-HT, histamine,
KC1 and HC1), noradrenaline enhanced the discharge in 7 of 9 afferents. The
adrenoceptor responsible for this noradrenaline-induced excitation was not
determined in this study. Studies of rat myelinated afferents ending in a neuroma also
report an adrenaline-induced excitation (Devor & Janig, 1981). This excitation was
blocked by the a-adrenoceptor antagonist, phentolamine, but not by the P~
adrenoceptor antagonist, propranolol (Devor & Janig, 1981).
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Noradrenaline-induced sensilisation of the response to mechanical stimulation has
been reported in rat cutaneous mechanonociceptors (Gold et al., 1994). Since such
mechanical sensitisations were blocked by yohimbine, this suggests the involvement of
0C2- adrenoceptors (Gold et al., 1994).
1.3.4.4 Location of action of adrenaline and noradrenaline
Of the many possible sites at which adrenaline and noradrenaline could cause
enhancement of neural discharge, two include the sympathetic efferent nervous system
and the terminals of C-fibre afferents. Regarding the sympathetic efferent nervous
system, various studies have suggested that there is an indirect coupling of
sympathetic efferent and afferent fibres (see Fitzgerald, 1989; Gonzales et al., 1991;
McMahon, 1991; Schaible & Grubb, 1993; Gold el al., 1994). In such a scenario,
adrenaline or noradrenaline act on adrenoceptors located on sympathetic
postganglionic terminals to cause the release of prostaglandins and/or leukotrienes
which then act on afferent terminals to cause excitation or sensitisation (see Rang et
al., 1991; McMahon, 1991). Indeed the long latency of the effects of adrenaline and
noradrenaline reported in various studies would fit with such an indirect mechanism of
action (see McMahon, 1991). Studies by Levine et al. (1986b) have shown that
noradrenaline-induced hyperalgesia in inflamed (chloroform-induced) paws of rats is
mediated through an interaction with terminals of sympathetic neurones rather than by
activation of primary afferent nociceptors. Similarly, the terminals of sympathetic
neurones have also been reported to be the site of action of adrenaline (adrenal
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medulla-derived) in contributing to the severity of adjuvant-induced arthritis (Coderre
et al., 1990).
Since adrenaline and noradrenaline only have an effect in inflamed tissues, it would
have to be postulated that the sympathetic nervous system undergoes changes under
inflammatory conditions, for example, by up-regulation and/or expression of
adrenoceptors, or the coupling of adrenoceptors to different second messenger
systems in the presence of a raised calcium concentration caused by inflammation
(Gold et al., 1994). However, the role of the sympathetic nervous system in affecting
afferent neural discharge has been questioned by Scott (1994), who presents powerful
arguments that it is more likely to be visceral afferents (terminology also includes
peripheral structures), which travel within autonomic nerves, which are the location of
action of adrenergic agents. Another possible location of action for adrenaline or
noradrenaline are the afferent nociceptive terminals, where it is suggested that there is
an expression or up-regulation of a-adrenoceptors (Devor, 1991; McMahon, 1991),
although this is not supported by the studies of Levine et al. (1986b; 1988).
1.4 Adjuvant-induced arthritis in the rat as a model of joint pain
and inflammation
1.4.1. Aetiology and pathological features
Arthritis induced by Freunds adjuvant is a widely used and accepted model of
arthritis in the rat, which is associated with chronic pain and inflammation, (see
Billingham & Davies, 1979; Rainsford, 1982; Billingham, 1983; Colpaert, 1987). This
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form of arthritis is induced by injecting Freunds complete adjuvant (FCA), a mixture
of heat-killed mycobacteria (Mycobacterium tuberculosum or Mycobacterium
butyricum) in mineral oil, into the tailbase or footpad. Other species of bacteria (Flax
& Waxman, 1963; Paronetto, 1970), water soluble peptidoglycans (Kohashi et al.,
1976; 1977) and inuramyl dipeptide (Kohashi et al., 1980) have also been used to
induce arthritis.
FCA-induced arthritis has an immunological origin, where an epitope contained on a
mycobacterial heat shock protein is cross-reactive with a self-antigen in joint cartilage
(Van Eden et al., 1985; 1989). This epitope is recognised by rat T-cells which then
leads to a hypersensitivity reaction to the bacterial antigen and also to the cartilage
proteoglycans (Van Eden et al., 1985).
Two phases of inflammation are produced by the injection of FCA into the foot pad
or tail base. In the first, there is an acute local inflammatory reaction which develops
within the first few hours after injection, but subsides after 3 - 5 days. There then
follows the second phase, where there is polyarthritis, with lesions in the eyes, ears,
nose, skin, tail or genitals as well as profound weight loss (Pearson & Wood, 1959;
Ward & Jones, 1962; Pearson, 1963; Pearson & Wood, 1963; Billingham & Davies,
1979; Rainsford, 1982). The severest inflammation in polyarthritis occurs in the joints
of the hind limbs, where there is bone destruction, damage to tendons and loss of
cartilage.
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The incidence, severity and consistent induction of FCA-induced polyarthritis is
affected by several factors including the concentration of mycobacterium and its
degree of dispersion (Ward & Jones, 1962; Newbould, 1963), the site of FCA
injection (Winder et al., 1969; Perper et al., 1971; Koga et al., 1976), strain of rat
used (Zideck & Perlik, 1971; Freeman & West, 1972; Eisen et al., 1973) and the
addition of compounds to FCA so as to improve the incidence of disease (Whitehouse
et al., 1974).
1.4.2 Adjuvant-induced arthritis as a model of chronic pain
In order to test whether or not the FCA-induced model of arthritis in the rat is
associated with chronic pain, investigators have measured several behavioural
parameters that are indicative of pain. Examples of such parameters include: reduction
in body weight (Colpaert et al., 1982; Colpaert & Van Den Hoogen, 1983; Calvino et
al., 1987), marked decrease in locomotor activity (Calvino et al., 1987), scratching
behaviour (De Castro Costa et al., 1981), irritability (Reuler et al., 1980; Colpaert et
al., 1982) and hyperventilation (Colpaert & Van Den Hoogen, 1983). Although
parameters such as body weight, scratching or hyperventilation are not direct pain
'markers', the similarity of their time-courses with the arthritis process is, albeit
indirectly, indicative of chronic pain in the FCA-induced arthritic model. Further
support that arthritic rats are associated with chronic pain comes from studies which
show that these animals preferentially consume drinking water that contains analgesic
drugs (Colpaert et al., 1980), and from studies which show that analgesic drugs (e.g.
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aspirin) can improve mobility (Larson & Ami, 1985) and reduce scratching behaviour
(De Castro Costa et al., 1987).
1.4.3 Adjuvant-induced arthritis and hyperalgesia
Several groups have measured the hyperalgesia associated with FCA-induced
arthritic rats by a range of tests including the Randall-Selitto (paw withdrawal on the
application of increasing pressure) test (Kayser & Guilbaud, 1981; Kayser &
Guilbaud, 1983; Hara et al., 1984; Butler et al., 1985; Calvino & LeBars, 1986;
Calvino et al., 1987), tail flick test (Colpaert, 1979; Yonehara et al., 1983), hot plate
test (Hara et al., 1984), rotorod grip strength (Perrine & Takesue, 1968),
compression with forceps (Hirose & Jyoyama, 1971), foot bend (extension or flexion)
procedure (Kuzuna & Kawai, 1975; Winter et al., 1979; Capetola et al., 1980;
Calvino & LeBars, 1986; Calvino et al., 1987) and transcutaneous electrical
stimulation (Okuyama & Aihara, 1984).
1.4.4. Mechanonociceptor responsiveness in adjuvant-arthritis: central and
peripheral considerations
Neurones at several sites in the central nervous system show marked changes in
activity when there is inflammation, such as in the FCA-induced arthritic rat model.
Thus, although spinal dorsal horn, thalamic and cortical neurones in the normal rat
respond only to intense noxious mechanical stimuli from the periphery (e.g. in joints),
they respond to mild mechanical stimuli in rats with FCA-induced arthritis (Gautron &
Guilbaud, 1982; Menetrey & Besson, 1982; Lamour et al., 1983; Kayser & Guilbaud,
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1984). In the rat superficial dorsal horn, a response is evoked by a stimulus such as
light pressure on the normal ankle joint, whereas in striking contrast, it is easy to
evoke a vigorous sustained discharge in the arthritic joint (Menetrey & Besson,
1982). More recently, it has been demonstrated by Grubb et al. (1993) that neurones
of the superficial and deep dorsal horn and of the ventral hom show either an
induction or an increase in ongoing discharges and a reduction in the mechanical
threshold (mechanical stimuli applied to the ankle joint) in rats with a unilateral
chronic inflammation induced by FCA. Following repetitive stimulation of C-fibres,
spinal cord neurones are also involved in the 'wind-up' phenomenon (Davis & Lodge,
1987; Dickenson & Sullivan, 1990; Thompson et al., 1990; Schaible & Grubb, 1993);
wind-up is a term which describes successive elevations in the magnitude of the
responses of a neurone to a constant repeated stimulus (see Schaible & Grubb, 1993).
The response properties of the spinal neurons during arthritis do not just reflect the
afferent impulses from the joint on a spike for spike basis. Indeed there are at least
three main components that may interact to determine the actual changes in response
properties, namely: 1) peripheral component (alterations in afferent inflow), 2) spinal
component (intraspinal modification) and, 3) supraspinal component (changes in
descending inhibition). Thus it is clear that the spinal cord shows a great deal of
plasticity following adjuvant-induced arthritis (see also Schaible & Grubb, 1993).
The alterations in the processing of nociceptive information during chronic
inflammation may be due to several mechanisms including: alterations in synaptic
mechanisms, or in the connectivity of neurones in the sensory pathway that lead to
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their becoming increasingly easily excited by formely ineffective sensory inputs (see
Iggo, 1988); changes in the sensitivity of sensory fibres that make them more effective
central excitants or less effective inhibitors (see Iggo, 1988);
changes in the concentrations of a large number of various ions and mediators
including: potassium (spinal cord: Heinemann et al., 1990), 5-HT (spinal cord,
brainstem and forebrain: Weil-Fugazza et al., 1979,1980), glutamate (spinal cord:
Sorkin et al., 1992), noradrenaline (spinal cord: Weil-Fugazza et al., 1986),
cholecystokinin (spinal cord: Chery-Croze et al., 1985) and endogenous opioids
(spinal cord: Hollt et al., 1987; Weihe et al., 1989).
As well as alterations in the central nervous system there are also changes in
peripheral nociceptors following inflammation. For example, Guilbaud et al. (1985)
have shown that increased responsiveness to mechanical stimuli given in the periphery
following chronic inflammation may be a result of alterations in the sensitivity (e.g.
induced by inflammatory mediators, see Section 1.4.6) of peripheral nociceptors. The
electrophysiological recordings by Guilbaud et al. (1985) in the periphery,
investigated the properties of high threshold mechanonociceptors (C-fibre afferents) in
ankle joints of normal and FCA-induced polyarthritic rats. In arthritic joints,
mechanonociceptors had lower mechanical activation thresholds, higher levels of
spontaneous discharge and a larger number of mechanically-sensitive receptive fields
(each corresponding to a single afferent unit) as compared to those from normal joints
(Guilbaud et al., 1985). The sizes of individual receptive fields were similar in normal
and arthritic joints. Histological studies of the articular nerve supply revealed no
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difference in the size or number of axons found in normal and arthritic joints
(Guilbaud et al., 1985). Thus, a change in the total number of afferent fibres cannot
explain the alterations in the sensitivity of joint mechanonociceptors in arthritic joints.
1.4.5 Adjuvant-induced monoarthritis
Although FCA-induced polyarthritis has been used widely, and justifiably, in a large
number of neurophysiological, biochemical and immunological studies, its systemic
and widespread nature is unnecessary in the study of nociceptive mechanisms as it is
difficult to attribute observed changes specifically to the arthritis process. There are
also ethical considerations in the use of such severely affected animals. Therefore, it
would be desirable both on scientific and ethical grounds if a less severe and more
localised FCA-induced arthritis could be obtained and used as an alternative to FCA-
induced polyarthritis for studying nociceptive processes. Recent studies have shown
that a discrete monoarthritis is obtained in rats following the localised injection of
FCA (100 - 150pg Mycobacterium tuberculosum or Mycobacterium butyricum)
around (subdermally) the ankle joint or into the foot pad (Grubb et al., 1991; Butler
1992; Donaldson et al., 1993). Thus, interpretation of data from studies examining the
role of various inflammatory mediators using the monoarthritic model will be made
easier, since any observed changes are more likely to be attributed to the arthritis
process per se.
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1.4.6 Role of inflammatory mediators in adjuvant-induced arthritis
The sensitisation of nociceptors in FCA-induced arthritis has been shown to be
partly attributable to the actions of prostanoids. For example, it has been
demonstrated that intra-venous injection of lysine acetylsalicylate reduces the
enhanced responsiveness of ventro-basal thalamic neurones in arthritic rats (Guilbaud,
1988). Electrophysiological recordings from C-fibre alTerents in polyarthritic rats also
suggest the important involvement of prostanoids. Thus, although lysine
acetylsalicylate had no effect on the discharge from mechanonociceptors in normal rat
ankle joints, it did reduce the elevated spontaneous discharge and the enhanced
responsiveness to mechanical stimuli that are associated with polyarthritic rat ankle
joints (Guilbaud & Iggo, 1985). In agreement with these results of Guilbaud & Iggo
(1985) in polyarthritic rats, lysine acetylsalicylate or paracetamol-induced reductions
in the elevated mechanonociceptor discharges have been reported in rats with a
discrete monoarthritis (McQueen et al„ 1991). Since aspirin or aspirin-like drugs only
partly reduce the raised neural discharges seen in arthritic joints it is, therefore, likely
that other inflammatory mediators (see Section 1.3) may also play a role in the
inflammation-induced sensitisation process.
1.5 Aims of the present investigation
From the discussions above it is apparent that certain chemical mediators can
modulate the responsiveness of peripheral sensory receptors in normal tissues and, in
particular, tissues which are chronically inflamed. Although many studies have
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demonstrated that prostanoids have a substantial role in altering nociceptor
responsiveness in chronically inflamed tissue, as lor example in the arthritic rat ankle
joint (Guilbaud & Iggo, 1985; Birrell, 1990; McQueen et al., 1991), it is possible that
other inflammatory mediators such as bradykinin (see Section 1.3.1), purines (see
Section 1.3.2 and 1.3.3) and catecholamines (see Section 1.3.4) may also be involved.
The aims of the present investigation were:
1) To confirm and further characterise the use of a localised FCA-induced arthritis of
the rat ankle joint in the study of chronic pain and inflammation.
2) To determine the role of bradykinin in affecting neural discharge (spontaneous and
mechanically-evoked) from C-fibre afferent mechanonociceptors in-vivo in normal rat
ankle joints, and in those with a localised FCA-induced arthritis. In order to further
characterise the effects of bradykinin and its analogs on neural excitability, two in-
vitro neural preparations were used. In one preparation, any change in membrane
potential was recorded extracellularly from various sensory nerves (vagus, tibial,
tibialis, sciatic and saphenous) using a 'grease-gap' technique. In the other
preparation, neurally as well as non-neurally-mediated responses were studied in the
electrically-stimulated rat vas deferens.
3) To determine the effects of indomethacin on the elevated spontaneous discharge
and the enhanced responsiveness to mechanical stimuli associated with C-fibre
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afferent mechanonociceptors in rat ankle joints with a localised FCA-induced arthritis.
Complementary behavioural studies were also performed in order to determine the
effects of indomethacin in monoarthritic rats.
4) To determine the role of purines on neural discharge (spontaneous and
mechanically-evoked) from C-fibre afferent mechanonociceptors in-vivo in normal rat
ankle joints and in those with a localised FCA-induced arthritis
5) To determine the role of adrenoceptors, particularly the p2-subtype, in modulating
neural discharge (spontaneous and mechanically-evoked) from C-fibre afferent
mechanonociceptors in-vivo in normal rat ankle joints and in those with a localised
FCA-induced arthritis. Complementary behavioural studies were also performed in
order to determine the role of p2-adrenoceptors in modifying the inflammation and






2.1 Induction oflocalised adjuvant-induced arthritis
Localised adjuvant arthritis was induced in male Wistar rats (200 - 350g) by the
subdermal injection of Freunds Complete Adjuvant (FCA) around the tibio-tarsal joint
of the left hind limb. Following induction of anaesthesia using ether or halothane (2%
in oxygen), the left hind limb was swabbed with alcohol, and a total volume of 150pl
of FCA (lrngmf1 heat killed Mycobacterium tuberculosis, mannide monooleate
0.15ml, paraffin oil 0.85ml) injected subdermally at two separate sites (75pl at each
site). Following recovery, the rats were housed in cages (5 rats per cage). The
development of inflammation was followed for up to 30 days, during which period the
animals were used for electrophysiological or behavioural experiments.
2.2 Behavioural studies using arthritic rats
2.2.1 Assessment of the arthritic lesion for behavioural studies
Quantitative measurements were obtained of ankle joint circumferences, and foot
withdrawal following the application of increasing pressure to the left (adjuvant-
injected) or right ankle (un-injected) joint. Qualitative measurements were also made
of inflammation and mobility. Rat body weight was used as a general indicator of
animal health. The various measurements were performed, blind to drug treatment, by
the same experienced investigator and are described in detail below.
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1) Ankle joint circumference: this was measured (in mm) hy placing a loop of
measuring tape around the ankle joints.
2) Foot withdrawal to pressure: rats were hand held, and the ankles of the right and
left hind limbs were in turn placed between the thumb of the investigator and a rubber
pad. The rubber pad was connected to a spring-loaded linear displacement transducer
with the measurement of pressure applied being displayed on a meter. To raise
pressure on the ankle joint, the experimenter manually increased the force on the
rubber pad. The pressure unit ( 0 - 8; 0 = ImmHg, 8 = >40mmHg) at which the rat
withdrew the hind limb was determined.
3) Mobility (walking foot placement score): rats were observed in the cage to assess
any change in gait of the left (adjuvant-injected) and right (un-injected) hind limb.
Animals were scored as follows:
0 = normal gait
1 = occasional lifting of foot
2 = foot mostly raised
3 = foot raised all the time (three legged gait)
4) Inflammation: the inflammation present on the left and right ankle joints was
determined by visual observation using the following scores:
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0 = normal
1 = mild redness
2 = moderate redness
3 = severe redness / lesions
2.2.2 Statistical assessment
2.2.2.1 Effects of adjuvant injection
Any difference in the various parameters measured (see Section 2.2.1) between the
ipsilateral (adjuvant-injected) and the contralateral (un-injected) ankle joint was
assessed statistically using analysis of variance (ANOVA) and the Mann Whitney IJ-
test (see Section 2.2.2.2 for details).
2.2.2.2 Effects of pharmacological agents in adjuvant-arthritic rats
For ankle joint circumferences, withdrawal to pressure or weight measurements, an
ANOVA test was first performed. This essentially involved summing the values for
each parameter for individual animals. For example, readings such as the left ankle
joint circumference for rat 1 in group A were totalled during a defined period to give
an integrated value which is equivalent to the "area under the curve". This calculation
was repeated for the other rats in the group. In the studies where drug treatment was
started before the injection of adjuvant, the defined period was days 2-9 and days 9-
19 for the acute and secondary phases, respectively. For the studies where rats with
an established arthritis were subsequently treated with drugs, the defined period was
14-29 days. Adjuvant was injected on day 0 (established arthritis studies) or day 1
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(all other studies). The individual summed measurements for drug-treated animals
were compared with those for the vehicle-treated group by ANOVA, and the null
hypothesis rejected at P < 0.05. If the ANOVA was found to significantly show a
difference between the groups, then further statistical analysis was performed using
the Mann Whitney U-test at varying time points. For the qualitative measurements
(inflammation and walking foot placement) the Mann Whitney U-test was used. P
values less than 0.05 were considered to be significant.
2.3 Electrophysiological experiments in-vivo
2.3.1 Assessment of the arthritic lesion for electrophysiological studies
The general condition and activity of the rats was monitored on a daily basis by
observing their behaviour in relation to motility and stress during handling (see
Colpaert, 1987) in the cage. Weight gain was monitored regularly along with visual
assessment of any secondary inflammatory lesions in the hind limbs, tail, snout,
genitalia and ears. Measurement of ankle joint swelling was made by using a
measuring tape around the arthritic joint and compared to the circumference of
contralateral (un-injected) ankle joint.
2.3.2 Anaesthesia and surgical preparation
Male Wistar rats (weight 312 ± 39g; range: 250-450g) were anaesthetised by intra¬
peritoneal injection of urethane (25% w/v aqueous ethylcarbamate solution,
O.bmllOOg"1 body weight). Body temperature was monitored continuously and
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maintained at 37 ± 0.5°C by an automated electronic heating blanket (Harvard
apparatus Ltd) connected to thermistor probe inserted in the rectum.
A midline incision was made in the ventral aspect of the neck, and a tracheal cannula
was inserted below the level of the larynx. The left carotid artery was cannulated with
a catheter (OD 0.75mm), and arterial blood pressure monitored by connection of the
catheter to a pressure transducer (Bell and Howell, 4-442). The signal from the
transducer was amplified and displayed on a chart recorder (Devices M4). A cannula
(OD 0.63mm) was inserted into the right femoral artery for the injection of drugs at
the level of the iliac bifurcation of the abdominal aorta.
The tibial nerve of the left hind limb was exposed through a longitudinal incision in
the groin and medial aspect of the leg from the pelvis to the sole of the foot. A free
exposure of the nerve was obtained by removing the semitendinosis,
semimembranosis, biceps femoris and medial gastrocnemius muscles. The plantar
nerves were then exposed by careful incision and reflexion of the crural fascia
overlying the stumps of the Achilles tendon and, the primary articulo-cutaneous ramus
(PACR) nerve identified where it left the medial plantar nerve (Guilbaud et al., 1985).
The dissection required to expose the PACR nerve and to provide sufficient skin flap
to form a liquid paraffin pool, adequate enough to cover the exposed nerve during
electrical recording, inevitably lead to rupture of the cutaneous branches of the PACR
so that neural recording was restricted to activity in nerve fibres innervating the
subcutaneous tissue and the ankle joint. Figure 2.1 shows a diagrammatic
representation of the recording arrangement together with a photograph of the
working preparation.
2.3.3 Recording afferent nerve activity
Electrical activity in afferent nerve fibres was recorded either from fine filaments
split from the PACR close to its origin from the medial plantar nerve, or from the
intact PACR after it had been dissected away from the adjacent tissues. The tibial
nerve was cut centrally to abolish efferent nerve activity in the PACR. Electrical
activity was recorded extracellularly using bipolar platinum-iridium wire electrodes
mounted on a micromanipulator. The electrodes were carefully placed in contact with
the lower side of the nerve filament.
The electrical signal was amplified (Neurolog) and displayed on a storage
oscilloscope (Tektronix 5113). The signal was then digitised using a digital audio
processor (Sony PCM 701-ES) for storage on the videotape (videotape recorder:
Sony Betamax SL-HF100 UB). The output from the amplifier was also passed
through a voltage discriminator (Digitimer D130) so that action potentials of a
selected amplitude could be counted. Output from the voltage discriminator was also




Figure 2.1 (a) Schematic diagram showing the primary articulo-cutaneous ramus
(PACR) nerve as prepared for recording purposes. The skin has been dissected from
the limb to form a paraffin oil pool, thus exposing the tissues of the ankle joint.
Labelled in the diagram is the PACR and the medial (mp) and lateral (lp) plantar
nerves. The PACR leaves the medial plantar nerve and passes under the saphenous
nerve to innervate the tissues of the joint, (b) Enlarged (x4) photograph of the
working preparation. The PACR is hooked up to a pair of platinum-iridium wire



















Figure 2.2 Schematic diagram showing the arrangement of apparatus used for
electrophysiogical recording, collection and storage of data, and in the application of
mechanical stimuli. P.C.M. = pulse code modulation. V.C.R. = video cassette
recorder.
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2.3.4 Mechanical and electrical stimulation
Afferent units were found by exploring the exposed medial aspect of the left ankle
joint using a hand held plastic probe of approximately 1mm diameter. Quantitative
mechanical stimuli were delivered using an electromechanical indentation generator
(Somedic, Sweden). Ramp and plateau stimulus waveforms were routinely used with
displacements of between l()()-5()()pm. Indentation stimuli were of two seconds
duration, applied at two minute intervals in order to minimise receptor fatigue. Once a
receptive field had been found, the threshold force needed to activate the
mechanoreceptor was determined by means of a strain gauge attached to the
mechanical probe.
The mechanical probe consisted of a silver wire core isolated from the metal cylinder
casing of 1mm external diameter. This bipolar arrangement of the probe allowed its
use in applying localised electrical stimuli of 1msec pulse duration at 1Hz - voltage
(0.1 - 5V) was slowly increased until there was activation of the spike. Conduction
velocity (v) was calculated from the conduction distance (d) measured in situ and the
conduction time (t) for the action potential to travel from the stimulating to the
recording electrodes (v = d / t, ms'1). Overall, this method for conduction velocity
measurement is likely to under-estimate the conduction velocity (nerve path longer
than measured distance because of 'coiling' in the nerve trunk).
The high level of technical ability required to dissect the PACR nerve for neural
recordings resulted in only a proportion of the preparations being functional. On
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average a successful neural recording was obtained in approximately 60% of the
preparations.
2.3.5 Data analysis
The output of the video tape recorder containing the neural recording was passed
through an amplifier and filter module (band pass 10 - 1(X)0 Hz) and fed to the spike
processor which counted selected action potentials. Each action potential that fell
within the window generated a pulse of 1ms duration. The number of impulses
occurring in 0.1s intervals was collected and stored by a personal computer (IBM PC)
programmed to collect over a period of up to 450s (software written and supplied by
Dr M. Dutia, Dept. of Physiology, University of Edinburgh). A marker was used to
indicate the point at which a drug injection was made. Collected data were stored on
floppy disc and subsequently analysed on the personal computer using the same
programme.
A computer-generated plot of the action potential discharge frequency as a function
of time was displayed on the computer monitor. From this plot neural discharges were
analysed in the pre-injection control period and during defined intervals following
injection of the drug. The defined time period (t seconds), for which the computer
was required to process discharge frequency was selected using a moving cursor
which directed the computer to the memory-stored data displayed on the monitor.
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2.3.5.1 Mechanically-evoked stimuli
The responses to mechanical stimuli were expressed as the number of action
potentials produced by each 2s indentation stimulus. Drug effects were expressed in
terms of the peak number of impulses above or below the pre-injection evoked
discharge. In experiments where a large increase in background discharge coincided
with the mechanical stimulus it became difficult to quantify the response to the
mechanical indentation only. In such cases, the response to the mechanical stimulus
was still determined over 2s even although the measurement will over-estimate the
actual evoked discharge. Subtraction of the raised background discharge from the
response to the mechanical stimulus was investigated but was rejected, since in this
calculation negative values could be obtained for the response to the mechanical
stimulus.
2.3.5.2 Spontaneous discharge
When analysing the actions of drugs on on-going or spontaneous discharge, the
control period was defined as the 60s period immediately prior to the drug injection.
Drug effects were quantified either as the mean peak discharge (measured over 10-
15s with the exception of indomelhacin, where successive 100s time periods were
used) above or below the mean pre-injection discharge (see analysis A below), or, as
with drugs showing small responses, the total number of action potentials above or
below the control rate of discharge (see analysis B below). The calculations used for
such quantifications were as follows.
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Preliminary definitions:
i) Xx: the total number of impulses (number of action potentials) occurring in the
period t seconds, for control and for test periods.
Units: impulses.
ii) 3?: the mean number of impulses per second occurring in each period t seconds
Hence x (control) = Xx (control) /1 (control),
and x (test) = Xx (test) /1 (test).
Units: impulses per second (i.p.s.).
Analysis A:
delta x: the difference in the mean discharge occurring between the test and
control periods. Thus,
delta x = x (test) - x (control).
Units: i.p.s.
Analysis B:
delta Ex: the absolute difference in discharge from control levels, given by
delta Xx = Xx (test) - [x (control) * t (test)],
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Units: impulses
with the assumption that the pre-injection discharge remains constant in the absence
of any modifying effect of the drug. Such an assumption is supported by the finding
that control injections of saline produced no significant change in discharge (P>0.05,
Wilcoxon, versus pre-injection discharge).
Whereas analysis A takes only the magnitude of the response into account, data
integrated with respect to control (delta Xx, analysis B) takes into account both the
magnitude and duration of the induced change in discharge. The results of analysis A
and B will have positive and negative values when there is enhancement and
depression of neural discharge, respectively.
2.3.6 Statistical assessment
Comparison of neural discharges obtained in normal and arthritic rats was assessed
using the Mann Whitney U-test. The Wilcoxon signed rank (Wilcoxon) was used to
determine the statistical significance of drugs at producing changes in neural discharge
as compared to the pre-injection control discharge period. P values less than 0.05
were considered to be statistically significant.
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2.3.7 Drug administration
All drugs were injeeted intra-arterially (i.a.) in a volume of 0.1 - 0.3ml into the
bifurcation of the abdominal aorta via the cannula inserted retrogradely through the
right femoral artery, and washed in with 0.2ml saline (0.9% w/v aqueous NaCl).
Bolus injections made in this way resulted in a transient high local concentration of
the drugs at the left ankle joint. Injections were completed within a period of Is. All
drugs were administered 15s prior to a mechanical stimulus so that any short-lasting
actions could be observed. If a drag produced a change in neural discharge, then the
next dose of the drag was only injected after neural discharge had returned to or near
the control resting discharge frequency; an exception to this was the studies in which
indomethacin was used (see Section 4). Control injections of 0.1ml saline, washed in
with 0.2ml saline, were made in each experiment. In all cases, injection of saline had
no significant effect on afferent discharge (spontaneous or mechanically-evoked).
Prior to the administration of drugs, consistent responses to the application (every
2min) of the mechanical stimulus were obtained when possible. Log dose-response
curves for agonists were constructed (when possible) before and after antagonists or
enzyme inhibitors.
2.4 Isolated nerve preparation
2.4.1 Preparation of tissues
Adult male Wistar rats (200-350g) were killed by cervical dislocation. Segments of
vagus, tibial, tibialis, sciatic or saphenous nerve of approximately 10 - 15mm were
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dissected out and placed in Krebs solution of the following composition (mM): NaCl
118, KC1 5.4, KH2F04 1.2, MgS04 1.2, NaHCOz 25, glucose 11.1 and CaCl2 2.5.
The Krebs solution was gassed with 95% 02 and 5% C02 and maintained at 27°C.
The connective tissue sheath around each nerve segment was carefully removed using
watchmaker forceps.
2.4.2 Extracellular recording
Within one hour of dissection, sections of desheathed nerve were transferred to two
compartment perspex baths to permit extracellular recording of membrane potential
changes. Each nerve was positioned so that approximately half of its length lay in the
First compartment, while the remainder projected through a greased (Dow-Corning
high vacuum grease) slot into the second. The DC potential between the two
compartments was recorded via silver-silver chloride electrodes connected to the
tissue preparation via agar-saline / filter paper bridges and was displayed on a
potentiometric chart recorder (Rikadenki). The perfusate containing Krebs with or
without the test drugs was dripped directly onto the tissues at a rate of 1 - l.Smlmin"1.
Drugs were applied at a known concentration via the superfusion stream into the first
compartment with a tissue contact time of 3 - 5min followed by drug washout using




Figure 2.3 (a) Apparatus for recording extracellular changes in membrane potential
from isolated nerves, (b) Layout of recording apparatus. The condnuous chart record
displays the whole nerve membrane potential when recording differentially from
chambers A and B.
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2.4.3 Experimental protocol
An attempt was made to obtain Log concentration-response curves to bradykinin
and des-Arg9-bradykinin (0.01- lOOOOpM). To test the hypothesis that bradykinin
receptors could be induced in the isolated nerves, a protocol was devised where a
single concentration of bradykinin or des-Arg9-bradykinin (O.lpM) was applied
repeatedly over 4 - 5hr; contact time was for 3 - 5min followed by drug washout
using drug-free Krebs for 20min. The effects of superfusing a combination of
bradykinin (O.lpM) and PGE2 (lpM) was also determined. To confirm that the
preparations were indeed capable of showing changes in membrane potential a
depolarising concentration of KC1 (lOmM - lOOmM) was used either before, but more
typically, after perfusion of the test drugs.
2.5 Rat vas deferens preparation
2.5.1 Preparation of isolated vas deferens
Adult male Wistar rats (200-350g) were killed by cervical dislocation and the vasa
deferentia immediately removed. The surrounding connective and adipose tissue and
the adjoining blood vessels were removed from the vas deferens. Only the prostatic
segment (1-1.5cm) of the vas deferens was used in the experiments.
Each prostatic segment was immersed in a 5ml organ bath containing Krebs solution
of the following composition (mM): NaCl 118, KCL 5.4, KH2PO4 1.2, MgS041.2,
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NaHC02 25, glucose 11.1 and CaCl2 2.5. The Krebs solution was gassed with
95% 02 and 5% C02 and maintained at 35°C.
Each prostatic segment was suspended between two parallel platinum electrodes
which were used lor transmural electrical stimulation. Electrical pulses were delivered
by a multi-stimulator (Digitimer System-D330) at a frequency of 0.33Hz, 1msec pulse
duration and at supramaximal voltage. To record isometric muscular contractions, the
segments were connected to a force transducer (Dynamometer UF1) coupled to a
chart recorder (Lectromed MT8-PX).
Prior to electrical field-stimulation or the application of drugs, the tissues were
allowed to equilibrate for 60min with 0.5g of basal tension. During this equilibration
period, the tissues were washed with Krebs solution every 15min and the tension re¬
adjusted to 0.5g.
2.5.2 Agonist / antagonist protocols
Agonists were added to the field-stimulated vas deferens in a cumulative manner.
After completion of a cumulative-concentration response curve, field-stimulation of
the tissues was stopped and the vas deferens washed with Krebs solution every 2min
for lOmin. A further 20min equilibration period (no electrical stimulation) was
allowed before constructing the next cumulative concentration-response curve.
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To evaluate the potency of the bradykinin (BK) antagonists, cumulative
concentration-response curves to BK were constructed in the absence and presence of
the test antagonist. Antagonists were added to the organ baths, in the absence of
electrical stimulation, 20min prior to the construction of the BK concentration-
response curves. Three successively increasing concentrations of antagonist were
equilibrated with the vas deferens, with each concentration of antagonist being
washed out before the addition of the next higher concentration. In another series of
BK antagonist studies, BK cumulative concentration-response curves were
constructed before and after co-incubation of NPC349 (30 and lOOpM) at varying
time periods with Hoe 140 (30nM).
Antagonist washout experiments were performed by constructing cumulative
concentration-response curves to BK before and after the addition of a high
concentration of the BK antagonist. To investigate the specificity of the BK
antagonists in the vas deferens, neurogenic and musculotropic response curves were
constructed to noradrenaline, angiotensin II and U46619 before and after the addition
of the BK antagonists.
In preliminary studies, neurogenic and musculotropic cumulative concentration-
response curves to BK, were constructed before and after prazosin, propranolol,
atropine, mepyramine, ranitidine, thioperamide, ondansetron, GR113808, GR82334,
Menl0207, indomethacin and staurosporine (0.3-lpM). These various agents were
also added (lpM) during basal electrically-evoked stimulation of the rat vas deferens.
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In another series of preliminary experiments, the P2 receptor was desensitised by two
successive additions of a,P-methylene-ATP (lOpM). The effects of basal electrically-
evoked stimulation, BK (lpM), ATP (ImM) and U46619 (lpM) were obtained
before and after inducing tachyphylaxis to a,P-methylene-ATP.
2.5.3 Data analysis
Increases in basal muscle tension (musculotropic response) are expressed as a
percentage of the maximal response that was attained by the test agent. The
potentiations in the magnitude of the electrically-driven twitches (neurogenic
response) are quantified as the percentage of the maximal response above the basal
twitch attained by the test agent. The potency of BK and the B2 receptor agonists at
producing the neurogenic and musculotropic responses are expressed as the
geometric mean (95% confidence limits) of the EC50 (concentration which produces
50% of the maximal response) values.
In the BK antagonist studies, pA2 and slope values were obtained from Schild plots
using a curve fitting program (Baspak, Glaxo Research & Development). Incubation
with Hoe 140 decreased the maximal BK musculotropic response (insurmountable
antagonism) such that conventional Schild analysis could not be used to determine the
potency of the antagonist. Nevertheless, an apparent pKB for Hoe 140 was derived
using a double regression plot (Kenakin, 1984). Essentially, such a plot involves
plotting 1/A vs 1/A' where A and A' are the equieffective concentrations of agonist in
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the absence and presence of Hoel40, respectively. An estimated pKB is then derived
by using the gradient (G) of this plot in the Gaddum Equation (pKB = -log ([B] / G-l),
where B is the antagonist concentration).
2.5.4 Statistical analysis
Experimental values are given as the mean ± s.e.mean. n represents the number of
vas deferens used. For the BK agonist studies, the student's paired t-test was used to
determine statistical differences between the neurogenic and musculotropic EC50
values of each test agent. The un-paired t-test was used to determine statistical
relevance between BK and B2 receptor agonists at the neurogenic and at the
musculotropic responses. For the B2 receptor antagonist studies, the paired t-test was
used to statistically compare the pA2 and slope values at the neurogenic response with
those obtained respectively at the musculotropic response. P values less than 0.05
were considered to be statistically significant.
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SECTION 3




Adjuvant-induced polyarthritis is a widely used and accepted model of arthritis in the
rat, which is associated with chronic pain and inflammation (see Billingham, 1983;
Colpaert, 1987). This form of arthritis is induced by injecting heat-killed mycobacteria
(suspended in mineral oil) into the tailbase or footpad with the resulting arthritis being
a whole-animal disease affecting multiple joints with lesions in the eyes, ears, nose,
skin, tail and genitals as well as profound weight loss (Pearson & Wood, 1959; Ward
& Jones, 1962; Pearson & Wood, 1963; Rainsford, 1982). The severest inflammation
in polyarthritis occurs in the joints of the hind limbs where there is bone destruction,
damage to tendons and loss of cartilage.
Although the use of adjuvant-induced polyarthritis is justifiable in many
neurophysiological, biochemical and immunological studies, in the study of
nociceptive mechanisms the systemic and widespread nature of the arthritis makes it
difficult to attribute observed changes specifically to the arthritis process. There are
also ethical considerations in the use of such severely affected animals. Therefore, it is
desirable both on scientific and ethical grounds to use a less severe and more localised
adjuvant-induced arthritis as an alternative to adjuvant-induced polyarthritis in the
study of nociceptive processes. Recent studies have shown that a discrete
monoarthritis is obtained in rats following the localised injection of Freunds adjuvant
around (subdermally) the ankle joint (Grubb et al., 1991; Donaldson et al., 1993).
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The aims of the present experiments were to verify the induction of monoarthritis in
the rat ankle joint by injecting locally adjuvant around (subdermally) the ankle joint,
and then to further assess this unilateral model of arthritis in behavioural,
histopathological and electrophysiological studies.
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3.2 MATERIALS & METHODS
3.2.1 Adjuvant-induced monoarthritis
Following induction of anaesthesia in male Wistar rats (200 - 250g) using ether or
halothane (2% in oxygen), a total volume of 150pl of Freunds complete adjuvant
(FCA, lmgml1 heat killed mycobacterium tuberculosis, mannide monooleate 0.15ml,
paraffin oil 0.85ml) was injected subdermally at two separate sites (75pl at each site)
around the left ankle joint, and the rats allowed to recover from the anaesthesia. Rats
were housed five to a cage. The development of inflammation was followed for up to
30 days.
Quantitative measurements were obtained of ankle joint circumferences, and foot
withdrawal following the application of pressure to the left (adjuvant-injected) and
right (un-injected) ankle joints. Qualitative measurements were made of joint
inflammation and mobility. Details of these various quantitative and qualitative
measurements are described in Section 2.2.1.
3.2.2 Electrophysiological studies
The in-vivo preparation, neural recording and off-line analysis are described in detail
in Section 2.3. In brief, male Wistar rats (normal and adjuvant-arthritic) were
anaesthetised with urethane and cannulations performed of the trachea, right carotid
artery (blood pressure monitoring) and right femoral artery (retrograde cannulation
for close intra-arterial bolus injection of drugs into left limb). The medial aspect of the
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left ankle joint was exposed and nerve fibres were isolated from the PACR nerve. C-
fibre afferent discharge (spontaneous and mechanically-evoked) from articular
mechanonociceptors was recorded extracellularly, using bipolar platinum-iridium
electrodes.
Afferent mechanosensitive units were identified by exploring the exposed medial
aspect of the left ankle joint using a hand held perpex probe of approximately 1mm
diameter. Quantitative mechanical stimuli were delivered using an electromechanical
indentation generator. Ramp and plateau stimulus waveforms were routinely used
with displacements of between 100-500pm. Indentation stimuli were of two seconds
duration, applied at two minute intervals in order to minimize receptor fatigue. Once a
receptive field had been found, the threshold force needed to activate the
mechanoreceptor was determined by a strain gauge attached to the mechanical probe.
The mechanical probe consisted of a silver wire core isolated from the metal cylinder
casing of 1mm external diameter. This bipolar arrangement of the probe allowed its
use in applying localised electrical stimuli. Conduction velocity (v) was calculated
from the conduction distance (d) measured in situ and the conduction time (t) for the
action potential to travel from the stimulating to the recording electrodes (v = d /1,
ms"1).
3.2.3 Effects of capsaicin on afferent neural discharge
In all the in-vivo electrophysiological recordings from C-fibre afferent
mechanonociceptors in both normal and arthritic joints, chemosensitivity of units was
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tested by a low dose of the C-fibre excitant, capsaicin (lpg, i.a.), injected at the start
and /or end of each experiment. The effects of capsaicin (lpg, i.a.) on mechanically-
evoked discharge was also determined. In preliminary studies, the increase in afferent
neural discharge induced by capsaicin (3pg, i.a.) was investigated before and after
injection of the novel capsaicin receptor antagonist, capsazepine (lmgkg1, i.a.). As
capsazepine has a very short duration of action in-vivo (Dr. M.N. Perkins, personal
communication) it was injected 2 - 5s prior to the injection of capsaicin (3pg, i.a.).
Data analysis
In this series of experiments, capsaicin-induced increase in spontaneous discharge
was assessed by determining the mean peak discharge (determined over 10s) above
the pre-injection control discharge level (see Section 2.3.5.2 for further details of the
formula used) with the delay to onset and the duration of the response also being
determined. The conuol period was defined as the 60s period immediately prior to the
addition of capsaicin. A significant increase in spontaneous discharge was defined as
an increase over basal discharge of greater than 1 i.p.s. for both normal and arthritic
joints. This value of 1 i.p.s. was derived from the results of saline injections in normal
(0.6 ±0.1 i.p.s above basal, 115 units) and arthritic (0.9 ± 0.1 i.p.s. above basal, 198
units) joints. Effects of capsaicin on the responsiveness of the standard mechanical
stimulus were assessed as the peak number of impulses above the pre-injection
evoked discharge. A significant increase in mechanically-evoked discharge was
defined as an enhancement of more than 5 impulses above the pre-injection evoked
discharge. This value of 5 impulses was derived from the results of saline injections in
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normal (2 ± 1 impulses above basal evoked discharge, 65 units) and arthritic (3
impulses above basal evoked discharge, 123 units) joints.
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3.3 RESULTS
3.3.1 Gross pathology and behaviour of monoarthric rats
The subdermal injection of Freunds complete adjuvant (FCA, 150pg) around the left
ankle joint produced a swelling within a few hours. This ankle joint swelling continued
to increase for 1 - 3 days (phase I) post-adjuvant before beginning to subside 4-8
days (phase II) post-adjuvant (Figure 3.1). From 8 days post-adjuvant (chronic phase)
swelling increased over 14 days (phase III), after which a plateau (phase IV) was
reached and maintained (Figure 3.1). These phases were also observed for all the
other measurents / assessments (see Figure 3.1 - 3.4). Ankle joint circumferences of
adjuvant-injected joints were significantly greater than the corresponding ankle joint
circumferences of contralateral un-injected joints (Figure 3.1). Inflammation scores of
adjuvant-injected left ankle joints were significantly higher as compared with scores
from the contralateral uninjected right ankle joints (Figure 3.2). Pressure thresholds
for hind limb withdrawal were significantly lowered in the adjuvant-injected left limb
as compared to the contralateral uninjected right limb (Figure 3.3). A small reduction,
from approximately 11 days and onwards, was observed for the right ankle joint
pressure scores, although these scores were still significantly different from those
measured in the left ankle joint (Figure 3.3). Walking (mobility) left foot placement
scores in rats with adjuvant-injected left ankle joints were significantly higher than the




Figure 3.1 Effects of injecting FCA (150pg) around the left ankle joint on ankle joint
circumferences. Each point is the mean ± s.e.mean from n=16-24. Statistical analysis:





Figure 3.2 Effects of injecting FCA (150pg) around the left ankle joint on ankle joint
inflammation scores. Each point is the mean ± s.e.mean from n=16-24. Statistical






Figure 3.3 Effects of injecting FCA (150pg) around the left ankle joint on hind limb
withdrawal pressure scores. Each point is the mean ± s.e.mean from n= 16-24.
Statistical analysis: P<0.05 ANOVA days 2-9 and 9-29. * P<0.05 Mann Whitney li¬
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Figure 3.4 Effects of injecting FCA (150jj.g) around the left ankle joint on walking
foot placement scores. Each point is the mean ± s.e.mean from n= 16-24. Statistical
analysis: * P<0.05 Mann Whitney U-test, versus right (uninjected) ankle joints.
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3.3.2 Histopathology of adjuvant-induced monoarthritis
Dissection of the left (adjuvant-injected) hind limb revealed the presence of fibrous
tissue, which bound together the inflamed muscles, tendons, fascia and skin. The
capsular tissues around the tibio-tarsal joint were markedly enlarged and thickened. In
contrast, none of these visible features was observed in the uninjected contralateral
hind limb.
3.3.3 In-vivo electrophysiology of normal and adjuvant-arthritic joints
Mechanosensitive receptive fields of the rat ankle joint were identified by mechanical
probing with a blunt hand-held perspex probe. In both nonnal and arthritic joints,
individual mechanosensitive units were represented by only a single receptive field,
each being approximately 1 - 2mm in diameter. In order to give a standard mechanical
stimulus (every 2min) a mechanical indentation generator was used; the mechanical
stimuli were of ramp and plateau waveform. Repetition (2min apart) of mechanical
stimuli led to a slow steady decline in the unit response with time. The responses of
mechanosensitive units in arthritic joints to repeatedly applying mechanical stimuli
were generally more susceptible to fatigue than units recorded from normal joints.
From 30 normal joints, 68 slowly adapting mechanosensitive units, with receptive
fields in the ankle joint, were identified. In contrast, an approximately three-fold
greater number (223 units from 30 joints) of slowly adapting mechanosensitive units
were identified in arthritic joints. The mechanical activation thresholds of
mechanoreceptors in normal joints were generally high, whereas in contrast,
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Figure 3.5 Mechanical activation thresholds for mechanonociceptors in normal (115
units from 89 experiments) and arthritic (198 units from 128 experiments) ankle joints
obtained using a stainless steel mechanical probe (tip diameter 1mm) with attached
strain gauge (see Section 2.3.4).
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in arthritic joints were easily found and could be activated by the application of light
mechanical pressure, whereas in normal joints the higher mechanical activation
thresholds often made finding receptive fields difficult, with compression of the
articular tissues against the underlying bone often being the only effective stimulus.
The mean afferent conduction velocity was in the C-fibre afferent range for all units
examined both in normal (0.70 ± 0.49 ms"1; range 0.22 - 1.50 ms"1, 58units) and
arthritic (0.76 ± 0.54 ms"1; range 0.20 - 1.35 ms"1, 76units) joints. No significant
difference was found between the afferent conduction velocities in normal and
arthritic joints (P>0.05, Mann Whitney U-test).
Single afferent units studied in normal joints had low levels of resting (spontaneous)
discharge from mechanonociceptors (0.96 ±0.09 i.p.s.; range: 0 - 1.8, 115units). In
contrast, spontaneous discharge was significandy greater (approximately 3 fold, 3.40
± 0.46 i.p.s.; range: 1.4 - 11.6, 198units) in single unit afferents recorded from
arthritic joints (P<0.05, Mann-Whitney U-test in comparison with normal joints).
Afferent units in both normal and arthritic joints generally had action potential
amplitudes of <40pV and spike widths of 2- 3ms.
3.3.4 Effects of capsaicin on mechanonociceptor discharge in normal and
arthritic joints
In order to test the chemosensitivity of C- fibre afferent mechanonociceptors, a close
arterial injection of a low dose of the selective C-fibre excitant, capsaicin (lpg), was
82
made. In the vast majority (> 95%) of units recorded in both normal and arthritic
joints, capsaicin caused an increase (excitation) in spontaneous discharge (see typical
response in Figure 3.6 & pooled data in Table 3.1). The small percentage (<5%) of
units which were apparently capsaicin (1 - 30pg, i.a.)-insensitive but responsive to
mechanical stimuli were not examined further in the present studies. Capsaicin-
induced excitation from mechanonociceptors in arthritic joints was significantly
greater and of longer duration than that obtained from mechanonociceptors in normal
joints (Table 3.1). Capsaicin (lpg, i.a.) also caused an increase in the responsiveness
(sensitisation) of mechanonociceptors to the application of the standard mechanical
stimulus in approximately 60% and 70% of units examined in normal and arthritic
joints, respectively (typical response in Figure 3.6 and pooled data in Figure 3.7);
there was either a slight decrease (< 5 impulses) or no change in the mechanical
responsiveness in the remaining percentage of units studied. The capsaicin-evoked
mechanical sensitisation in arthritic joints was significantly larger (Figure 3.7) and of
longer duration (Figure 3.8) than that observed in joints from normal rats.
3.3.5 Effects of capsazepine
In preliminary studies, both the capsaicin (3pg, i.a.)-induced excitation, and the
sensitisation of mechanically-evoked responses recorded in two units (two
experiments) from arthritic joints, were antagonised by the capsaicin receptor
antagonist, capsazepine (lmgkg"1, i.a.) (Figures 3.9 - 3.10). Since capsazepine was
injected 2 - 5s prior to the injection of capsaicin (because it has a short duration of
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Figure 3.6 Computer generated plot showing capsaicin (lpg, i.a.)-induced excitation
and sensitisation of a single C-fihre unit in the (a) normal (conduction velocity
0.5ms"1) and (b) arthritic (conduction velocity 0.7ms"1, 16 days post-adjuvant) rat
ankle joint. Each bar represents a Is time interval. Arrowheads indicate the
application of the mechanical stimulus. The number of impulses evoked by the
mechanical stimulus is given above each response. The insets show fast oscilloscope
sweeps of the unit counted.
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Table 3.1 Effects of capsaicin (lpg, i.a.) on spontaneous discharge recorded
from articular mechanonociceptors in normal and arthritic rat ankle joints.
mean peak delay
units increase above to
(experiments) basal dicharge onset duration
(i.p.s.) f (s) (s)
normal joints 115 (89) 6.88 ± 0.95 1.58 ±0.17 11.27 ±0.62
arthritic joints 198 (128) 12.55 ±1.93* 1.51 ± 0.13 16.12 ±1.69*
* P<0.05 Mann Whitney U-test, versus value for normal joint, f mean discharge was
determined over a 10s time period. The pre-injection basal spontaneous discharge











Figure 3.7 Capsaicin (lpg, i.a.)-induced enhancement in the responsiveness to the
mechanical stimulus of mechanonociceptors in normal (65units from 40 experiments)
and arthritic (123units from 80 experiments) ankle joints. The pre-injection
mechanically-evoked discharge was 44 ± 5 and 39 ± 4 impulses for units recorded in







time (s) of indent post-capsaicin (1 pig)
Figure 3.8 Duration of capsaicin (lpg, i.a.)-induced sensitisation of mechano-

















time (s) post-injection capsaicin (3(ig)
Figure 3.9 Effects of capsaicin (3pg, i.a.), before and after capsazepine (lmgkg"1, i.a.), on
(a) spontaneous and (b) mechanically-evoked discharge from a single C-afferent fibre unit
(conduction velocity 0.33ms'1) in an arthritic (40 days post-adjuvant) ankle joint. The pre-injection
spontaneous discharge, was 4.2 i.p.s pre-capsaicin and 5.1 i.p.s pre-capsaicin in the presence of
capsazepine. The pre-injection mechanically-evoked discharge, was 104 impulses pre-capsaicin and
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Figure 3.10 Effects of capsaicin (3pg, i.a.), before and after capsazepine (lmgkg1), on
(a) spontaneous and (b) mechanically-evoked discharge from a single C-afferent fibre unit
(conduction velocity 0.50ms"1) in an arthritic (33 days post-adjuvant) ankle joint. The pre-injection
spontaneous discharge, was 1.6 i.p.s pre-capsaicin and 1.9 i.p.s pre-capsaicin in the presence of
capsazepine. The pre-injection mechanically-evoked discharge, was 32 impulses pre-capsaicin and
30 i.p.s pre-capsaicin in the presence of capsazepine. Note the capsaicin-induced desensitisation of
the response to first mechanical stimulus post-capsaicin (b).
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determine the effects of capsazepine itself on afferent neural discharge in these two
units. Nevertheless, once neural discharge had returned to pre-capsazepine values a
further injection of capsazepine (lmgkg1, i.a.) was made with the assumption that the
initial capsazepine was no longer active. This second injection of capsazepine had no
effect on either spontaneous (3.5 ± 1.5 i.p.s. pre-capsazepine versus 3.6± 1.5 i.p.s.
post-capsazepine) or mechanically-evoked (65 ± 35 impulses pre-capsazepine versus
66 ± 33 impulses post-capsazepine) discharge in the two units examined.
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3.4 DISCUSSION
3.4.1 Gross pathology and behaviour of adjuvant-induced monoarthritic
rats
The results of the present investigation confirm previous reports (Grubb et al., 1991;
Donaldson et al., 1993) that a local injection (subdermally) of low dose Freunds
adjuvant around a rat ankle joint induces an arthritis which remains confined to the
injected joint, thus allowing the contralateral (uninjected) joint to be used as a within-
animal control. Moreover, since the animals showed no other obvious systemic
lesions, this monoarthritic model has advantages in terms of data interpretation, as any
observed changes are more likely to be directly due to the inflammatory process itself.
In contrast to these results, adjuvant-induced polyarthritis has a much more severe
and widespread pathology; various joints are affected (particularly the hind limbs) and
there is lesions in the eyes, ears, nose, skin, tail and genitals (Pearson & Wood, 1959;
Ward & Jones, 1962; Pearson & Wood, 1963; Rainsford, 1982). In the current
investigation, the localised nature of the adjuvant-induced arthritis is a result of the
low dose (150pg) of adjuvant used (Ward & Jones, 1962; Donaldson et al., 1993) and
the subdermal site of injection around the ankle joint (Billingham, 1983; Donaldson et
al., 1993). Moreover, it has been shown by Donaldson et al. (1993) that by increasing
the dose of adjuvant injected around the rat ankle joint to 250pg, a bilateral ankle
joint arthritis can be induced. Thus, the method of injecting adjuvant locally around
the ankle joint of the rat offers advantages in terms of experimental protocol as the
degree of inflammation, whether uni- or bilateral, is simply determined by the dose of
adjuvant injected.
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In the present investigation two measurements (one quantitative, the other
qualitative) indicative of mechanical hyperalgesia were made in adjuvant-induced
monoarthritic rats. In the quantitative measurement, the pressure threshold for paw
withdrawal in response to the application of direct pressure on the ankle joints was
determined. The results from this test for mechanical hyperalgesia showed that the
pressure required to evoke withdrawal of the limb was markedly reduced on the
injected joint as compared to the contralateral uninjected joint (Figure 3.3). In
agreement with this result, it has been shown that in polyarthritic rats direct pressure
on the inflamed hind paw as in the Randall-Selitto test (Hirose & Jyoyama, 1975;
Winter, 1979; Kayser & Guilbaud, 1981, 1983; Hara el al., 1984; Butler et al., 1985;
Calvino & Le Bars, 1986) or by flexion of the arthritic ankle joint (Kuzuna & Kawai,
1975) causes hind limb withdrawal (mechanical hyperalgesia). Subjective
measurements of foot placements (mobility) were made in order to obtain a measure
of any mechanical hyperalgesia. Such a subjective measurement has the advantage that
there is no need to either handle or restrain the rat, and thus the degree of stress is
minimised. The significant reduction in the use of the chronically inflamed joint as
shown by the subjective walking foot placement scores (Figure 3.4) probably reflects
the reluctance of animals to experience the acute discomfort in the ankle joint
associated with walking and load bearing.
It has been shown by Donaldson et al. (1993) that the gain in body weight of rats
with a localised adjuvant-induced arthritis is not significantly different from that in
untreated control rats. This result provides further evidence of the mild nature of
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adjuvant-induced monoarthritis. In contrast, polyarthritic rats have been reported to
show a profound loss of body weight (Pearson & Wood, 1959; Rainsford, 1982).
Following the injection of adjuvant around the rat ankle joint, the time course of
the various parameters measured / assessed displayed four phases (Figures 3.1 - 3.4).
For example, the limb circumference of the injected joint showed an initial increase
(phase I: 1-3 days post-adjuvant) which then declined (phase II: 4-8 days post
adjuvant) but then began to increase again (phase III: 8-18 days post-adjuvant) until a
plateau was reached and maintained (phase IV: > 18 days post-adjuvant). These four
phases are similar to those observed by investigators using adjuvant-induced
monoarthritis (Birrell et al., 1990; Donaldson et al., 1993) or polyarthritis (see
Rainsford, 1982; Billingham, 1983; Calvino et al., 1987). No studies to date have
been done using the monoarthritic model to ascertain if these phases can be correlated
to particular changes in the immune system. However, it has been shown in adjuvant-
induced polyarthritis that different components in the immune system can be
correlated with changes in inflammation and mechanical hyperalgesia. For example, it
has been shown that lymphocytes play a major role in the early inflammation and
hyperalgesia of adjuvant-induced arthritis (Burnstein & Waksman, 1964). The chronic
phase of inflammation has been attributed to the increasing involvement of
macrophages, monocytes and synoviocytes (Burnstein & Waksman, 1964). In the
present study, there was a transient reduction in inflammation and hyperalgesia 4-8
days post adjuvant (phase II). This reduction, which requires investigation, may be
explained by the gradual replacement of lymphocytes with macrophages and the
involvement of synoviocytes and fibroblasts. In addition it has been shown that serum
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albumin levels rise during this remission of acute inflammation (Billingham, 1983).
Clearly, studies are required to determine the precise interactions between
lymphocytes, macrophages and other cells (e.g. fibroblasts), the influence of
inflammatory mediators (e.g. cytokines), which underlie each phase in adjuvant-
induced poly- and mono-arthritis.
3.4.2 Histopathology of monoarthritic joints
Examination (by Mr H. F. Littlewood, Dr. P. Pilling and Mr. B. Reed, Department
of Pathology, Glaxo Research & Development) of histological sections of the tibio-
tarsal joints from rats with localised adjuvant-induced arthritis showed the presence of
inflammatory cell infiltrate, synovial proliferation, fibroplasia, oedema and new bone
formation (data not shown in this thesis). Such histopathogical features are
substantially less severe than those associated with adjuvant-induced polyarthritis
(Pearson & Wood, 1959). Moreover, bony ankylosis and joint deformation which
occur in polyarthritis are not found in the monoarthritic model. Importantly,
histological features of arthritis were localised to the injected joint with the
contralateral uninjected tibio-tarsal joint showing a normal histological appearance
(data not shown). Thus, the contralateral uninjected joint can be used as a within
animal control.
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3.4.3 In-vivo electrophysiology in normal and adjuvant-induced arthritic
joints
The response characteristics of the high threshold slowly adapting articular
mechanonociceptors found in the present investigation in rat ankle joints are similar to
those reported previously in the rat ankle joint (Guilbaud et al., 1985; Grubb et al.,
1988; Birrell et al., 1990; Grubb et al., 1991). The conduction velocities of all
articular afferenls were in the C-fibre range (< 1.5ms"1); there was no difference
between conduction velocities obtained in normal joints and those from arthritic
joints. In normal joints, mechanonociceptors exhibited little or no resting
(spontaneous) discharge. In agreement with this result, little or no resting activity was
seen in articular afferent units studied in normal rat ankle joints (Guilbaud et al., 1985;
Grubb et al., 1988; Birrell et al., 1990; 1993) or in normal cat knee joints (Coggeshall
et al., 1983; Grigg et al., 1986; Schaible & Schmidt, 1985; 1988). In contrast to
normal ankle joints, the results of the present investigation from articular
mechanonociceptors in chronically inflamed (adjuvant-arthritic) joints showed greater
(approximately 3 fold) levels of spontaneous discharge. Such inflammation-induced
elevations in spontaneous C-fibre afferent discharge has also been reported in many
preparations including chronically inflamed (adjuvant-induced) rat ankle joints
(Guilbaud et al., 1985; Grubb et al., 1988; Birrell et al., 1990; 1993), acutely inflamed
(via intra-articular injection of kaolin and carrageenan) cat knee joints (Coggeshall et
al., 1983) and in inflamed (induced by carrageenan or ultra-violet radiation) muscle
(Berberich et al., 1988) and skin (Kocher et al., 1987; Szolcsdnyi, 1987).
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Mechanical activation thresholds of mechanonociceptors in arthritic joints were
generally lower than those in normal joints (Figure 3.5). Similarly, it has been reported
by Schaible & Schmidt (1983a,b,; 1988) that nociceptors in the normal cat knee
respond mainly to intense mechanical stimuli, to extreme flexion or extension and to
joint rotation, whereas in contrast, there was a sensitisation to mechanical stimuli in
the inflamed joint. Moreover, in these studies by Schaible & Schmidt, units in normal
joints that were initially mechanoinsensitive became responsive to mechanical stimuli
following inflammation of the joint. Therefore, it appears that during inflammation
there is recruitment of mechanoreceptors which in normal tissues are unresponsive to
mechanical stimuli. Such receptors have been termed 'silent or sleeping nociceptors'
or more appropriately by Iggo (1988) as 'inflammation receptors'. The elevated
resting discharge and mechanical sensitisation of mechanonociceptors seen in
chronically-inflamed joints of the present investigation suggests that these altered
neural discharges are important for the development of inflammatory pain and
mechanical hyperalgesia. In subsequent sections of this thesis, the role of bradykinin,
purines and adrenoceptor agents in altering the elevated neural discharges in
chronically inflamed (adjuvant-induced arthritic) joints will be determined.
Electrophysiological recordings from rat articular (ankle joint) C-fibres obtained
previously in this laboratory have established using peristimulus time histogram
analysis that the majority (> 95%) of C-fibres from normal or arthritic ankle joints
adapt slowly to steady mechanical indentation (see Guilbaud et al., 1985; Birrell,
1990; Grubb et al., 1991). A dynamic discharge during the application of the ramp
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stimulus (indent) was followed by a static phase (slowly declining discharge) during
the plateau of the mechanical indentation. On withdrawal of the probe there was an
abrupt termination of the discharge (i.e. there was no after discharge). In the current
investigation, the ability of articular C-fibres to adapt to mechanical stimuli was not
studied in detail using peri-stimulus time histograms since previous investigators
(McQueen, Grubb & Birrell) in this laboratory found it to be time consuming and did
not show any change in response to the drugs being studied. Nevertheless, a visual
analysis of the time interval between spikes was made routinely using a fast sweep of
the oscilloscope face. Such visual analysis confirmed previous findings in this
laboratory that C-fibres innervating rat ankle joints adapt slowly to mechanical
indentation with dynamic and static phases; these two phases were still present even
after the administration of the drugs used in this investigation (see Sections 3 - 7).
It is possible that the increase in spontaneous discharge and reduction of mechanical
activation thresholds seen in single afferent units from arthritic joints were not due to
a change in the excitability of mechanonociceptors but was secondary to changes in
the mechanical properties of the inflamed joint. For example, in the arthritic joint there
may have been more turgidity, tension and stiffness of the tissue such that pressure is
applied more effectively to the individual mechanonociceptor. However, such
inflammation-induced changes in tissue properties are unlikely to fully account for the
large differences between activation thresholds between normal and arthritic joints
(see Figure 3.5). It could also be argued that in the inflamed joint there is more
connective tissue such that it becomes necessary to apply even more pressure to
mechanically activate the mechanonociceptor. In effect this means that the activation
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thresholds for units in arthritic joints are overestimates, and thus represents an even
larger difference between normal and arthritic joints (see Figure 3.5).
It is impossible to say whether or not the chronic increase in mechanonociceptor
discharge / reduction in mechanical activation threshold seen in arthritic joints of the
rat leads to what is known as pain / hyperalgesia in man. However, elevations in
mechanonociceptor discharge recorded from arthritic joints can be correlated with the
results of behavioural studies by the application of Occams razor. For example, the
reduction in latency of withdrawal of the arthritic rat hind limb following mechanical
stimuli to the rat ankle joint (indicating nociception / hyperalgesia) can be related with
the reduced mechanical activation thresholds seen in units recorded from arthritic
joints. In humans, microneuropathy studies have correlated the 'pain' sensation of
nociceptor C-fibre activation with its increase in neural discharge.
The elevations in receptor discharge seen in arthritic joints can also play a part in the
inflammation process via the axon reflex (neurogenic inflammation). Essentially the
axon-reflex involves antidromic stimulation of the primary afferent neurone; one
branch of the neurone is regarded as the input side (via the nociceptor) and the other
branch as the effector site where neuropeptides (e.g. substance P, neurokinin A and
calcitonin-gene-related peptide) are released, following stimulation of the nociceptor,
to act on target cells (e.g. mast cells) to generate an inflammatory response (see
Foreman, 1987). Thus, via this axon-reflex-induced release of neuropeptides from the
afferent neurone, elevations in receptor discharge are likely to contribute to the
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changes seen in the behavioural studies such as enhanced limb circumference,
increased inflammation and mechanical hyperalgesia.
3.4.4 Effects of capsaicin on mechanonociceptor discharge in normal and
arthritic joints
Studies which examine the effects of drugs on sensory receptors using intra-arterial
injection rely on access to the receptor terminals via the local microvasculature. One
problem of such a route of drug administration is that if a sensory receptor is not
excited then it is difficult to tell if this is a result of the drug being inactive or not
reaching the receptor site. Thus, in order to test the responsiveness of sensory
receptors a chemical known to cause sensory receptor excitation is required.
Although injection of KC1 causes sensory receptor excitation, it is unsuitable as its
excitatory action is not selective for C-fibre afferents. The pungent constituent of hot
peppers, capsaicin, has been used extensively as an agent which selectively excites C-
fibre afferents (see Szolcsanyi, 1993; Dray & Dickenson, 1993). In the current
investigation, close arterial injection of capsaicin potently excited (high discharge,
rapid onset and short response duration) articular mechanonociceptors. Therefore,
capsaicin can be used as a suitable pharmacological probe to test the chemosensitivity
of articular mechanonociceptors.
In the present investigation, capsaicin-induced increases in spontaneous and
mechanically-evoked discharge were of greater magnitude and of longer duration in
arthritic joints than in normal joints (Table 3.1, Figure 3.7 - 3.8). In agreement with
these results, Birrell (1990) also reported an enhanced sensitivity of
99
mechanonociceptors to capsaicin in the arthritic ankle joint. Such an enhanced
responsiveness to capsaicin in the inflamed joint may be a result of the presence of
inflammatory mediators such as prostanoids or neuropeptides. Indeed, it has been
shown in the neonatal rat spinal-cord preparation that PGEi and PGE2 markedly
potentiate capsaicin-induced ventral depolarisation via an effect on peripheral nerve
endings (Yanagisawa et al., 1986). Moreover, capsaicin has been shown to release
neuropeptides (e.g. substance P) from sensory terminals in the periphery, which in
turn can also cause the release of mediators such as prostanoids or 5-HT (see Holzer,
1988).
Capsaicin-induced desensilisation has been extensively reported for C- fibre afferent
nociceptors (see Dray & Dickenson, 1993; Szolcs&nyi, 1993). Such desensitisation
was not observed in the present studies as only a low dose of capsaicin (lpg) was
used in the experiments. Nevertheless, desensitisation of capsaicin-induced elevations
in spontaneous and mechanically-evoked discharge have been shown in rat ankle joint
mechanonociceptors when higher doses of capsaicin (10 - 30pg) are used (Birrell,
1990).
3.4.5 Preliminary studies of the effects of capsazepine
Recently, development of the novel capsaicin receptor antagonist, capsazepine, has
provided convincing evidence for the existence of a capsaicin receptor (Dray &
Dickenson, 1993; James et al., 1993; Walpole & Wrigglesworth, 1993). Capsazepine
has been shown to be a highly selecdve antagonist of capsaicin-induced activation of
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nociceptors both in-vitro (Bevan, 1991; Dickenson & Dray, 1991; Maggi et al., 1993)
and in-vivo (Dickenson & Dray, 1991; Perkins & Campbell, 1992). In line with these
studies, the current preliminary investigation showed that capsazepine antagonised the
effects of capsaicin on both spontaneous and mechanically-evoked discharge of
articular mechanonociceptors. Capsazepine itself appeared to have no effect on
spontaneous or mechanically-evoked discharge. In agreement, other investigators also
report a lack of direct effect of capsazepine on nociceptor activity (Dickenson &
Dray, 1991; Perkins & Campbell, 1992). Thus, it is unlikely that capsaicin antagonists
per se will be of use as analgesics.
3.5 SUMMARY
A monoarthritis was induced in the ankle joint of the rat by a localised injection of
Freunds complete adjuvant. Such a model has scientific and ethical advantages over
the polyarthritis model as only mild features of arthritis occur unlike the systemic
disease seen in adjuvant-induced polyarthritis. Moreover, since arthritis is only present
in the injected ipsilateral joint, this allows the uninjected contralateral joint to be used
as a 'within-animal' control.
Electrophysiological recordings from C-fibre mechanonociceptors in adjuvant-
arthritic joints showed higher levels of spontaneous discharge and lower mechanical
activation thresholds than did those from normal joints.
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Since close arterial injection of the selective C-fibre excitant, capsaicin, excited
mechanonociceptors it can be used as a pharmacological probe to test the accessibility
of chemosensitive C-fibre afferents via the blood supply. In preliminary studies, the
novel selective capsaicin receptor antagonist, capsazepine, antagonised capsaicin-
induced enhancements in spontaneous and mechanically-evoked discharge.




EFFECTS OF INDOMETHACIN IN NORMAL AND ADJUVANT-ARTHRITIC




In humans, disease states such as arthritis are characterised by pain, inflammation,
and hyperalgesia, a state in which normally innocuous movement of limbs causes pain.
In various animal behavioural models of nociception and hyperalgesia, sensitisation to
mechanical stimuli (pressure, flexion / extension) have been observed. For example,
behavioural investigations of rats with adjuvant-arthritis have established that the
tibio-tarsal joints of the hind limbs of these animals become very sensitive
(hyperalgesic) to mechanical stimuli (Kuzuna & Kawai, 1975; De Castro et al., 1981;
Colpaert et al., 1982; Kayser & Guilbaud, 1983).
In electrophysiological studies, neural activity (spontaneous and mechanically-
evoked) has been recorded from primary afferent C- and A8-fibres innervating normal
and chronically arthritic rat ankle joints. The joint capsule of the rat ankle joint
contains high threshold mechanoreceptors (Guilbaud et al., 1985) which are classified
as type IV articular receptors having a nociceptive function (Wyke, 1981). In normal
rat joints, such sensory articular receptors respond only to intense mechanical stimuli,
and spontaneous discharge is either absent or very low (Guilbaud et al., 1985;
Guilbaud & Iggo, 1985; Birrell et al., 1990; Grubb et al., 1991; McQueen et al.,
1991). In contrast, articular mechanoreceptors in poly- or mono-arthritic ankle joints
become sensitised to mechanical stimuli, and afferent fibres show higher levels of
spontaneous discharge as compared to normal joints (Guilbaud & Iggo, 1985;
Guilbaud et al., 1985; Birrell et al., 1990; Grubb et al., 1991; McQueen etal., 1991;
see also Section 3). Raised resting (spontaneous) discharge and enhanced discharge to
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mechanical stimuli from articular mechanonociceptors have also been demonstrated in
the cat following inflammation of the knee joint (Coggeshall et al., 1983; Grigg et al.,
1986; Schaible & Schmidt, 1985; Schaible & Schmidt, 1988).
One of the most commonly prescribed group of agents for treating the pain,
hyperalgesia and inflammation found in inflammatory states such as rheumatoid
arthritis are the non-steroidal anti-inflammatory drugs (NSAIDs). The various
NSAIDs available vary considerably in their ability to produce analgesia and in their
anti-inflammatory properties (Rang & Dale, 1991). Indomethacin is a NSAID which
has both analgesic and anti-inflammatory actions (Rang & Dale, 1991), and is used for
the treatment of rheumatic disorders (Hellberg, 1981; Seideman & Eriksson, 1988;
Seideman & Melander, 1988).
The aims of the present investigation were two-fold. Firstly, an electrophysiological
study to determine the ability of indomethacin to modify neural discharge
(spontaneous and mechanically-evoked) from fine articular afferents innervating
normal joints, and in joints with Freunds adjuvant-induced chronic monoarthritis.
Secondly, a behavioural study, in order to examine the effects of indomethacin on
parameters of hyperalgesia and inflammation in rats with an established localised
arthritis induced by Freunds adjuvant.
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4.2 MATERIALS & METHODS
4.2.1 Electrophysiological studies
The in-vivo preparation, neural recording, off-line analysis and statistical analysis are
described in detail in Section 2. In brief, male Wistar rats (normal and adjuvant-
arthritic) were anaesthetised with urethane and cannulations performed of the trachea,
right carotid artery (blood pressure monitoring) and right femoral artery (retrograde
cannulation for close intra-arterial bolus injections of drugs into the left limb). The
medial aspect of the left ankle joint was exposed and nerve fibres were isolated from
the PACR nerve. C-fibre afferent discharge (spontaneous and mechanically-evoked)
from articular mechanonociceptors was recorded extracellularly, using bipolar
platinum-iridium electrodes.
Protocol
A single close intra-arterial injection of indomethacin (lOmgkg"1) was made in either
normal rats or in rats with chronic adjuvant-induced monoarthritis. This dose of
lOmgkg"1 is consistent with that used once daily by other investigators in the rat
(lOmgkg"1, i.v.: Ferreira et ah, 1978; 8mgkg~' i.v.: Jurna & Brune, 1990; lOmgkg"1
s.c.: Novo et ah, 1992).
Data analysis
Mechanically-evoked neural discharge was quantified as the number of impulses per
stimulus. The reduction in spontaneous discharge induced by indomethacin was
quantified by averaging discharge over successive 100s time periods (i.e. between
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mechanical indentations). The control period of spontaneous discharge was defined as
the 60s period immediately prior to the injection of indomethacin.
4.2.2 Behavioural studies
The effects of injecting indomethacin (bolus injection i.p. once daily, 0.5mgkg"') in
rats with established (14 days post-adjuvant) localised Freunds adjuvant-induced
arthritis of the left ankle joint was examined. Rats were subjected to a series of
quantitative tests involving the measurement of ankle joint circumferences, and foot
withdrawal following the application of pressure to the left (adjuvant-injected) and
right (un-injected) ankle joints. Qualitative tests were also performed to obtain
measurements of inflammation and mobility of the left (adjuvant-injected) and right
(un-injected) ankle joints. The various measurements were made approximately 30min
after drug injections. Rat body weight was used as a general indicator of animal
health. All measurements were made blind to drug treatment by the same experienced
investigator. The various quantitative and qualitative tests and the statistical analysis
are described in detail in Section 2.2.1
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4.3 RESULTS
4.3.1 In-vivo electrophysiology in normal and adjuvant-arthritic rat ankle
joints
The effects of indomethacin, were examined in six units (six experiments) from
normal joints and in six units (six experiments) from adjuvant-arthritic (21 ± 2 days
post-adjuvant) joints. The mean afferent conduction velocity was in the C-fibre range
for units examined either from normal (0.66 ±0.15; range: 0.22 - 1.30) or arthritic
(0.70 ± 0.13; range: 0.20 - 1.20ms"1) joints. There was no significant difference
between the afferent conduction velocities of units in normal joints with those in
arthritic joints (P>0.05, Mann Whitney U-test). Before the addition of any drugs, all
units showed resting (spontaneous) discharge, although these were significantly
greater (P<0.05, Mann Whitney U-test) in units from arthritic joints (4.58 ± 1.07
i.p.s.; range:1.4 - 8.0 i.p.s.) than in those from normal joints (1.03 ± 0.58 i.p.s.; range:
0.5 - 1.3 i.p.s.). All the units examined were excited by close intra-arterial injection of
capsaicin (1 - 3pg).
4.3.1.1 Effects of indomethacin on mechanonociceptor discharge from
arthritic joints
4.3.1.1.1 Effects of indomethacin on spontaneous mechanonociceptor discharge
Compared to pre-injection discharge levels, injection of indomethacin (lOmgkg1,
1.a.) caused a significant reduction in ongoing (spontaneous) discharge in all six units











































































































reduction and pooled data in Figure 4.2). As reflected in the standard errors in
Figure 4.2, the indomethacin-induced reduction in spontaneous discharge varied
between experiments. This variability is a consequence of pooling data that have a
wide range of basal values, coupled with the observation that individual
mechanoreceptors differed in their responsiveness to indomethacin: all showed
depression of spontaneous discharge, but the magnitude of the reduction and the time
course was variable. Consequently, in order to eliminate inter-experiment variability
attributable to differing basal values, the data were normalised as a percentage of the
pre-injection control values. Plotting the data in this way shows that indomethacin
caused similar reductions (Figure 4.2). In comparison with vehicle injections,
indomethacin caused a significant reduction in spontaneous discharge (Figure 4.3).
The indomethacin induced reduction in spontaneous discharge had a mean latency to
onset of 2.7 ± 0.67min (range: 2 - 4min). After injection of indomethacin,
spontaneous discharge reached a mean minimum value to 24% (range 0 - 50%) of the
pre-injection control level (100%), after a delay of 15 ± 4min (range: 12 - 24min).
4.3.1.1.2 Effects of indomethacin on mechanically-evoked discharge
Injection of indomethacin (lOmgkg1, i.a.) caused a significant reduction in
mechanically-evoked discharge in all six units (six experiments) examined (see Figure
4.1 for a typical indomethacin-induced reduction). As described previously
(Section 4.2.1.1.1), in order to eliminate inter-experiment variability attributable to
differing basal values (Figure 4.4), the data were normalised as a percentage of the
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Figure 4.2 Effects of injecting indoraethacin (lOmgkg1, i.a.) on spontaneous
discharge from articular mechanonociceptors in arthritic ankle joints. Basal (a) and
normalised (b, dashed line represents the pre-injection response: 100%) values are
shown. Each point is the mean ± s.e.mean from n=6 units (6 experiments). * P<0.05,
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Figure 4.3 Normalised data showing the effects of injecting indomethacin (lOmgkg1
i.a. 0.3 - 0.5ml, n=6 units: 6 experiments) or vehicle (0.5ml, n=6 units: 4 experiments)
on spontaneous discharge from articular mechanonociceptors in arthritic ankle joints.
The dashed line represents the pre-injection response (100%). Each point is the mean
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Figure 4.4 Effects of injecting indomethacin (lOmgkg1, i.a.) on the discharge evoked
by mechanical stimulation of articular mechanonociceptors in arthritic ankle joints.
Basal (a) and normalised (b, dashed line represents the pre-injection response: 100%)
values are shown. Each point is the mean ± s.e.mean from n=6 units (6 experiments).
* P<0.05, Wilcoxon test, versus pre-injection control discharge.
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pre-injection control values. Plotting the data in this way shows that indomethacin
caused similar reductions in mechanically-evoked discharge (Figure 4.4). In
comparison with vehicle injections, indomethacin significantly produced a decrease in
the responsiveness of the standard mechanical stimulus (Figure 4.5)
The indomethacin-induced reduction in the responsiveness to the standard mechanical
stimulus had a mean latency to onset of 5 ± 2min (range: 2 - 12min).
Mechanoreceptor responsiveness reached a mean minimal value to 45% (range 0 -
68%) of the pre-injection control following a mean delay period of 32 ± 4min (range:
26 - 36min).
4.3.1.1.3 Duration of indomethacin-induced depression in mechanonociceptor
discharge
As the preparations were used for other experiments between 42-44min post-
injection of indomethacin (see Section 7.3.6), the lime in which spontaneous and
mechanically-evoked discharge returned to pre-injection control discharge values
could not be determined. Nevertheless, spontaneous and mechanically-evoked
discharge 90-100min post-injection of indomethacin (bradykinin l-3()pg, i.a. was
injected 40-70min after indomethacin) were depressed by 75 ± 8% and 51 ± 7%,
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Figure 4.5 Normalised data showing the effects of injecting indomethacin (lOmgkg"1
i.a. 0.3 - 0.5ml, n=6 units: 6 experiments) or vehicle (0.5ml, n=6 units: 4 experiments)
on the discharge evoked by mechanical stimulation of articular mechanonociceptors in
arthritic ankle joints. The dashed line represents the pre-injection response (100%).
Each point is the mean ± s.e.mean. * P<0.05, Mann Whitney U-test, versus vehicle.
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4.3.1.2 Effects of indomethacin on mechanonociceptor discharge from
normal joints
Compared to pre-injection discharge levels, indomelhacin (lOmgkg1) had no effect
on either spontaneous discharge (Figure 4.6) or on the responsiveness to the standard
mechanical stimulus (Figure 4.7) in any of the six units (six experiments) examined.
4.3.2 Influence of indomethacin on an established adjuvant-induced
arthritis in the rat
The subdermal injection of Freunds adjuvant (0.15mg: 0.15ml of lmgrnl"1 solution)
around the left ankle joint resulted in a swelling, hyperalgesia and inflammation of the
joint which became established around 10-14 days post-injection of adjuvant (see
Section 3). In indomethacin-treated rats, there were reductions in the circumference
(Figure 4.8) and inflammation (Figure 4.9) of the arthritic ankle joint, and in the
mobility of the left hind limb (Figure 4.10) as compared with vehicle-treated rats.
Indomethacin also caused a significant increase in the pressure required to cause
withdrawal of the adjuvant-arthritic left hind limb (Figure 4.11). Indomethacin had no
significant effect (P>0.05) on circumference, and on inflammation, mobility and paw
withdrawal pressure scores, of the contralateral (un-injected) ankle joint (data not
shown). Indomethacin-treated rats showed significant weight gains as compared with
vehicle-treated rats (Figure 4.12).
In general, it was found that the effects of indomethacin on the various parameters
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Figure 4.6 Effects of injecting indomethacin (lOmgkg1, i.a.) on spontaneous
discharge from articular mechanonociceptors in normal ankle joints. Basal (a) and
normalised (b, dashed line represents the pre-injection response: 100%) values are
shown. Each point is the mean ± s.e.mean from n=6 units (6 experiments). P>0.05,
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Figure 4.7 Effects of injecting indomethacin (lOmgkg"1, i.a.) on the discharge evoked
by mechanical stimulation of articular mechanonociceptors in normal ankle joints.
Basal (a) and normalised (b, dashed line represents the pre-injection response: 100%)
values are shown. Each point is the mean ± s.e.mean from n=6 units (6 experiments).
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Figure 4.8 Effects of vehicle or indomethacin (0.5mgkg~\ i.p.) on the circumference
of adjuvant-arthritic left ankle joints. Each point is the mean ± s.e.mean from n=8
experiments. Statistical analysis: P<0.05, ANOVA days 20-29.









Figure 4.9 Effects of vehicle or indomethacin (0.5mgkg"\ i.p.) on inflammation
scores of adjuvant-arthritic left ankle joints. Each point is the mean ± s.e.mean from













Figure 4.10 Effects of vehicle or indomethacin (0.5mgkg"' ,i-P-) on left walking foot
placement (mobility) scores in rats with adjuvant-arthritic left ankle joints. Each point
is the mean ± s.e.mean from n=8 experiments. Statistical analysis: * P<0.05, Mann





Figure 4.11 Effects of vehicle or indomethacin (0.5mgkg"', i.p.) on the pressure-
evoked withdrawal thresholds of adjuvant-arthritic left ankle joints. Each point is the
mean ± s.e.mean from n=8 experiments. Statistical analysis: P<0.05 ANOVA days 14-





Figure 4.12 Effects of vehicle or indomethacin (0.5mgkg~\ i.p.) on weight of rats
with adjuvant-arthritic left ankle joints. Each point is the mean ± s.e.mean from n=8
experiments. Statistical analysis: P<0.05 ANOVA days 14-29. * P<0.05, Mann
Whitney U-test, versus vehicle.
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4.4 DISCUSSION
4.4.1 Effects of indomethacin in electrophysiological studies
The results of the present investigation have shown that neural discharge
(spontaneous and mechanically-evoked) from C-fibre afferents innervating adjuvant-
arthritic rat ankle joints was reduced by the NSAID, indomethacin. These findings are
in general agreement with similar electrophysiological investigations using adjuvant
arthritic (mono- and poly-arthritic) rat ankle joint preparations where the NSAIDs,
lysine acetylsalicylate and paracetamol, caused depressions in spontaneous and
mechanically-evoked discharge (Guilbaud & Iggo, 1985; Birrell, 1990; Grubb et al.,
1991; McQueen et al., 1991). However, whereas McQueen et al. (1991) reported that
lysine acetylsalicylate (lOOmgkg1; equivalent to 50mgkg"' aspirin) or paracetamol
(50mgkg"') decreased neural discharge (spontaneous and mechanically-evoked) to 60-
70% of pre-injection levels, the results of present study show that indomethacin
(lOmgkg1) produces much greater depressions (to 25-45% of pre-injection levels).
An insufficient dose of aspirin or paracetamol used in the study by McQueen et al.
(1991) cannot explain why these agents caused smaller depressions in neural
discharge as compared with the present results using indomethacin, since McQueen et
al. (1991) showed that lysine acetylsalicylate (lOOmgkg"1) and paracetamol (50mgkg~
*) evidently caused maximal reductions in neural discharge as second doses of each
agent failed to cause additional depression. One explanation that may account for the
greater magnitude of depression in neural discharge seen with indomethacin is related
to its anti-inflammatory ability; although indomethacin and aspirin have both analgesic
and anti-inflammatory properties, it is indomethacin which has the greater anti-
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inflammatory effect (Rang & Dale, 1991). Taking together the results of the present
study and those of McQueen et al. (1991) it appears that the order of potency for the
NSAIDs tested is indomethacin > lysine acetylsalicylate = paracetamol. A similar
order of potency (indomethacin > lysine acetylsalicylate) has also been reported in
afferents innervating inflamed cat knee joints (Heppelmann et al., 1986).
In the study by McQueen et al. (1991), reductions in mechanonociceptor
responsiveness induced by lysine acetylsalicylate or paracetamol returned to pre-
injection levels 60-80min post-injection of the drugs, whereas in the present
experiments no recovery of resting or mechanically-evoked discharge was observed
(maximal observation time lOOmin post-injection of indomethacin). These results,
therefore, indicate that indomethacin has a longer duration of action than does lysine
acetylsalicylate or paracetamol. This conclusion is also supported by the findings of
Heppelmann et al. (1986) in afferent units innervating inflamed knee joints of cats,
where there was no recovery of indomethacin-induced depressions in neural discharge
within the observation period of 60 - 120min.
The present data showing that indomethacin is effective in reducing neural discharge
from mechanonociceptors in arthritic joints is strong evidence for a peripheral action
of the drug in or near the ankle joint. A peripheral site of action of other NSAIDs
(lysine acetylsalicylate and paracetamol) has also been suggested in similar
electrophysiological recordings from C- and A5-fibres innervating arthritic ankle joints
(Guilbaud & Iggo, 1985; McQueen et al., 1991). However, electrophysiological
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recordings from C-fibre neurons of the rat thalamus suggest that NSAIDs may also
have central actions (Jurna & Brune, 1990).
Although NSAIDs were effective in reducing the sensitisation of mechano-
nociceptors in inflamed joints in the present experiments and in those reported by
Guilbaud & Iggo (1985) and McQueen et al. (1991), there remained residual neural
discharge which was not affected by these agents. Since leukotrienes have been shown
to sensitise mechanonociceptors (Martin et al., 1987), and since NSAIDs block cyclo-
oxygenase activity (Vane, 1971; Collier and Schneider, 1972; Ferreira & Vane, 1974;
Yamamoto et al., 1980; Vane & Botting, 1987) without having an affect on the
enzyme 5-lipoxygenase [which leads to the formation of leukotrienes (Granstrom,
1983)], it is therefore possible that the NSAID-resistant component observed is
mediated by leukotrienes. Further studies using dual inhibitors of cyclo-oxygenase and
5-lipoxygenase (e.g. 3-amino-l-[/»-(trifluoromelhyl)-phenyl]-2-pyrazoline, BW755C)
would aid in elucidating the role of leukotrienes in this model of arthritis. The fact that
NSAIDs could potentially divert arachidonate metabolism from the cyclo-oxygenase
pathway to the lipoxygenase pathway, thereby increasing leukotriene production
(Walker & Harvey, 1984) has therapeutic implications. Indeed a study (Rashad et al.,
1989) of arthritic patients showed that arthritis progressed more rapidly in patients
treated with a strong inhibitor of cyclo-oxygenase (indomethacin) than those treated
with a weak inhibitor (azapropazone). Corticosteroid drugs have the ability to block
the production of both prostaglandins and leukotrienes and therefore would be
expected to show much greater anti-inflammatory properties than the NSAIDs.
Indeed, as detailed in Section 6 of this thesis, the corticosteroid, dexamethasone,
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shows much greater reductions in inflammation and hyperalgesia associated with
adjuvant-arthritic joints as compared to indomethacin.
The results of the current investigation showed that indomethacin had no significant
effect on the discharge (spontaneous and mechanically-evoked) from articular
mechanonociceptors in normal joints. Similar electrophysiological recordings using
other NSAIDs (lysine acetylsalicylate and paracetamol) have also shown that these
agents do not alter neural discharge from joint capsule mechanonociceptors in normal
joints (Guilbaud & Iggo, 1985; McQueen et al., 1991). The conclusion from
electrophysiogical studies is that, unless inflammation is present NSAIDs will not
affect neural discharge. In agreement with this conclusion is the observation that
NSAIDs are only effective in experimental models which involve prior induction of
inflammation (Randall & Selitto, 1957; Gilfoil et al., 1963; Winter, 1965; Pardo &
Rodriguez, 1966; Vane & Botting, 1991). This is in contrast to opiate analgesics,
where these drugs are analgesic both in inflamed and in normal tissues (Winter &
Flataker, 1965; Vane & Botting, 1991).
4.4.2 Actions of indomethacin in adjuvant arthritis
In rats with established adjuvant-induced arthritis of the left ankle joint, treatment
with indomethacin was found to reduce inflammation (Figures 4.8 & 4.9) and
hyperalgesia (Figures 4.10 & 4.11). Such anti-inflammatory and analgesic actions
induced by indomethacin have also been reported by other investigators using
adjuvant-arthritic (Winter & Nuss, 1966; Kuzuna & Kawai, 1975; Wong & Gardocki,
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1983; Elmadfa et al., 1987; Schmollack & Steup, 1988; Pettipher et al., 1989) or
carrageenan, kaolin and urate-crystal (Rosenthale et al., 1972; Vinegar et al., 1976;
Elling, 1987; Novo et al., 1992) models of joint inflammation in animals. In agreement
with these animal studies, indomethacin has been demonstrated to be an effective
analgesic and anti-inflammatory agent in patients with rheumatoid arthritis (Seideman
& Eriksson, 1988; Seideman & Melander, 1988; Saul & Korlipara, 1991).
The finding that indomethacin-treated arthritic rats could sustain analgesia and
reduced inflammation after withdrawal of the drug was interesting. Such an effect was
also observed by Winter & Nuss (1966) after discontinuing indomethacin treatment in
adjuvant-arthritic rats. Whether this could represent an effect of indomethacin on the
underlying disease process rather than a mere anti-inflammatory action requires
further investigation.
In the present experiments, the potency of indomethacin in this established model of
arthritis was not determined in relation to other NSAIDs such as aspirin.
Nevertheless, it has been determined using various parameters of inflammation and
hyperalgesia in an established model of adjuvant-induced arthritis in rats, that the
order of potency is indomethacin > aspirin (Winter & Nuss, 1966; Kuzuna & Kawai,
1975; Elmadfa et al., 1987). This order of potency agrees with that observed in the
present electrophysiological studies (see Section 4.3.1).
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4.4.3 Mechanism(s) of action of indomethacin
The precise mechanism(s) of action of indomethacin in both the present
electrophysiological and behavioural studies requires investigation. NSAIDs have
been shown to inhibit prostanoid synthesis (Vane, 1971; Ferreira & Vane, 1974;
Moncada et al„ 1975; Fitzpatrick & Wynalda, 1976; Sturge et al„ 1978; Van der
Ouderas et al., 1980; Vane & Botting, 1991) and are believed to cause reductions in
tissue prostanoid content resulting in analgesia (Collier et al., 1972; Ferreira & Vane,
1974; Moncada et al., 1975; Vane & Botting, 1991). Electrophysiological studies
using adjuvant-arthritic rat ankle joints have shown that the stable and selective IP
receptor agonist, cicaprost (Skubulla et al., 1986), restored neural discharge which
had been reduced by lysine acetylsalicylate (McQueen et al., 1991). This result
suggests that IP receptors are involved in the sensitisation of mechanonociceptors in
this model of arthritis. Reversal by PGE2 of indomethacin-induced decreases in neural
discharge from inflamed (kaolin-carrageenan induced) cat knee joints indicates that
EP receptors may also be involved in the sensitisation process (Heppelmann et al.,
1986). However, no reversal was obtained with PGE2 in electrophysiological studies
using adjuvant-arthritic rat joints (McQueen et al., 1991), indicating that sensitisation
of mechanonociceptors is dependent on the inflammatory stimulus and / or species
used.
As discussed by Lands (1981; 1985) inhibition of cyclo-oxygenase by NSAIDs can
occur by different mechanisms such as irreversible inactivation, reversible competitive
inhibition and reversible non-competitive inhibition. Aspirin acts through an
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irreversible inactivation of the enzyme - it acetylates the a-amino group of the
terminal serine to form a covalent bond. Thus, the effects of aspirin continue after the
drug itself has apparently been cleared from the tissue. A similar effect as aspirin has
been observed with indomethacin on isolated cyclo-oxyygenase (Lands, 1985).
However, on whole cells the action of indomethacin on cyclo-oxygenase appears to
be reversible (Lands, 1985).
Although it is generally accepted that the mechanism of action of NSAIDs is via
inhibition of cyclo-oxygenase several other mechanisms (at equivalent doses) may also
be involved. For example, NSAIDs can inhibit enzymes other than cyclo-oxygenase
(Kuehl & Egan, 1980; Brune, 1983). Other mechanisms of action of NSAIDs include
their ability to act directly on neuronal membranes (Neto & Narahashi, 1976), to
counteract the effects of excitatory substances (Guzman et al., 1964; Lim et al.,
1970), and to reduce intracellular free Ca2+ (Northover, 1971; 1977).
4.5 SUMMARY
In summary, the present electrophysiological results provide evidence that
indomethacin has an action in the periphery to reduce the elevated spontaneous
discharge, and the enhanced responsiveness to mechanical stimuli, of articular
mechanonociceptors in chronically arthritic (Freunds adjuvant-induced) rat ankle
joints. In line with these neuropharmacological studies, complementary behavioural
studies showed that indomethacin reduced the hyperalgesia, swelling and
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inflammation associated with an established monoarthritis of the rat ankle joint
induced by Freunds adjuvant.
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SECTION 5
PURINE RECEPTORS AND ARTICULAR MECHANONOCICEPTOR
DISCHARGE FROM NORMAL AND ARTHRITIC RA T ANKLE JOINTS.
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5.1 INTRODUCTION
Observations by Bleehen & Keele (1977) have shown that pain results from the
application of adenosine to a cantharadin-induced blister base of the human forearm.
Pain can also be evoked in humans when adenosine is injected into the coronary (Crea
et al., 1990; Lagerqvist et al., 1990a), brachial (Sylvan et al., 1988b) and
iliac (Lagerqvist et al., 1990a) arteries, or when it is injected intravenously
(Conradsson et al., 1987; Sylvdn et al., 1988a; Crea et al., 1990; Lagerqvist et al.,
1990b) or into the abdominal aorta (Lagerqvist et al., 1990a).
Purinoceptors are classified into the Pi (adenosine receptors) and P2 (ATP
receptors) types (Burnstock & Kennedy, 1985; Burnstock, 1990; Hoyle & Burnstock,
1991; Stiles, 1991). Adenosine receptors are further subclassified into the Ai, A2 and
A3 subtypes with evidence emerging for further divisions of these subtypes
(Hamprecht & Calker, 1985; Linden, 1991; Collis & Hourani, 1993). Behavioural
studies in rats, have shown that intra-dermal injections of adenosine causes direct
cutaneous mechanical hyperalgesia (Taiwo & Levine, 1990). This hyperalgesia was
mimicked by A2 receptor agonists and reversed by A2 receptor antagonists , whereas
Ai selective adenosine analogues were without effect. Various electrophysiological
studies in animals have also demonstrated an excitatory role for adenosine [e.g. there
is activation of carotid body (McQueen & Ribeiro, 1981; Moteiro & Ribeiro, 1987),
vagal pulmonary (Cherniack et al., 1987; Runold et al., 1987) and renal pelvis
(Katholi et al., 1985) afferents].
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Paradoxically, it has been reported that adenosine or adenosine agonists (Ai and/or
A2 selective) have antinociceptive or anti-inflammatory actions in various animal
models, including carrageenan-induced pleurisy (Schrier et al., 1990; Lesch et al.,
1991) or paw inflammation (Firestein et al., 1993) and tail flick (Holmgren et al,
1983) or hot plate (Holmgren et al., 1986) tests in rats, and acetylcholine-induced
writhing (Herrick-Davis et al., 1989) or substance P or N-Methyl-D-aspartate-induced
nociceptive behaviour (Delander & Wahl, 1988) in mice.
The main aim of the present investigation was to determine the effects of adenosine
and agonists and antagonists selective for adenosine receptors on the discharge
(spontaneous and mechanically-evoked) from articular mechanonociceptors in normal
rat ankle joints as well as in ankle joints with localised adjuvant-induced arthritis.
Preliminary studies were also performed to determine the effects of the P2 receptor
agonists, ATP and a,p-methylene-ATP, on mechanonociceptor responsiveness in
both normal and arthritic rat ankle joints.
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5.2 MATERIALS & METHODS
5.2.1 Electrophysiological studies
The in-vivo preparation, neural recording, off-line analysis and statistical analysis are
described in detail in Section 2. In brief, male Wistar rats (normal and adjuvant-
arthritic) were anaesthetised with urethane and cannulations performed of the trachea,
right carotid artery (blood pressure monitoring) and right femoral artery (retrograde
cannulation for close intra-arterial bolus injections of drugs into the left limb). The
medial aspect of the left ankle joint was exposed and nerve fibres were isolated from
the PACR nerve. C-fibre afferent discharge (spontaneous and mechanically-evoked)
from articular mechanonociceptors was recorded extracellularly, using bipolar
platinum-iridium electrodes.
Protocol
The protocol in these experiments involved an attempt to construct log dose-
response curves to the non-selective adenosine receptor agonist, 5*-N-
ethylcarboxamidoadenosine (NECA, 0.01 - lOOpg i.a.), in both normal and arthritic
rats. In some of the experiments, the selective Ai receptor agonist, N6-
cyclopentyladenosine (CPA), and the agonist, metrifudil (A2 > AO, were
injected (lOpg, i.a.) either before, or more typically, after injections of NECA (0.01 -
lOOpg). The effects of the non-selective adenosine receptor antagonists, theophylline
and 8-phenyltheophylline (8-PT, lOOpgkg"1 i.a.), were also determined. In a series of
preliminary experiments, the effects of the non-selective P2 agonist, ATP (lOOpg,
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i.a.), and the P2x selective agonist, a.fl-methylene-ATP (lOOpg, i.a.), were determined
in both normal and arthritic rats.
Data analysis
In this series of experiments, if the test agent evoked an obvious change in
spontaneous discharge then this was assessed by determining the number of impulses
the test agent induced ahove, or below, the control level of discharge (see Section
2.3.5.2 for further details of the formula used) with the delay and duration of the
response also being determined. If the test agent showed no clear response, then the
largest number of impulses both above and below basal discharge was determined by
using an arbitrary time period of 60s over 0 - 15min post-injection of drug. The
control period was defined as the 60s period immediately prior to the addition of the
test substance. A significant change in spontaneous discharge was defined as a change
over basal discharge of more than 5 impulses for normal joints and over 6 impulses for
arthritic joints. These values of 5 and 6 impulses were derived from the results of
saline injections in normal (3 ± 2 and 4 ± 1 impulses above and below basal discharge,
respectively, 7 units) and arthritic (4 ± 2 and 5 ± 1 impulses above and below basal
discharge, respectively, 11 units) joints. Effects of the test substances on the
responsiveness of the standard mechanical stimulus were assessed as the peak number
of impulses above, or below, the pre-injection evoked discharge. A significant change
in mechanically-evoked discharge was defined as a change of more than 5 impulses
over the basal mechanically-evoked discharge for both normal and arthritic joints.
This value of 5 impulses, was derived from the results of saline injections in normal (4
136
± 1 and 4 ± 1 impulses above and below basal discharge, respectively, 6 units) and




5.3.1 In-vivo electrophysiology in normal and adjuvant-arthritic rat ankle
joints
In this series of experiments the effects of adenosine agonists and antagonists were
examined in 11 single units (10 experiments) from normal joints and 16 single units
(14 experiments) from adjuvant-arthritic (mean 26 ± 9 days post-adjuvant) joints.
Although conduction velocities of the action potential spikes recorded in this series of
experiments were not determined, it is likely that they were in the C- or A8-fibre
range since a) the action potential spike shape characteristics and duration of all the
articular afferent units recorded were similar to those of C- or A-8 fibres (see Section
3) and b) all the units examined showed chemosensitivity to the C-fibre excitant,
capsaicin (1 - 3pg, i.a.). Before the addition of any drugs, all units showed resting
(spontaneous) discharge, although this was significantly greater in units from arthritic
joints (3.6 ±1.3 i.p.s.; range: 1.4 - 5.5) than in those from normal joints (0.8 ± 0.2
i.p.s.; range: 0.3 - 1.5)[P<0.05, Mann-Whitney U-test],
5.3.1.1 Effects of adenosine receptor agonists and antagonists on
mechanonociceptor discharges from normal joints
In comparison with saline injections, none of the units recorded from normal joints
showed any significant change in either spontaneous or mechanically-evoked
discharge after close arterial injections of the non-selective adenosine agonist, NECA
(0.01 - 30pg; Tables 5.1 & 5.2), the selective Ai receptor agonist, CPA (lOpg;
Tables 5.3 & 5.4), and the A2 > Ai receptor agonist, metrifudil (lOpg;
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Table 5.1 Lack of effect of NECA on spontaneous discharge from articular













saline 7(6) 3 ± 2 - 4 ± 1 -
NECA O.Olpg 5(5) 3 ± 1 NS 3 ± 1 NS
NECA O.lpg 6(6) 3 ± 1 NS 4 ± 1 NS
NECA Ipg 6(6) 4 ± 1 NS 4 ± 1 NS
NECA lOpg 7(6) 3 ± 2 NS 4 ± 1 NS
NECA 30pg 6(6) 4 ± 1 NS 3 ± 1 NS
f Statistical comparisons (Mann Whitney U-test) between saline and 5"-N-
ethylcarboxamidoadenosine (NECA). NS = P>0.05. The pre-injection discharge, before the injection
of any drugs, was 0.9 ± 0.2 i.p.s.
Table 5.2 Lack of effect of NECA on mechanically-evoked discharge from















saline 4(4) 3 ± 1 - 3 ± 1 -
NECA O.Olpg 4(4) 1 ±2 NS 3 ± 2 NS
NECA 0.1 pg 4(4) -1 ±2 NS 3 ± 2 NS
NECA Ipg 4(4) 2 ± 3 NS 2 ± 2 NS
NECA lOpg 4(4) 2 ± 2 NS 4 ± 1 NS
NECA 30pg 3(3) -1 ±2 NS 4 ± 1 NS
f Statistical comparisons (Mann Whitney U-test) between saline and 5*-N-
ethylcarboxamidoadenosine (NECA). NS = P>0.05. The pre-injection mechanically-evoked
discharge, before the injection of any drugs, was 48 ± 8 impulses.
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Table 5.3 Lack of effect of CPA and metrifudil on spontaneous discharge from













saline 4(4) 3 ± 1 - 4 ± 1 -
CPA lOpg 3(3) 4 ± 1 NS 3 ± 2 NS
metrifudil lOpg 3(3) 3 ± 2 NS 1 ±2 NS
f Statistical comparisons (Mann-Whitney U-test) between saline and the test adenosine agonist.
NS = P>0.05. CPA: N6-cyclopentyladenosine. The pre-injection discharge, was 1.1 ± 0.4 i.p.s pre-
saline, 0.7 ± 0.2 i.p.s. pre-CPA and 1.0 ± 0.4 i.p.s. pre-metrifudil.
Table 5.4 Lack of effect of CPA and metrifudil on mechanically-evoked















saline 3(3) 3 ± 1 - 4 ± 1 -
CPA lOpg 2(2) 4 ± 1 NS 3 ± 2 NS
metrifudil lOpg 2(2) 2 ± 1 NS 5 ± 0 NS
f Statistical comparisons (Mann-Whitney U-test) between saline and the test adenosine agonist.
NS = P>0.05. CPA: N6-cyclopentyladenosine. The pre-injection mechanically-evoked discharge, was
48 ± 17 impulses pre-saline, 36 ± 19 impulses pre-CPA and 43 ± 21 impulses pre-metrifudil.
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Tables 5.3 & 5.4). The non-selective adenosine receptor antagonists, theophylline and
8-PT (lOOpgkg1, i.a.), also had no significant effect on either spontaneous (Table 5.5)
or mechanically- evoked discharge (Table 5.6).
5.3.1.2 Effects of adenosine receptor agonists and antagonists on
mechanonociceptor discharges from arthritic joints
In all the units recorded from arthritic joints, there was no significant effect (in
comparison with saline injections) on either spontaneous discharge or on the
responsiveness to the standard mechanical stimulus after close intra-arterial injections
of NECA (0.01 - lOOpg; Tables 5.7 & 5.8), CPA (lOpg; Tables 5.9 & 5.10) and
metrifudil (lOpg; Tables 5.9 & 5.10). The non-selective adenosine receptor
antagonists, theophylline and 8-PT (lOOpgkg"1, i.a.), had no significant effect on either
spontaneous discharge (Table 5.11) or on the responsiveness to the standard
mechanical stimulus (Table 5.12).
5.3.1.3 Effects of ATP and oc,p-methylene-ATP on mechanonociceptor
discharges in normal and arthritic rat ankle joints
In preliminary studies, a high dose (lOOpg, i.a.) of either the non-selective P2
receptor agonist, ATP, or the selective P2x receptor agonist, oc,P-methylene-ATP,
failed to cause any significant change in spontaneous or mechanically-evoked
discharge in any of the units recorded from either normal (Tables 5.13 & 5.14) or
arthritic (Tables 5.15 & 5.16) joints.
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Table 5.5 Lack of effect of theophylline and 8-PT on spontaneous discharge













saline 5(5) 4 ± 1 - 3 ± 1 -
theophylline lOOpgkg"1 5(5) 2 ± 1 NS 4 ± 1 NS
8-PT lOOpgkg"1 3(3) 3 ± 1 NS 4+1 NS
f Statistical comparisons (Mann-Whitney U-test) between saline and the test adenosine antagonist.
NS = P>0.05. 8-PT: 8-phenyltheophylline. The pre-injection discharge, was 1.2 ± 0.3 i.p.s pre-
saline, 1.2 ± 0.2 i.p.s. pre-theophylline and 1.2 ± 0.5 i.p.s. pre-8-PT.
Table 5.6 Lack of effect of theophylline and 8-PT on mechanically-evoked
































f Statistical comparisons (Mann-Whitney U-test) between saline and the test adenosine antagonist.
NS = P>0.05. 8-PT: 8-phenyltheophylline. The pre-injection mechanically-evoked discharge, was
50 ± 13 impulses pre-saline, 36 ± 14 impulses pre-theophylline and 43 ± 15 impulses pre-8-PT.
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Table 5.7 Lack of effect of NECA on spontaneous discharge from articular













saline 11(9) 4 ±2 - 5 ± 1 -
NECA O.Olpg 5(3) 2 ±2 NS 3 ± 1 NS
NECA O.lpg 9(7) 4 ± 1 NS 5 ± 1 NS
NECA iMg 9(7) 4 ± 1 NS 4 ± 2 NS
NECA lOpg 11 (9) 4 ± 2 NS 4 ± 2 NS
NECA 30jjg 6(4) 4 ± 2 NS 5 ± 1 NS
NECA lOOpg 5(3) 5 ± 1 NS 4 ± 2 NS
f Statistical comparisons (Mann Whitney U-test) between saline and 5V-N-
ethylcarboxamidoadenosine (NECA). NS = P>0.05. The pre-injection discharge, before the injection
of any drugs, was 3.7 ± 0.5 i.p.s.
Table 5.8 Lack of effect of NECA on mechanically-evoked discharge from















saline 7(6) 2 ± 1 - 3 ± 1 -
NECA 0.01 Mg 3(2) 1 ± 1 NS 4 ± 1 NS
NECA O.lftg 5(4) 1 ±3 NS 4 ± 1 NS
NECA iMg 5(4) 2 ± 3 NS 2 ± 1 NS
NECA 10pg 7(6) 1 ±2 NS 2 ± 1 NS
NECA 30(ig 4(3) 2 ± 3 NS 3 ± 1 NS
NECA lOOpg 4(3) 3 ± 1 NS 4 ± 1 NS
f Statistical comparisons (Mann Whitney U-test) between saline and 5V-N-
ethylcarboxamidoadenosine (NECA). NS = P>0.05. The pre-injection mechanically-evoked
discharge, before the injection of any drugs, was 55 ± 10 impulses.
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Table 5.9 Lack of effect of CPA and metrifudil on spontaneous discharge from













saline 6(5) 5 ± 1 - 4 ± 1 -
CPA lOpg 6(5) 4 ± 2 NS 5 ± 1 NS
metrifudil lOpg 5(4) 4 ± 2 NS 4 ± 2 NS
f Statistical comparisons (Mann-Whitney U-test) between saline and the test adenosine agonist.
NS = P>0.05. CPA: N6-cyclopentyladenosine. The pre-injection discharge, was 2.2 ± 0.4 i.p.s pre-
saline, 2.2 ±0.1 i.p.s. pre-CPA and 2.2 ± 0.3 i.p.s. pre-metrifudil.
Table 5.10 Lack of effect of CPA and metrifudil on mechanically-evoked















saline 6(5) 3 ± 1 - 3 ± 1 -
CPA 10pg 6(5) 4+1 NS 3 ± 1 NS
metrifudil lOpg 5(4) 4 ± 1 NS 2 ± 1 NS
f Statistical comparisons (Mann-Whitney U-test) between saline and the test adenosine agonist.
NS = P>0.05. CPA: N6-cyclopentyladenosine. The pre-injection mechanically-evoked discharge, was
37 ± 9 impulses pre-saline, 26 ± 6 impulses pre-CPA and 30 ± 3 impulses pre-metrifudil.
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Table 5.11 Lack of effect of theophylline and 8-PT on spontaneous discharge













saline 11(10) 4 ± 1 - 3 ± 1 -
theophylline lOOpgkg"1 6(5) 3 ± 2 NS 4 ± 2 NS
8-PT lOOpgkg1 5(5) 4 ± 2 NS 4 ± 2 NS
f Statistical comparisons (Mann-Whitney U-test) between saline and the test adenosine antagonist.
NS = P>0.05. 8-PT: 8-phenyltheophylline. The pre-injection discharge, was 2.8 ± 0.3 i.p.s pre-
saline, 3.1 ± 0.4 i.p.s. pre-theophylline and 2.4 ± 0.5 i.p.s. pre-8-PT.
Table 5.12 Lack of effect of theophylline and 8-PT on mechanically-evoked
discharge from articular mechanonociceptors in arthritic rat ankle joints.





saline 11(9) 3 ± 1 - 3 ± 1 -
theophylline lOOpgkg"1 5(4) 4 ± 1 NS 1 ±2 NS
8-PT lOOpgkg"1 6(5) 3 ± 1 NS 2 ± 1 NS
f Stadstical comparisons (Mann-Whitney U-test) between saline and the test adenosine antagonist.
NS = P>0.05. 8-PT: 8-phenyltheophylline. The pre-injection mechanically-evoked discharge, was
39 ± 4 impulses pre-saline, 44 ± 12 impulses pre-theophylline and 30 ± 6 impulses pre-8-PT.
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Table 5.13 Lack of effect of ATP & a,P-methylene-ATP on spontaneous













saline 5(5) 3 ± 1 - 4 ± 1 -
ATP lOOpg KD 3 ± 1 NS 3 ± 1 NS
a,P-methylene-ATP lOOjag 5(5) 4 ± 1 NS 2 ± 1 NS
f Statistical comparisons (Mann-Whitney U-test) between saline and the test P2 agonist.
NS = P>0.05. The pre-injection discharge, was 0.6 ± 0.3 i.p.s pre-saline, 0.8 ± 0.2 i.p.s. pre-ATP and
0.5 ± 0.2 i.p.s. pre-a,p-methylene-ATP.
Table 5.14 Lack of effect of ATP & a,P-methylene-ATP on mechanically-















saline 4(4) 3 ± 1 - 4 ± 1 -
ATP lOOpg KD 2 ± 1 NS 4 ± 1 NS
a,p-methylene-ATP lOOpg 4(4) 2 ± 2 NS 3 ± 1 NS
f Statistical comparisons (Mann-Whitney U-test) between saline and the test P2 agonist.
NS = P>0.05. The pre-injection mechanically-evoked discharge, was 25 ± 6 impulses pre-saline, 29
± 8 impulses pre-ATP and 17 ± 7 impulses pre-a,P-methylene-ATP.
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Table 5.15 Lack of effect of ATP & cc,P-methylene-ATP on spontaneous













saline 7(6) 2 ± 1 - 3 ± 1 -
ATP lOOpg 2(2) 3 ± 1 NS 4 ± 1 NS
a,P-methylene-ATP lOOpg 7(6) 4 ± 1 NS 4 ± 2 NS
t Statistical comparisons (Mann-Whitney U-test) between saline and the test P2 agonist.
NS = P>0.05. The pre-injection discharge, was 2.4 ± 0.6 i.p.s pre-saline, 2.6 ± 0.9 pre-ATP and 2.1
±1.1 i.p.s. pre-a,p-methylene-ATP.
Table 5.16 Lack of effect of ATP & a,P-methylene-ATP on mechanically-
















saline 4(3) 4 ± 1 - 3 ± 2 -
ATP lOOpg 2(2) 3 ± 1 NS 4 ± 1 NS
a,P-methylene-ATP 1 OOjag 4(3) 4 ± 1 NS 2 ± 1 NS
f Statistical comparisons (Mann-Whitney U-test) between saline and die test P2 agonist.
NS = P>0.05. The pre-injecdon mechanically-evoked discharge, was 55 ± 25 impulses pre-saline,
48 ± 22 impulses pre-ATP and 42 ± 21 impulses pre-a,p-methylene-ATP.
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5.3.2 Blood pressure studies
Intra-arterial injection of either NECA (0.01 - lOOpg) or metrifudil (lOpg) caused a
fall in systemic blood pressure, whereas CPA (lOpg) caused an increase. These effects
to adenosine receptor agonists were antagonised by theophylline or 8-PT (lOOpgkg1,
i.a.)(see Figure 5.1 for typical responses). The P2 receptor agonists, ATP and oc,p~
methylene-ATP (lOOpg, i.a.), caused a decrease and increase, respectively, in
systemic blood pressure (see Figure 5.2 for typical responses).
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a) absence of 8-PT b) presence of 8-PT
Figure 5.1 Chart recording traces showing typical responses to intra-arterial injection
of NECA (10pg), metrifudil (lOpg) and CPA (lOpg) on systemic blood pressure (a)
before and (b) after 8-PT (lOOpgkg1, i.a.). The traces in the above figures were all






























Figure 5.2 Chart recording traces showing the typical changes in systemic blood
pressure associated with intra-arterial injection (lOOpg) of ATP (a) and a,p,-
methylene-ATP (b). The traces in the above figures were from arthritic rats (normal
rats also showed similar responses).
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5.4 DISCUSSION
5.4.1 Adenosine receptor agonists and antagonists on mechanonociceptor
discharge from normal and adjuvant-arthritic rat ankle joints
The results of the present investigation have shown that none of the adenosine
receptor agonists (non-selective: NECA; Arselective: CPA; A2 > Ai selective:
metrifudil) had any significant effect on spontaneous or mechanically-evoked
discharge from mechanonociceptors in either normal or chronically inflamed
(adjuvant-arthritic) rat ankle joints. These results are in agreement with those of
Klement & Arndt (1992), who found that adenosine injected into the human finger
vein failed to evoke pain from venous and paravascular nociceptors, nor did it alter
the intensity of electrically-evoked pain. Since non-selective adenosine receptor
antagonists (theophylline and 8-PT) had no effect on either the enhanced spontaneous
discharge or the sensitisation of mechanonociceptors to mechanical stimuli seen in
chronically arthritic ankle joints, these results suggest that, in this model of chronic
inflammation, adenosine and adenosine receptors are unlikely to play a significant role
in the excitation or sensitisation of mechanonociceptors.
It is possible that a change in neural discharge was not observed in the current
experiments because adenosine analogues, even when injected at high concentrations,
failed to reach effective concentrations at the nociceptor terminals in the ankle joint
because of, for example, rapid degradation of the analogues. However, this is unlikely
since stable adenosine agonists such as NECA produced prolonged changes in blood
pressure (Figure 5.1). Moreover, since the blood pressure effects to the adenosine
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receptor agonists were antagonised by theophylline or 8-PT (Figure 5.1) this shows
that these antagonists were bioactive in the concentrations used in the experiments.
The possibility that articular afferent units studied in this series of experiments were
incapable of showing alterations in neural discharge is unlikely, since chemosensitivity
of all the units recorded was confirmed by responsiveness to the C-fibre excitant,
capsaicin.
In contrast to the findings of the present study, it has been shown that adenosine can
evoke pain in humans when applied to the blister base (Bleehen & Keele, 1977) or
when injected intra-arterially (Sylvdn et al., 1988b; Crea et al., 1990; Lagerqvist et al.,
1990a) or intravenously (Conradsson et al., 1987; Sylvdn et al., 1988a; Crea et al.,
1990; Lagerqvist et al., 1990b). In further contrast with the results of the current
investigation, it has been reported that intra-dermal injection of adenosine causes
direct cutaneous mechanical hyperalgesia in the rat, an effect mediated by
A2 receptors (Taiwo & Levine, 1990). A central mode of action might explain why
adenosine had effects in these studies but lacked action in the present experiments,
which examined the effects of adenosine only on peripheral tissue. However, it
appears that when A, and/or A2 selective agonists are injected intracerebroventrically
(Herrick-Davis et al., 1989) or intrathecally (Holmgren et al., 1986; Sawynok et al.,
1986) antinociception (tail flick, hot plate or acetylcholine-induced writhing tests),
rather than nociception, results. It would be of interest to perform behavioural studies
using the Freunds adjuvant-induced mono-arthritic rat model (see Section 3) so as to
determine what effects, if any, adenosine agonists and antagonists would have in this
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model of chronic inflammation, and then to relate these results to those of the present
neuropharmacological study.
It has been shown that, although PGEi or PGE2 cause little or no increase in afferent
discharge, they can cause potentiation of the excitatory response to bradykinin (Chahl
& Iggo, 1977; Birrell et al., 1993). Thus, although in the present experiments
adenosine analogues caused no change in neural discharge from articular
mechanonociceptors, it may be the case that adenosine could affect afferent discharge
to other inflammatory agents such as bradykinin, prostanoids or 5-HT. Further
neuropharmacological studies will be required to test this hypothesis.
5.4.2 Role of P2 receptors on mechanonociceptor discharges from normal
and adjuvant-arthritic rats
Purinoceptors at which ATP acts are classified as P2 receptors. These P2 receptors
have been classified into two subtypes, P2x and P2y (O'Conner et al., 1991; O'Conner,
1992; Illes & Norenberg, 1993). It has been shown that application of the non¬
selective P2 receptor agonist, ATP, to the human blister base produces pain (Bleehen
& Keele, 1977). In various sensory neurons, it has been demonstrated that P2
receptors (in particular P2x subtypes) are activated by ATP and ATP analogues
(Krishtal et al., 1988; Burnstock, 1990; Illes & Norenberg, 1993). ATP, and the
selective P2x receptor agonist, a,(3-methylene-ATP, have also been reported to cause
depolarisation of the rat isolated vagus (Trezise et al., 1993). In this study,
depolarisations were blocked by the non-selective P2 receptor antagonist, suramin. In
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contrast to these reports in the literature, preliminary findings of the present
investigation have shown that P2 receptors are unlikely to have any significant role in
modulating articular afferent discharge because close intra-arterial injection of the
non-selective P2 receptor agonist ATP, or of a selective P2x receptor agonist (a,(3-
methylene-ATP) failed to alter articular afferent discharge from mechanonociceptors
in either normal or arthritic rat ankle joints. Although ATP and a,p-methylene-ATP
had no effect on neural discharge, they were bioactive since they caused a decrease
and an increase, respectively, in systemic blood pressure (Figure 5.2). Further
experiments examining the role of P2 receptor antagonists such as suramin or
arylazidoamino propionyl-ATP (ANAPP3) would be of interest, in order to determine
whether ATP could be involved in the tonic sensitisation of mechanonociceptors in
chronically inflamed joints.
5.5 SUMMARY
In summary, the results of the present neuropharmacological investigation provide
strong evidence that neither adenosine Ai or A2 receptors (subtypes of the Pi
receptor) affect neural discharge from mechanonociceptors in either normal or
arthritic rat ankle joints. Preliminary studies indicate that purine P2 receptors are also
unlikely to be involved in altering articular mechanonociceptor discharge in either
normal or chronically inflamed joints.
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SECTION 6
ROLE OF P-ADRENOCEPTORS IN NORMAL AND ADJUVANT-ARTHRITIC




In humans, adrenoceptors have been implicated in chronic inflammatory disease
states such as reflex sympathetic dystrophy (Schott, 1986; Schwartzman &
McLellan, 1987) and rheumatoid arthritis (Kaplan et al., 1980; Levine et al., 1986a;
Hannington-Kiff, 1990). In these disorders a reduction in pain and inflammation can
be achieved by the use of adrenergic neurone blocking drugs, such as guanethidine
(Loh & Nathan, 1978; Bonica, 1979; Levine et al., 1986a Hannington-Kiff, 1990).
A contribution of adrenoceptors, particularly p2-adrenoceptors, has been suggested
from the results of behavioural studies of chronic pain and inflammation associated
with arthritis (see Fitzgerald, 1989). For example, treatment with the non-selective P-
adrenoceptor antagonist, propranolol, was found to decrease the signs and symptoms
of inflammation in patients with rheumatoid arthritis (Kaplan et al., 1980). Similarly, it
has been reported in animal studies that treatment with propranolol reduces the
severity of joint injury in arthritic (Freunds adjuvant-induced) rats (Levine et al.,
1988). Moreover, in this model of arthritis, cti, a2 or pi-adrenoceptor antagonists
were without effects, whereas the p2-adrenoceptor antagonists, butoxamine or
ICI 118551, were found to decrease the severity of joint injury (Levine et al., 1988).
It has also been demonstrated that the (^-adrenoceptor agonist, salbutamol, or the
catecholamine, adrenaline (acting at (^-adrenoceptors), exacerbate adjuvant-induced
arthritis in the rat (Coderre et al., 1990; Coderre et al., 1991). Paradoxically, in other
studies, (^-adrenoceptor agonists have been reported to have anti-inflammatory
actions. For example, p2-adrenoceptor agonists such as salbutamol, and in particular
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the longer-duration p2-adrenoceptor agonist, salmeterol (Ball et al., 1991), are
inhibitors of, mediator (histamine, leukotrienes and prostaglandins) release (Butchers
et al., 1979; Butchers et al., 1991), bradykinin-induced plasma protein
extravasation (Whelan et al., 1993), vascular permeability and granulocyte
accumulation (Whelan & Johnson, 1992) and carrageenan-induced oedema (Green,
1972).
Electrophysiological recordings from C-fibre afferents have also suggested a role for
adrenoceptors, particularly in inflamed tissues. For example, electrophysiological
recordings from C-fibres in rabbit ears have shown that, although noradrenaline did
not excite C-polymodal nociceptors in undamaged ears, approximately 60% of C-fibre
nociceptors were excited by this catecholamine in ears with damaged auricular nerves
(Sato & Perl, 1991). Noradrenaline-induced excitation was blocked by a2
(predominately) and oti-adrenoceptor antagonists; the effects of P -adrenoceptor
antagonists were not examined (Sato & Perl, 1991). In chronically lesioned nerves
(neuromas) in the cat, adrenaline was shown to excite 12 of 30 unmyelinated skin
afferents (Habler et al., 1987), although the adrenoceptor mediating this action was
not studied. In the investigation by Sanjue & Jun (1989), rat skin nociceptors showed
no response to noradrenaline, although when there was a sustained neural discharge,
induced by a compound algogenic substance (mixture of 5-HT, histamine, KC1 and
HC1), noradrenaline did enhance discharge in 7 of 9 afferents. The adrenoceptor
responsible for this noradrenaline-induced excitation was not determined in this study.
Noradrenaline-induced mechanical sensitisation has also been reported in rat
cutaneous mechanonociceptors (Gold et al., 1994). Since such mechanical
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sensitisation was blocked by yohimbine, this suggests the involvement of a2-
adrenoceptors.
The aims of the present investigation were two-fold. Firstly, an electrophysiological
study was performed in order to determine the effects of P-adrenoceptor agonists and
antagonists and the catecholamines, adrenaline and noradrenaline, on neural discharge
(spontaneous and mechanically-evoked) from fine articular afferents innervating
normal rat ankle joints and in joints with Freunds adjuvant-induced monoarthritis.
Secondly, behavioural studies, to examine the effects of P-adrenoceptor agonists and
antagonists on the onset and progression of arthritis induced by Freunds adjuvant and
their effects on rats with established localised adjuvant-arthritis.
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6.2 MATERIALS & METHODS
6.2.1 Electrophysiological studies
The in-vivo preparation, neural recording, off-line analysis and statistical analysis are
described in detail in Section 2. In brief, male Wistar rats (normal and adjuvant-
arthritic) were anaesthetised with urethane and cannulations performed of the trachea,
right carotid artery (blood pressure monitoring) and right femoral artery (retrograde
cannulation for close intra-arterial bolus injections of drugs into the left limb). The
medial aspect of the left ankle joint was exposed, and nerve fibres were isolated from
the PACR nerve. C-fibre afferent discharge (spontaneous and mechanically-evoked)
from articular mechanonociceptors was recorded extracellularly, using bipolar
platinum-iridium electrodes.
Protocol
The protocol in these experiments involved an attempt to construct log dose-
response curves to the p2-adrenoceptor agonist, salbutamol (l-10pg i.a.). In a
separate series of experiments, the effects on mechanonociceptor discharges of the
long acting p2 adrenoceptor agonist, salmeterol (5pg, i.a.), were examined. The
effects of the non-selective p-adrenoceptor antagonist, propranolol, or of the selective
p2-adrenoceptor antagonist, ICI 118551 (lmgkg1, i.a.) were also determined. In some
experiments, the catecholamines, adrenaline (lOpg, i.a.) and noradrenaline (lOpg,
i.a.), were injected either before, or more typically, after injections of salbutamol (1 -
lOpg) or salmeterol (5pg). Adrenaline (lOpg) and noradrenaline (lOpg) were also
injected in the presence of propranolol (lmgkg"1, i.a.).
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Data analysis
In this series of experiments, if the test agent evoked an obvious change in
spontaneous discharge then this was assessed by determining the number of impulses
the test agent induced above or below the control discharge level (see Section 2.3.5.2
for further details of the formula used) with the delay and duration also being
measured. If the test agent showed no clear response then the largest number of
impulses both above and below basal discharge were determined by using an arbitrary
time period of 60s over 0 - 20min post-injection of drug. The control period was
defined as the 60s period immediately prior to the addition of the test substance. A
significant change in spontaneous discharge was defined as a change over basal
discharge of greater than 5 impulses for normal joints, and 10 impulses for arthritic
joints. These values of 5 and 10 impulses were derived from the results of saline
injections in normal (3 ± 1 and 2 ± 1 impulses above and below basal discharge,
respectively, 8 units) and arthritic (5 ± 4 and 5 ± 3 impulses above and below basal
discharge, respectively, 15 units) joints. Effects of the test substances on the
responsiveness of the standard mechanical stimulus were assessed as the peak number
of impulses above and / or below the pre-injection evoked discharge. A significant
change in mechanically-evoked discharge was defined as a change of greater than 5
impulses for both normal and arthritic joints over the basal mechanically-evoked
discharge. This value of 5 impulses was derived from the results of saline injections in
normal (2 ± 1 and 3 ± 2 impulses above and below basal discharge, respectively, 8
units) and arthritic (3 + 2 and 3 ± 1 impulses above and below basal discharge,
respectively, 15 units) joints.
160
6.2.2 Behavioural studies
Two protocols were used in this series of behavioural experiments using the Freunds
adjuvant model of arthritis, where the effects of injecting the (^-adrenoceptor agonist,
salmeterol, the non-selective p-adrenoceptor antagonist, propranolol, and the steroid,
dexamethasone, were determined and compared to vehicle injections (the salmeterol
vehicle was used: 99.9% phosphate buffer pH 7; 0.1% glacial acetic acid). In one
protocol the effects of injecting (bolus injection i.p. once daily) test substances in rats
with established (14 days post-adjuvant) localised adjuvant-induced arthritis of the left
ankle joint were examined. In the other series of experiments, injections of test
substances (bolus injection i.p. once daily) were started 2 days before the induction of
adjuvant-arthritis. In both protocols, the following measurements were made: ankle
joint circumference, and inflammation, mobility and pressure threshold scores (see
Section 2.2.1 for details of these measurements). The various measurements were
made approximately 3()min after drug injections. Rat body weight was used as a
general indicator of animal health. All measurements were made blind to drug
treatment by the same experienced investigator.
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6.3 RESULTS
6.3.1 In-vivo electrophysiology in normal and adjuvant-arthritic rat ankle
joints
In this series of experiments, the effects of adrenoceptor agents were examined in 9
single units (8 experiments) from normal joints and in 21 single units (19 experiments)
from adjuvant arthritic (22 ± 6 days post-adjuvant) joints. The mean afferent
conduction velocity was in the C-fibre range for all the units recorded in normal (0.76
± 0.23 ms1 ; range 0.3 - 1.5 ms"1) and arthritic (0.83 ±0.19 ms"1; range 0.4 - 1.7 ms"1)
joints. No significant difference was found between the afferent conduction velocities
in normal and arthritic joints (P>0.05, Mann Whitney U-test). Before the addition of
any drugs, all units showed resting (spontaneous) discharge, although this was
significantly greater in units from arthritic joints (3.1 ± 1.3 i.p.s.; range: 1.5 - 5.8
i.p.s.) than in those from normal joints (0.9 ± 0.3 i.p.s.; range: 0.2 - 1.7 i.p.s.)
(P<0.05, Mann Whitney U-test). All the units examined were excited by close intra¬
arterial injection of capsaicin (1 - 3pg).
6.3.1.1 Effects of adrenoceptor active drugs on mechanonociceptor discharge
from normal joints
In all the units recorded from normal joints, the injection of the (L-adrenoceptor
agonists, salbutamol (1 - lOpg) and salmeterol (5pg) or the catecholamines,
adrenaline (10pg) and noradrenaline (lOpg), showed no significant effect (in
comparison with saline injections) on spontaneous discharge (Table 6.1), nor in the
responsiveness to the standard mechanical stimulus (Table 6.2). Similarly, the P-
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Table 6.1 Lack of effect of adrenoceptor agonists on spontaneous discharge













saline 8(8) 3 ± 1 - 2 ± 1 -
salbutamol iMg 5(4) 2 ± 2 NS 2 ± 1 NS
salbutamol 3pg 5(4) 3 ± 2 NS 3 ± 2 NS
salbutamol lOpg 8(8) 4 ± 1 NS 1 ±2 NS
salmeterol 5pg 3(3) 2 ± 1 NS 3 ± 1 NS
adrenaline lOpg 8(7) 2 ± 2 NS 2 ± 2 NS
noradrenaline 10pg 8(7) 2 ± 2 NS 1 ±2 NS
f Statistical comparisons (Mann Whitney U-test) between saline and the test adrenergic drug.
NS = P>0.05. The pre-injection discharge, before the injection of any drugs, was 0.9 ± 0.3 i.p.s.
Table 6.2 Lack of effect of adrenoceptor agonists on mechanically-evoked















saline 8(8) 1 ±2 - 3 ± 2 -
salbutamol Ibg 4(4) 3 ± 2 NS 2 ± 1 NS
salbutamol 3pg 4(4) 2 ± 1 NS 2 ± 3 NS
salbutamol 10pg 8(8) 1 ±2 NS 1 ±2 NS
salmeterol 5pg 3(3) 3 ± 1 NS 1 ±3 NS
adrenaline lOpg 8(7) 2 ± 2 NS 1 ±2 NS
noradrenaline 10pg 8(7) 2 ± 2 NS 3 ± 2 NS
f Statistical comparisons (Mann Whitney U-test) between saline and the test adrenergic drug.
NS = P>0.05. The pre-injection mechanically-evoked discharge, before the injection of any drugs,
was 38 ± 9 impulses.
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adrenoceptor antagonist, propranolol (lmgkg"1, i.a.), had no significant effect on
either spontaneous (Table 6.3) or mechanically- evoked discharge (Table 6.4).
6.3.1.2 Effects of p2-adrenoceptor agonists on mechanonociceptor discharge
from arthritic joints
The effects of the (^-adrenoceptor agonist, salbutamol (1 - lOpg), was examined in
14 units (13 experiments) recorded from arthritic joints. Of these, 11 units (10
experiments) showed no significant change in either spontaneous discharge (Figure
6.1) or in the response to the standard mechanical stimulus (Figure 6.2). However, in
the remaining 3 units (3 experiments) a significant increase in spontaneous discharge
(excitation response) was produced by the high dose of salbutamol (lOpg) (see Figure
6.3 for typical response and pooled data in Figure 6.4). This salbutamol-induced
excitation had a delay to onset of 140 ± 20s and a response duration of 45 ± 10s, and
was antagonised by the P-adrenoceptor antagonist, propranolol (lmgkg"1, i.a.)
(Figure 6.4). None of the 3 units excited by salbutamol showed any significant effects
on the responsiveness to the mechanical stimulus (P>0.05, Mann Whitney U-test,
versus saline). The long-acting p2-adrenoceptor agonist, salmeterol (5pg), did not
cause any significant change in either spontaneous (Figure 6.5) or mechanically-
evoked (Figure 6.6) discharge in any of the 6 units (5 experiments) recorded.
Although salmeterol (5pg) produced no change in afferent neural discharge, it did
cause a prolonged fall in arterial blood pressure (see Figure 6.7 for a typical
response).
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Table 6.3 Lack of effect of propranolol on spontaneous discharge from
























f Statistical comparisons (Mann Whitney U-test) between saline and propranolol. NS = P>0.05. The
pre-injection discharge, was 0.9 ± 0.3 i.p.s pre-saline and 0.8 ± 0.4 i.p.s. pre-propranolol.
Table 6.4 Lack of effects of propranolol on mechanically-evoked discharge
























f Statistical comparisons (Mann Whitney U-test) between saline and propranolol. NS = P>0.05. The
































































Figure 6.1 Absence of either (a) enhancement or (b) depression by salbutamol (1 -
lOpg) of spontaneous discharge from mechanonociceptors in chronically arthritic (15-
23 days post-adjuvant) joints. The pre-injection discharge, was 2.9 ± 1.3 i.p.s. pre-















































































Figure 6.2 Absence of either (a) enhancement or (b) depression by salbutamol (1 -
lOpg) of mechanically-evoked discharge from mechanonociceptors in chronically
arthritic (15-23 days post-adjuvant) joints. The pre-injection mechanically-evoked
discharge, was 49 ± 10 impulses pre-saline and 47 ±12 impulses pre-salbutamol. Each
point is the mean ± s.e.mean from 11 units (10 experiments).
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Figure 6.4 Salbutamol (lOpg)-induced enhancement, in the absence and presence of
propranolol (lmgkg"1, i.a.), of spontaneous discharge from mechanonociceptors in
chronically arthritic (18-30 days post-adjuvant) rat ankle joints (pre-injection
discharge was 2.5 ±1.2 i.p.s. pre-saline; 2.6 ± 1.4 i.p.s. pre-salbutamol; 2.9 ± 0.8
i.p.s. pre-salbutamol in the presence of propranolol). Each point is the mean ±
s.e.mean from 3 units (3 experiments). * P<0.05, paired t-test, versus salbutamol.
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Figure 6.5 Absence of either (a) enhancement or (b) depression by salmeterol (5pg)
of spontaneous discharge from mechanonociceptors in chronically arthritic (15-24
days post-adjuvant) joints ( pre-injection discharge was 3.3 ± 0.8 i.p.s. pre-saline; 3.4












Figure 6.6 Absence of either (a) enhancement or (b) depression by salbutamol (5pg)
of mechanically-evoked discharge from mechanonociceptors in chronically arthritic
(15-24 days post-adjuvant) joints (pre-injection mechanically-evoked discharge was
50 ± 13 impulses pre-saline; 42 ±11 impulses pre-salmeterol). Each point is the mean
± s.e.mean from 5 units (4 experiments).
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Figure 6.7 Chart recording showing the typical long-lasting hypotension associated
with intra-arterial injection of salmeterol (5pg).
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6.3.1.3 Effects of P-adrenoceptor antagonists on mechanonociceptor
discharge from arthritic joints
In none of the units recorded, did either the non-selective p-adrenoceptor
antagonist, propranolol (lmgkg"1, i.a.), or the selective p2-adrenoceptor antagonist,
ICI 118551 (lmgkg"1, i.a.), have any significant effect on either spontaneous
(Table 6.5) or mechanically- evoked (Table 6.6) discharge.
6.3.1.4 Effects of adrenaline and noradrenaline on mechanonociceptor
discharge from arthritic joints
6.3.1.4.1 Effects of adrenaline and noradrenaline on spontaneous discharge
from arthritic joints
The effects of the catecholamines, adrenaline (lOpg, i.a.) and noradrenaline (lOpg,
i.a.), on spontaneous discharge are summarised in Table 6.7. Of the 14 units (13
experiments) tested with adrenaline (lOpg), 7 units (7 experiments) showed an
excitatory response (see Figure 6.3 for typical response) with the remaining units
having no effect. The effects of noradrenaline (lOpg) were examined on 12 units (11
experiments). Of these units, noradrenaline excited (see Figure 6.3 for typical
response) 7 units (7 experiments) with the remaining units showing no change in
spontaneous discharge. The excitation evoked by adrenaline or noradrenaline was
unaffected by the P-adrenoceptor antagonist, propranolol (lmgkg"1, i.a.)(Table 6.7).
The excitations induced by adrenaline (lOpg) and noradrenline (lOpg) were
significantly greater (approximately 2 and 2.5 fold, respectively) than the excitation
evoked by salbutamol (lOpg, 3 units) (Table 6.7). Moreover, the duration of the
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Table 6.5 Lack of effect of ^-adrenoceptor antagonists on spontaneous













saline 15(14) 5 ± 4 - 5 ±3 -
propranolol lmgkg"1 9(8) 6 ± 3 NS 3 ± 2 NS
ICI118551 lmgkg"1 4(4) 6 ± 4 NS 7 ± 3 NS
f Statistical comparisons (Mann Whitney U-test) between saline and the test P-adrenoceptor
antagonist. NS = P>0.05. The pre-injection discharge, was 3.1 ±1.3 i.p.s pre-saline, 3.4 ± 1.5 i.p.s.
pre-propranolol and 2.7 ±1.4 i.p.s. pre-ICI 118551.
Table 6.6 Lack of effect of (3 -adrenoceptor antagonists on mechanically-evoked

















15 (14) 3 ± 2 - 3 ± 1
9(8) 3 ± 1 NS 1 ± 1




f Statistical comparisons (Mann Whitney U-test) between saline and the test P-adrenoceptor
antagonist. NS = P>0.05. The pre-injection mechanically-evoked discharge, was 49 ± 9 impulses
pre-saline, 32 ± 13 impulses pre-propranolol and 38 ± 8 impulses pre-ICI 118551.
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Table 6.7 Enhancement of spontaneous discharge from mechanonociceptors
by salbutamol, adrenaline and noradrenaline in the (a) absence and (b) presence
of propranolol in arthritic rat ankle joints.
a) absence of propranolol
units units impulses delay
examined excited above basal (s)*
(n) (n) discharge *
salbutamol lOpg 14(13) 3(3) 55 ±6 140 ±20
adrenaline 1 Opg 14(13) 7(7) 90 ± 29 * 146 ±50




78 ± 11 *
94 ± 17 *
* indicates a statistically significant (P<0.05, Mann Whitney U-test) difference as compared to
salbutamol. The pre-injection discharge, was 2.5 ±1.2 i.p.s pre-salbutamol, 2.7 ±1.4 i.p.s. pre-
adrenaline and 2.9 ± 0.8 i.p.s. pre-noradrenaline. * these values refer only to the units that were
excited.
b) presence of propranolol (lmgkg1 ,i.a.)
units units impulses delay duration
examined excited above basal (s) * (s)*
discharge *
salbutamol 10pg 3(3) 3(3) 11± 4 t 107 ± 20 25 ± 17
adrenaline lOpg 7(7) 7(7) 111± 38 77 ±23 84 ± 14
noradrenaline 10pg 7(7) 7(7) 100 ±43 112 ± 28 80 ± 10
t indicates a statistically significant (P<0.05, Mann Whitney U-test) difference as compared to the
value in the absence of propranolol (see Table 6.7a). The pre-injection discharge, was 2.7 ±1.4 i.p.s
pre-salbutamol, 2.9 ± 0.8 i.p.s. pre-adrenaline and 2.9 ± 0.9 i.p.s. pre-noradrenaline. * these values
refer only to the units that were excited.
176
excitation induced by adrenaline (lOpg) or noradrenline (lOpg) was approximately
two-fold greater than that induced by salbutamol (lOpg, 3 units) (Table 6.7).
6.3.1.4.2 Effects of adrenaline and noradrenaline on mechanically-evoked
discharge from arthritic joints
Table 6.8 summarizes the effects of adrenaline (lOpg) and noradrenaline (lOpg) on
the responsiveness to the standard mechanical stimulus. In approximately half of the
units recorded, adrenaline (lOpg) and noradrenaline (lOpg) enhanced (sensitised) the
response to the mechanical stimulus (see Figure 6.3 for typical responses). All units
that were sensitised by adrenaline (lOpg) were also sensitised by noradrenaline
(lOpg). In all the units tested, the sensitisations induced by adrenaline (lOpg) and
noradrenaline (lOpg) were unaffected by the p-adrenoceptor antagonist, propranolol
(lmgkg1, i.a.) (Table 6.8).
6.3.2 Behavioural studies using rats with adjuvant-induced arthritis
6.3.2.1 Influence of salmeterol on an established localised adjuvant-induced
arthritis in the rat
In rats with an established localised adjuvant-induced arthritis of the left ankle joint,
the selective P2-adrenoceptor agonist, salmeterol (50pgkg_1, i.p.), caused no
significant change (compared with vehicle injections) in any of the parameters
measured. Thus, left ankle joint circumference (Figure 6.8), left hind limb withdrawal
pressure score (Figure 6.9), left walking foot placement score (Figure 6.10), left ankle
joint inflammation score (Figure 6.11) and rat body weight (Figure 6.12) were all
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Table 6.8 Enhancement of mechanically-evoked discharge from
mechanonociceptors by adrenaline and noradrenaline in the (a) absence and (b)
presence of propranolol in arthritic rat ankle joints.




noradrenaline lOpg 12 (11)
The pre-injection mechanically-evoked discharge,
impulses pre-noradrenaline. * these values refer oi
inits excited impulses above basal
(n) discharge *
7 (7) 17 ± 3
7(7) 13 ±2
was 43 ±15 impulses pre-adrenaline and 54 ± 16
ily to die units that were excited.
b) presence of propranolol (lmgkg"1, i.a.)
adrenaline lOpg
units units impulses above fP
examined excited basal discharge *
(n) (n)
4(4) 4(4) 16 ± 3 NS
4(4) 4(4) 12 ± 3 NS
f Statistical comparison (Mann Whitney U-test) between values obtained in the absence of
propranolol against those in its presence (see Table 6.8a). NS = P>0.05. The pre-injection
mechanically-evoked discharge in the presence of propranolol, was 36 ± 10 impulses pre-adrenaline
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Figure 6.8 Effects of vehicle, salmeterol (50pgkg"\ i.p.) and dexamethasone
(200fjgkg~\ i.p.) on the circumference of adjuvant-arthritic left ankle joints. Each
point is the mean ± s.e.mean from n=8 experiments. Statistical analysis: P<0.05,
ANOVA days 14-29. * P<0.05, Mann Whitney U-test, versus vehicle.
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treatment period
Figure 6.9 Effects of vehicle, salmeterol (50pgkg"\ i.p.) and dexamethasone
(200|igkg"1, i.p.) on the withdrawal thresholds of adjuvant-arthritic left ankle joints.
Each point is the mean ± s.e.mean from n=8 experiments. Statistical analysis: P<0.05









Figure 6.10 Effects of vehicle, salmeterol (50|igkg_1, i.p.) and dexamethasone
(200|igkg"1, i.p.) on left walking foot placement scores in rats with adjuvant-arthritic
left ankle joints. Each point is the mean ± s.e.mean from n=8 experiments. Statistical








Figure 6.11 Effects of vehicle, salmeterol (50pgkg~\ i.p.) and dexamethasone
(200pgkg_1, i.p.) on inflammation scores of adjuvant-arthritic left ankle joints. Each
point is the mean ± s.e.mean from n=8 experiments. Statistical analysis: * P<0.05,








Figure 6.12 Effects of vehicle, salmeterol (50pgkg~\ i.p.) and dexamethasone
(200pgkg~\ i.p.) on weight of rats with adjuvant-arthritic left ankle joints. Each point
is the mean ± s.e.mean from n=8 experiments. Statistical analysis: P<0.05 ANOVA
days 14-29. * P<0.05, Mann Whitney U-test, versus vehicle.
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unchanged. A higher dose of salmeterol (150pgkg_1, i.p.) also had no significant effect
(P>0.05, Mann Whitney U-test, versus vehicle) in any of the parameters
examined (for clarity of Figures, data is not shown). In contrast,
dexamethasone (200pgkg"', i.p.), caused significant changes in all of the parameters
measured (Figures 6.8 -6.12). Once dexamethasone treatment was terminated there
was an increase in left ankle joint circumference (Figure 6.8), a decrease in left hind
limb withdrawal pressure score (Figure 6.9) and increases in left walking foot
placement score (Figure 6.10), left ankle joint inflammation score (Figure 6.11) and
rat body weight (Figure 6.12) to such an extent that the parameters did not differ
significantly (5-10 days after terminating treatment) from those of the vehicle-treated
rats.
6.3.2.2 Influence of salmeterol and propranolol on the development of a
localised adjuvant-induced arthritis in the rat
Intra-peritoneal injections of the selective (^-adrenoceptor agonist,
salmeterol (50pgkg"'), or of the (i-adrenoceptor antagonist, propranolol (lmgkg1),
caused no significant change (compared to vehicle injections) in the development of
either the acute (day 2 - 9) or chronic (day 9-19) phases of arthritis (Freunds
adjuvant injected day 1); there was no change in left ankle joint circumference
(Figure 6.13), left hind limb withdrawal pressure score (Figure 6.14), left walking foot
placement score (Figure 6.15), left ankle joint inflammation score (Figure 6.16) and
rat body weight (Figure 6.17). In contrast, treatment with dexamethasone (200pgkg1,
i.p.), showed significant changes in all of these parameters (Figures 6.13 -6.17) in
both the acute and chronic phases of the arthritis. Once dexamethasone treatment was
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treatment period
Figure 6.13 Effects of vehicle, salmeterol (50pgkg'\ i.p.), propranolol (Imgkg"1, i.p.)
and dexamethasone (200pgkg"\ i.p.) on the circumference of adjuvant-arthritic left
ankle joints. Each point is the mean ± s.e.mean from n=8 experiments. Statistical




Figure 6.14 Effects of vehicle, salmeterol (50pgkg"\ i.p.), propranolol (lmgkg1, i.p.)
and dexamethasone (200pgkg"\ i.p.) on the withdrawal thresholds of adjuvant-
arthritic left ankle joints. Each point is the mean ± s.e.mean from n=8 experiments.









Figure 6.15 Effects of vehicle, salmeterol (50|agkg_1, i.p.), propranolol (lmgkg1, i.p.)
and dexamethasone (200pgkg1, i.p.) on left walking foot placement scores in rats
with adjuvant-arthritic left ankle joints. Each point is the mean ± s.e.mean from n=8








Figure 6.16 Effects of vehicle, salmeterol (50pgkg"\ i.p.), propranolol (lmgkg"1, i.p.)
and dexamethasone (200pgkg"\ i.p.) on inflammation scores of adjuvant-arthritic left
ankle joints. Each point is the mean ± s.e.mean from n=8 experiments. Statistical
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Figure 6.17 Effects of vehicle, salmeterol (50pgkg"\ i.p.), propranolol (lmgkg1, i.p.)
and dexamethasone (200pgkg~\ i.p.) on weight of rats with adjuvant-arthritic left
ankle joints. Each point is the mean ± s.e.mean from n=8 experiments. Statistical
analysis: P<0.05 ANOVA days 2-9 and days 9-19. * P<0.05, Mann Whitney U-test,
versus vehicle.
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terminated, there was an increase in left ankle joint circumference (Figure 6.13), a
decrease in left hind limb withdrawal pressure score (Figure 6.14), and increases in
left walking foot placement score (Figure 6.15), left ankle joint inflammation score
(Figure 6.16) and rat body weight (Figure 6.17).
190
6.4 DISCUSSION
6.4.1 p2 adrenoceptors and mechanonociceptor discharge from normal and
adjuvant-arthritic rats
The results of the present study have shown that neural discharge (spontaneous and
mechanically-evoked) from mechanonociceptors in normal rat ankle joints was
unaffected by either p2-adrenoceptor agonists of either short (salbutamol) or of long
(salmeterol) duration, or by the non-selective (^-adrenoceptor antagonist, propranolol.
The catecholamines, adrenaline and noradrenaline, also had no effect on neural
discharge (spontaneous or mechanically-evoked) from C-afferent fibres in normal
ankle joints. These findings are in agreement with the electrophysiological studies in
rabbit auricular (Sato & Perl, 1991) and rat skin (Sanjue & Jun, 1989) C-afferent
fibres which show the absence of effect of noradrenaline on neural discharge in
undamaged tissue. As discussed below, sympathetic efferents can produce pain and
hyperalgesia in damaged or diseased tissues. However, in normal tissues, the inability
of sympathetic nerve stimulation to produce any change in neural discharge from
nociceptors (Roberts & Elardo, 1985; Shea & Perl, 1985; Barasi & Lynn, 1986;
Sanjue & Jun, 1989) adds further support to the conclusion that adrenoceptors are
not involved in affecting afferent discharges from nociceptors in normal tissues.
In the current investigation, the p2-adrenoceptor agonist, salbutamol, produced
excitation in only a few afferent units recorded from adjuvant-arthritic ankle joints.
This salbutamol-induced excitation was reduced by the P-adrenoceptor antagonist,
propranolol. Even though this salbutamol-induced excitation was small, these results
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could suggest that (^-adrenoceptors may play a minor role in modulating neural
discharges in a small proportion of C-fibre afferents. However, in the present
experiments (^-adrenoceptor agonists (salbutamol and salmeterol) failed to produce
either a change in spontaneous or mechanically-evoked discharge in the vast majority
of C-fibre units recorded from adjuvant-arthritic rat ankle joints. Moreover, since (3-
adrenoceptor antagonists (non-selective: propranolol; (32-selective: ICI118551) had
no effect on the enhanced (compared to normal joints) spontaneous discharge and
sensitisation of mechanical stimuli associated with chronically arthritic joints, these
data suggest that in this model of chronic inflammation (adjuvant-arthritis), (32-
adrenoceptors are unlikely to play a significant role in the excitation and sensitisation
of mechanonociceptors. In accord with this conclusion, an absence of effects of (3-
adrenoceptor drugs has been reported in thermal-sensitised cat skin A-8 nociceptors
(Roberts & Elardo, 1985) and in rat myelinated afferents innervating neuromas (Wall
& Gutnik, 1974).
6.4.2 Effects of adrenaline and noradrenaline on mechanonociceptor
discharge
Although adrenaline and noradrenaline had no effect on articular afferent neural
discharge (spontaneous and mechanically-evoked) from normal rat ankle joints, they
did produce both an increase in spontaneous discharge (excitation) and in the
responsiveness to the standard mechanical stimulus (sensitisation) in approximately
50% of articular afferents recorded from chronically inflamed (adjuvant-arthritic) rat
ankle joints. In line with these results of the present study, noradrenaline or
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adrenaline-induced enhancements in neural discharge have been reported in 78% of
rat skin afferents when there was a sustained background discharge induced by a
compound algogenic substance (Sanjue & Jun, 1989), and in 42% of rat skin C-fibre
(Sato & Perl, 1991), in 40% of cat skin unmyelinated (Habler et al., 1987) and in
most rat myelinated (Wall & Gutnik, 1974; Devor & Jiinig, 1981) afferents originating
from inflamed tissue (stump neuromata).
In the current study, noradrenaline caused mechanical sensitisation of
mechanonociceptors in chronically inflamed (adjuvant-arthritic) joints. In agreement,
it has been reported by Gold et al. (1994) that, although noradrenaline alone did not
affect mechanical thresholds of rat cutaneous mechanonociceptors, there was a
reduction in mechanical thresholds (sensitisation) when noradrenaline was applied in
the presence of the calcium ionophore, A23187. Thus, it appears that a local increase
in Ca2+ concentration accompanying tissue injury (Nayler et ah, 1979) is required for
noradrenaline-induced mechanical sensitisation.
The delay to the onset of both adrenaline (146 ± 50s) and noradrenaline (124 ± 36s)
induced excitation of mechanonociceptors from arthritic joints in the current study
were much longer than the delays (10 - 25s) observed by investigators in studies of
unmyelinated or myelinated afferents from neuromas (Wall & Gutnik, 1974; Devor &
Janig, 1981 ; Habler et ah, 1987; Koltzenburg & McMahon, 1991; Sato & Perl,
1991). These differences in delays may be explained by differences in the models used
(adjuvant-induced arthritis versus neuromas). The delay before the onset of adrenaline
and noradrenaline-induced enhancements in neural discharge suggests that the
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mechanism of action of these agents may involve the release of other inflammatory
mediators such as prostanoids and/or leukotrienes (see discussion below). Similar
duration (60 - 120s) of action for adrenaline or noradrenaline-induced excitation were
also reported by Sanjue & Jun (1989) and Sato & Perl (1991) in cutaneous C-fibre
afferents from neuromas.
Since adrenaline and noradrenaline-induced excitation and sensitisation of
mechanonociceptors from arthritic joints were unaffected by propranolol, this
indicates that these catecholamines were not acting via p-adrenoceptors to produce
their effects. In agreement with these results, it has been shown that activation of
afferents ending in a neuroma by adrenaline were unaffected by propranolol (Wall &
Gutnick, 1974; Devor & Janig, 1981). Since adrenaline and noradrenaline are also
potent a-adrenoceptor agonists (Bowman & Rand 1980) it is probable that the
excitation and sensitisation evoked in the current experiments was due to an action at
a-adrenoceptors - whether co or a2-adrenoceptors, or a contribution of both, are
responsible for the adrenaline and noradrenaline-induced enhancements in neural
discharge (excitation and sensitisation) in arthritic joints requires further investigation
using selective oti and a2-adrenoceptor agonists and antagonists. Indeed,
electrophysiological recordings from afferent fibres suggest that a-adrenoceptors
mediate the actions of adrenaline and noradrenaline, since the a-adrenoceptor
antagonist, phentolamine, but not the (^-adrenoceptor antagonist, propranolol,
blocked the enhancements in neural discharge induced by these catecholamines (Wall
& Gutnik, 1974; Devor & Jiinig, 1981). Furthermore, the study by Sato & Perl (1991)
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points to the involvement of (X2-adrenoceptors, since noradrenaline-induced excitation
of cutaneous nociceptors following peripheral nerve injury could be blocked by the
a2-adrenoceptor antagonists, yohimbine and rauwolscine. However, this study by
Sato & Perl (1991) also showed that noradrenaline-induced excitations could be
blocked, albeit to a lesser degree, by the ai-adrenoceptor antagonist, prazosin,
indicating that there may also be a contribution from oci-adrenoceptors. Regarding the
catecholamine-induced mechanical sensitisation of mechanonociceptors observed in
the present experiments, oc2-adrenoceptors are likely to be involved, since it has been
shown that noradrenaline-induced mechanical sensitisation of cutaneous
mechanonociceptors was blocked by the a2-adrenoceptor antagonist, yohimbine, but
not by the aradrenoceptor antagonist, prazosin (Gold et al., 1994).
Since adrenaline and noradrenaline are potent vasoconstrictors, it is possible that the
excitation or sensitisation observed with these catecholamines in the present
investigation, was due to an effect on blood pressure. However, since ot,P-methylene-
ATP (see Section 5) or endothelin (Kelly & McQueen, unpublished) cause large
increases in blood pressure without affecting neural discharge (spontaneous or
mechanically-evoked) it is unlikely that the increase in blood pressure or local
vasoconstriction induced by adrenaline or noradrenaline influenced neural discharge in
the current experiments.
195
6.4.2.1 Location(s) of action of adrenaline and noradrenaline-induced
enhancements of discharge from articular mechanonociceptors
Of the various sites at which adrenaline and noradrenaline could cause enhancement
of neural discharge (spontaneous and mechanically-evoked) from articular
mechanonociceptors in adjuvant-arthritic rat ankle joints, two possibilities include the
sympathetic efferent nervous system and the terminals of C-fibre afferents. Regarding
the sympathetic efferent nervous system, various studies have suggested that there is
an indirect coupling of sympathetic efferents and afferent fibres (see Fitzgerald, 1989;
Gonzales et al., 1991; McMahon, 1991; Schaible & Grubb, 1993; Gold et al., 1994).
In such a scenario, adrenaline or noradrenaline act on adrenoceptors on sympathetic
postganglionic terminals to cause the release of prostaglandins and/or leukotrienes (or
other mediators e.g. 5-HT, substance P) which then act on afferent terminals to cause
excitation or sensitisation. Indeed the long latency to the onset of adrenaline and
noradrenaline-induced excitation observed in the present investigation would propose
such an indirect mechanism of action. Further experiments where the effects of
adrenaline and noradrenaline are studied in preparations where prostaglandin and/or
leukotriene production is blocked would aid in determining whether or not these
catecholamines act indirectly. It would be of interest to perform further experiments in
order to determine whether sympathetic stimulation or sympathectomy could affect
neural discharge from mechanonociceptors in both normal and chronically inflamed
(adjuvant-arthritic) joints. Moreover, it would be interesting to determine if chronic
inflammation could affect the resting discharge of sympathetic efferents.
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Since in the present investigation, adrenaline and noradrenaline affected
mechanonociceptor discharge in arthritic joints, but not in normal joints, it would have
to be postulated that the sympathetic system undergoes changes under inflammatory
conditions, for example, by up-regulation and/or expression of adrenoceptors, or the
coupling of adrenoceptors to different second messenger systems in the presence of a
raised calcium concentration caused by inflammation (Gold et al., 1994). However,
the role of the sympathetic nervous system in affecting afferent neural discharge has
been questioned by Scott (1994), who presents powerful arguments that it is more
likely to be visceral afferents (terminology also includes peripheral structures), which
travel within autonomic nerves, which are the location of action of adrenergic agents.
Another possible location of action for adrenaline or noradrenaline-induced increases
in afferent discharge in the present study are the afferent nociceptive terminals, where
there may be expression or up-regulation of a-adrenoceptors (see Devor, 1991;
McMahon, 1991).
6.4.3 Behavioural studies of the effects of fl-adrenoceptor agonists and
antagonists on a localised Freunds adjuvant-induced arthritis in the
rat
Two studies were performed to determine the effects of (^-adrenoceptor agonists
and antagonists in rats with a localised adjuvant-induced arthritis of the left ankle
joint. In the first study, the (^-adrenoceptor agonist, salmeterol, showed no effects on
measures of inflammation (Figures 6.8 & 6.11) or hyperalgesia (Figures 6.9 & 6.10)
associated with rats with an established adjuvant-induced arthritis. In the second
investigation, treatment (i.p. injections started 2 days before injection of adjuvant)
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with the (^-adrenoceptor agonist, salmeterol, or the non-selective (^-adrenoceptor
antagonist, propranolol, was found not to have any effects on the onset and
progression (acute and chronic phases) of the localised adjuvant-induced arthritis of
the rat ankle joint as determined by parameters of inflammation (Figures 6.13 & 6.16)
and hyperalgesia (Figures 6.14 & 6.15). In contrast to these results of the present
investigation, it has been shown in the same model that propranolol, or more
specifically the (^-adrenoceptor antagonists, butoxamine and ICI 118551, attenuated
the progression of joint injury when treatment began before or after the onset of
experimental arthritis (Levine et al., 1988), and that the (^-adrenoceptor agonist,
salbutamol, significantly increased joint injury (Coderre et al., 1990; Coderre et al.,
1991). There are several explanations which could account for the differences
between these observations and those of the present study. For example, in the
present study propranolol was injected once daily at a dose of lmgkg"1, whereas a
significantly higher dose (20mgkg"1, 3 times daily) was used in the studies by Levine
et al. (1988). Since high doses of propranolol can cause effects unrelated to (3-
adrenoceptor blockade, including membrane stabilisation (Bowman & Rand, 1980), it
is possible that propranolol may have caused a reduction in joint severity in the study
by Levine et al. (1988) by some non-specific mechanism. Another difference relates to
the measurements of adjuvant-arthritis; the studies by Levine et al. (1988) and
Coderre et al. (1990; 1991) used radiological scores, whereas the current
investigation used other measures (see Section 2.2.1). However, since it has been
shown that measurements of limb joint circumference in adjuvant-arthritis correlates
well with joint histology (Donaldson et al., 1993), it is unlikely that differences in the
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measurements of the adjuvant-induced arthritis between the studies can account for
the differences observed to p-adrenoceptor agents.
The failure of salmeterol to enhance experimental arthritis in the current
investigation may have been because severity of joint damage was already at a peak.
Indeed, it has been reported by Coderre et al. (1991) that salbutamol could not
increase joint injury in rats with adjuvant-induced arthritis, although when salbutamol
was given to a rat strain (Wistar-Kyoto) which develops only a mild experimental
arthritis, there was an exacerbation of the arthritis (Coderre et al., 1991). However,
since in the current study, not only did salmeterol treatment not increase the degree of
adjuvant-induced arthritis, but neither did it enhance its onset or progression, it
appears that salmeterol has no effect on adjuvant-induced arthritis.
P2-adrenoceptor agonists such as salbutamol, and in particular longer-duration p2-
adrenoceptor agonists such as salmeterol (Ball et al., 1991), have been shown to have
anti-inflammatory effects including inhibition of mediator (histamine, leukotrienes and
prostaglandins) release (Butchers et al., 1979; Butchers et al., 1991), bradykinin-
induced plasma protein extravasation (Whelan et al., 1993), vascular permeability and
granulocyte accumulation (Whelan & Johnson, 1992) and carrageenan-induced
oedema (Green, 1972). In contrast, no anti-inflammatory or analgesic effects were
observed in the current investigations using a model of chronic inflammation
(adjuvant-induced arthritis). It could be that the rat adjuvant model of arthritis is not
capable of detecting slight anti-inflammatory or analgesic actions, even although it can
clearly detect the actions of anti-inflammatory drugs such as dexamethasone (Figures
199
6.8 - 6.17 & Section 6.4.4) or indomethacin (see Section 4), or it could show a
difference in the ability of (^-adrenoceptor agonists to produce acute and chronic anti¬
inflammatory effects.
6.4.4 Effects of dexamethasone on localised adjuvant-induced arthritis.
The corticosteroid, dexamethasone, has been long established as a drug which
significantly reduces inflammation and hyperalgesia in adjuvant-arthritic rats (see
Winter & Nuss, 1966; Schmollack & Steup, 1988). Thus, in the present behavioural
experiments, involving the study of (5-adrenoceptor active drugs, it was decided to
inject dexamethasone in one group of rats - this group then functioned as the positive
control group. As expected from the literature (see above), dexamethasone in the
current investigation was anti-inflammatory and reduced mechanical hyperalgesia. The
mechanism of action of dexamethasone involves, following its entry into the cell,
interactions with intracellular specific receptors in the nucleus with the subsequent
formation of various polypeptides which have anti-inflammatory effects. For example,
one such peptide is lipocortin which inhibits phospholipase A2 activity, and thus
inhibits the release of arachidonic acid (see Vane & Botting, 1987). Consequently,
there is inhibition in the formation of both prostaglandins and leukotrienes. Indeed, in
the present studies dexamethasone was more potent at reducing inflammation and
hyperalgesia than was the NSAID, indomethacin, which only inhibits the formation of
prostaglandins (see Section 4.4.3). This rank order of potency of dexamethasone >
indomethacin seen in the current study confirms the same potency order seen by other
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investigators in adjuvant-arthritic rats (Winter & Nuss, 1966; Schmollack & Steup,
1988).
6.5 SUMMARY
In summary, the results of the present investigation show that (^-adrenoceptor
agonists and antagonists do not affect neural discharge from mechanonociceptors in
either normal or adjuvant-arthritic rat ankle joints - all units recorded were excited by
the selective C-fibre excitant, capsaicin. In line with these neuropharmacological
studies, the results of complementary behavioural investigations also showed that p-
adrenoceptor agonists and antagonists do not affect the inflammation and hyperalgesia
associated with chronic arthritis (adjuvant-induced) of the rat ankle joint - the steroid,
dexamethasone, was clearly anti-inflammatory and analgesic in this model of arthritis.
Although adrenaline and noradrenaline did not affect neural discharge from
mechanonociceptors in normal joints, they did enhance both spontaneous and
mechanically-evoked discharge in approximately 50% of C-fibre units recorded from
chronically-inflamed (adjuvant-arthritic) joints. Since these effects were not affected
by propranolol, this strongly suggests that the catecholamines are not acting at p-
adrenoceptors, but rather at a-adrenoceptors. Further studies, which were not
possible during the present investigation, would be needed to confirm this.
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SECTION 7
EFFECTS OF BRADYKININ AND ITS ANALOGUES ON ARTICULAR




The levels of plasma kinins are increased markedly during various types of
inflammatory reaction, including rheumatoid arthritis in humans (Bhoola et al., 1992;
Sharma, 1992), and adjuvant-induced arthritis in animals (VanArman & Nuss, 1969;
Reis et al., 1982). Bradykinin (BK) produces many pro-inflammatory effects such as
vasodilation, tissue oedema and increased vascular permeability, and is one of the
most potent endogenous occurring algogenic agents. In man, BK produces pain when
applied to the cantharadin-induced blister base (Keele & Armstrong, 1964; Whalley et
al., 1987), or when it is injected intra-arterially (Coffman, 1966), intra-abdominally
(Lim et al., 1967), sub-dermally (Ferreira, 1972), intra-muscularly (Jensen et al.,
1990a) or intra-dermally (Jensen et al., 1990b). In animal studies, pseudoaffective
responses (e.g. vocalisation, dextrorotation, biting, scratching, licking, and reflex
increase in blood pressure) are obtained following injection of BK intra-arterially
(Guzman et al., 1962; Hashimoto et al., 1964) or intra-articularly (Moncada et al.,
1975).
In electrophysiological studies, BK has been shown to excite nociceptors in skin
(Beck & Handwerker, 1974; Szolcsdnyi, 1987; Lang et al., 1990; Dray et al., 1992),
viscera (Haupt et al., 1983; Mizumura et al., 1990) and joints (Kanaka et al., 1985). It
has also been demonstrated that bradykinin can sensitise the response to mechanical
(Mense & Mayer, 1987; Grubb et al., 1991; Birrell et al., 1993) and thermal
(Koltzenburg et al., 1992) stimuli.
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Evidence that is consistent with a role of BK as a physiological mediator of pain has
been provided by autoradiographic studies, where BK receptors were shown to be
localised to sensory neurones (Steranka et al., 1988). BK receptors are classified into
Bi and B2 subtypes (Regoli & Barabe, 1980). In most models of BK-induced pain,
hyperalgesia or inflammation it is the B2 receptor which mediates these actions of BK.
Although early generation B2 receptor antagonists (e.g. D-Arg-[Hyp3, Thi5'8, D-Phe7]-
BK) have been shown to block the hyperalgesic and inflammatory effects of BK, their
susceptibility to fast enzymatic degradation (Griesbacher et al., 1989) has limited their
therapeutic usefulness. Recently D-Arg-[Hyp3, Thi5, D-Tic7, Oic8]-BK (Hoel40), a
subsequent generation, potent, and long-acting B2 receptor antagonist (Bao et al.,
1991; Lembeck et al., 1991) has been synthesised and shown to block the actions of
BK in various models of acute and chronic inflammation (Wirth et al., 1991; Damas &
Remacle-Volon, 1992; Correa & Calixto, 1993; Heapy et al., 1993; Griesbacher et al.,
1993; Griesbacher et al., 1994).
Evidence has accumulated in recent years which implies that Bi receptors play a role
in chronic or persistent pain, hyperalgesia and inflammation. Studies by Farmer et al
(1991a) have shown that, although Bi receptors are not present under normal
conditions, they could be induced under inflammatory (antigen-induced arthritis)
situations. More recently, a role for Bi receptors has been demonstrated in rat models
of persistent inflammatory thermal (Perkins & Kelly, 1993) or mechanical (Davis &
Perkins, 1994) hyperalgesia. There is also evidence that B[ receptors participate in
both phases of the formalin-induced pain model in the mouse (Correa & Calixto,
1993).
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The aims of the present investigation on articular mechanonociceptors in both
normal and adjuvant-arthritic ankle joints were fourfold, namely: 1) to study the
actions of BK, 2) to determine whether prostaglandins are involved in the BK-induced
responses, 3) to examine the actions of Bi-selective receptor agonists and antagonists,
and 4) to investigate the effects of the potent B2 receptor antagonist, Hoe 140.
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7.2 MATERIALS AND METHODS
7.2.1 Electrophysiological studies
The in-vivo preparation, neural recording, off-line analysis and statistical analysis are
described in detail in Section 2. In brief, male Wistar rats (normal and adjuvant-
arthritic) were anaesthetised with urethane and cannulations performed of the trachea,
right carotid artery (blood pressure monitoring) and right femoral artery (retrograde
cannulation for close intra-arterial bolus injections of drugs into the left limb). The
medial aspect of the left ankle joint was exposed, and nerve fibres were isolated from
the PACR nerve. C-fibre afferent discharge (spontaneous and mechanically-evoked)
from articular mechanonociceptors was recorded extracellularly, using bipolar
platinum-iridium electrodes.
Protocol
In normal and arthritic rats log dose-response curves (spontaneous and
mechanically-evoked discharge) were constructed to bradykinin (1 - lOOpg, i.a.)
before and after des-Arg9-Leu8-BK (bradykinin Bi receptor antagonist, lOOpgkg"1
i.a.), Hoel40 (bradykinin B2 receptor antagonist, 10 - lOOpgkg"1 i.a.) or indomethacin
(cyclo-oxygenase enzyme inhibitor, lOmgkg"1 i.a.). In another series of experiments,
an attempt was made to construct log dose-response curves (spontaneous and
mechanically-evoked discharge) to the Bi receptor agonist, des-Arg9-BK (1 - lOOpg,
i.a), in normal, and acutely (3 -5 days post-adjuvant) or chronically (19 - 30 days
post-adjuvant) arthritic, rats; log dose-response curves to bradykinin (1 - 30pg) were
also constructed either before or after injection of des-Arg9-BK (1 - lOOpg).
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Data analysis
In order to compare the effects of BK and des-Arg9-BK on spontaneous discharge,
ongoing discharges were quantified as the peak increase in discharge (averaged over
15s) above the control discharge (averaged over 60s prior to drug injection). A
significant increase in spontaneous discharge in this analysis was defined as an
increase above basal spontaneous discharge of >0.5i.p.s. for units in both normal and
arthritic joints. This value was obtained from the results of saline injections in normal
(0.41 ± 0.07i.p.s. above basal discharge) and arthritic (0.36 ± O.lli.p.s. above basal
discharge) joints. The delay and duration of the enhancement in spontaneous
discharge was also measured when possible.
Since des-Arg9-BK, des-Arg9-Leu8-BK and Hoe 140 had no obvious effect on
spontaneous discharge, the largest number of impulses both above and below the
basal discharge were determined by using an arbitrary time period of 60s over 0 -
15min post-injection of the drug; the control period was defined as the 60s period
immediately prior to the addition of the test substance (see Section 2.3.5.2 for details
of the formula used). In this analysis a significant change in spontaneous discharge
was defined as a change over basal discharge of at least 10 impulses for both normal
and arthritic joints. This value of 10 impulses was derived from the results of saline
injections in normal (6 ± 2 and 6 ± 3 impulses above and below basal discharge,
respectively, 9 units) and arthritic (5 ± 2 and 6 ± 3 impulses above and below basal
discharge, respectively, 9 units) joints.
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Drug effects on mechanically-evoked discharge were quantified as the peak number
of impulses above or below the pre-injection evoked discharge. When there was no
obvious effect of the test substance on the response to the standard mechanical
stimulus, the peak number of impulses above and below the pre-injection evoked
discharge were calculated. A significant change in mechanically-evoked discharge was
defined as a change of 2 or more impulses for both normal and arthritic joints over the
basal mechanically-evoked discharge. This value of 2 impulses, was derived from the
results of saline injections in normal (1.4 ± 0.2 and 1.1 ± 0.3 impulses above and
below basal discharge, respectively, 8 units) and arthritic (1.3 ± 0.3 and 1.1 ±0.2
impulses above and below basal discharge, respectively, 8 units) joints.
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7.3 RESULTS
7.3.1 In-vivo electrophysiology in normal and adjuvant-arthritic rat ankle
joints
A total of sixteen normal (twenty one units), four acutely arthritic (five units; 3 -5
days post-adjuvant) and twenty two chronically arthritic (thirty five units; 28 ± 3 days
post-adjuvant) joints were examined in this series of experiments. The mean afferent
conduction velocities were in the C-fibre range for all the units studied in both normal
(0.72 ± 0.06 ms"1; range: 0.43 - 1.0 ms"1) and arthritic (0.74 ± 0.10 ms"1; range: 0.41-
1.5 ms"1) joints. There was no significant difference in the afferent conduction velocity
between normal and arthritic joints (P>0.05, Mann-Whitney U-test). Before the
addition of any drugs, all the units in both normal and arthritic joints had on-going
(spontaneous) neural discharges. However, the spontaneous discharges from arthritic
joints (3.9 ± 0.8 i.p.s.: range 1.7 - 11.6 i.p.s.) were significantly (P<0.05, Mann-
Whitney U-test) greater than those from normal joints (1.1 ± 0.3 i.p.s.: range 0.2 -
1.8 i.p.s.). All the units examined in both normal and arthritic joints were excited by
close intra-arterial injection of capsaicin (l-3pg).
7.3.2 Effects of bradykinin on spontaneous discharge
7.3.2.1 Bradykinin-induced excitation in normal joints
Twenty one units from fifteen individual experiments were examined for their
response to bradykinin (BK). BK(l-30pg)-induced increase in spontaneous afferent
discharge was observed in eighteen units (86%) from thirteen experiments (see
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Figure 7.1 for a typical BK-induced excitation). The remaining three units from two
experiments were not affected by BK (l-100pg) although they were excited by
capsaicin (lpg, i.a.).
Examination of dose-dependency was carried out on eleven responsive units from
eight experiments. BK(1 - 30pg)-induced dose-dependent excitatory responses were
observed in nine units from seven joints (Figure 7.2). In the remaining two units (one
experiment) desensitisation occurred at the highest dose of BK (30pg).
The delay to the onset of BK-induced excitation was similar (approximately 60s) for
the two lower doses of BK (1 and 3pg) but was more rapid (approximately 10s) for
the higher doses (10 and 30pg) of BK (Figure 7.3). The duration of the BK-induced
excitation was similar (approximately 100s) for lower doses of BK but was longer
(>150s) for higher ones (Figure 7.4).
7.3.2.2 Bradykinin-induced excitation in arthritic joints
The effects of BK were determined on thirty five units from twenty two
experiments. Thirty one units (89%) from nineteen experiments showed an increase in
spontaneous discharge following the application of BK (l-100pg); Figure 7.5 shows a
typical BK-induced excitation response. In the remaining four units (three
experiments) no excitatory responses were obtained to BK (1 - lOOpg) although these




Figure 7.1 (a) Computer generated plot illustrating the excitatory and sensitising
effects of bradykinin (3()pg, i.a.) on a single C-fibre (conduction velocity 0.6ms"1) unit
from a normal rat ankle joint. Each bar represents a Is time interval. Arrowheads
indicate the application of the mechanical stimulus. The number of impulses evoked
by the mechanical stimulus is given above each response, (b) Neurogram showing
response of the unit to a mechanical indentation stimulus (waveform below
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Figure 7.2 Comparison between normal and arthritic (25 ± 5 days post-adjuvant)
joints of the effects of bradykinin (l-30pg, i.a.) on (a) spontaneous and (b)
mechanically-evoked discharge. Each point is the mean ± s.e.mean from 8 - 10 units
(6 - 10 individual experiments). The mean ± s.e.m. pre-injection spontaneous
discharge before the injection of any drugs in units recorded from normal and arthritic
joints was 1.25 ± 0.12 and 3.89 ± 1.03, respectively. The mean ± s.e.m. pre-injection
mechanically-evoked discharge before the injection of any drugs in units recorded
from normal and arthritic joints was 40 ± 13 and 47 ± 9, respectively.
212
bradykinin (pg)
Figure 7.3 Comparison between normal and arthritic joints of the delay to the onset
of bradykinin(l-30pg)-induced increase in spontaneous discharge. Each point is the
mean ± s.e.mean from 9-11 units (7-10 individual experiments).* P<0.05 Mann
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Figure 7.4 Comparison between normal and arthritic joints of the duration of
bradykinin(l-30pg)-induced increase in spontaneous discharge. Each point is the
mean ± s.e.mean from 9-11 units (7 - 10 individual experiments).* P<0.05 Mann












Figure 7.5 (a) Computer generated plot illustrating the excitatory and sensitising
effects of bradykinin (30pg, i.a.) on a single C-fibre (conduction velocity 0.6ms"1) unit
from an adjuvant-arthritic rat ankle joint. Each bar represents a Is time interval.
Arrowheads indicate the application of the mechanical stimulus. The number of
impulses evoked by the mechanical stimulus is given above each response, (b)
Neurogram showing response of the unit to a mechanical indentation stimulus
(waveform below neurogram). (c) A fast oscilloscope sweep of the unit that was
counted.
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Investigation of dose-dependency was carried out on fifteen responsive units from
twelve arthritic (25 ± 5 days post-adjuvant) joints. BK(1 - 30pg)-induced dose-
dependent excitation was observed in eleven units from ten arthritic joints (Figure
7.2). In the remaining four units (two experiments) desensitisation occurred at higher
doses of BK (10 - 30pg).
BK(10 and 30pg)-induced excitation was greater in normal joints than in arthritic
joints, although this difference did not reach statistical significance (P>0.05, Mann
Whitney U-test)(Figure 7.2).
The delay to the onset of the BK-induced excitation in arthritic joints was similar
across the dose (1 - 3()pg) range tested (Figure 7.3). In comparison with units in
normal joints, the units recorded in arthritic joints showed significantly longer delays
to the onset of the BK (10 and 30pg)-induced increase in spontaneous discharge
(Figure 7.3).
The durations of the BK-induced excitation were similar (approximately 100s)
across the dose (1 - 30pg) range tested (Figure 7.4). The duration of BK (10 and
30pg)-induced excitation in units recorded from arthritic joints was significantly lower
than the corresponding duration obtained in normal joints (Figure 7.4).
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7.3.3 Effects of bradykinin on the responsiveness to mechanically-evoked
stimuli
7.3.3.1 Bradykinin-induced sensitisation of mechanically-evoked discharge in
normal joints
Twenty units from sixteen experiments were examined for their response to BK. Of
these, sixteen units (80%) from thirteen experiments showed enhancements in the
responsiveness to the application of the standard mechanical stimulus following the
application of BK (l-100pg); Figure 7.1 for a typical BK-evoked sensitisation. In the
remaining four units (20%) from three normal joints there were no significant effects
of BK on mechanically-evoked discharge.
Eleven units from nine normal joints were examined for the dose-dependency of
their response to BK (1 - 30pg). Dose-dependent sensitisations to mechanical stimuli
were obtained in eight units from six experiments (Figure 7.2). In the remaining three
units (three experiments) there was no dose-dependent sensitisation.
7.3.3.2 Bradykinin-induced sensitisation of mechanically-evoked discharge in
arthritic joints
Sixteen units (fifteen experiments) were examined for their response to BK.
Fourteen units (88%) from thirteen experiments showed that BK(l-lOOpg) increased
responsiveness to the applied standard mechanical stimulus; Figure 7.5 for a typical
BK-induced sensitisation. In the remaining two units, from two arthritic joints, BK
had no effect on mechanically-evoked discharge.
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The dose-dependency of BK (1 - 30pg) in enhancing mechanically-evoked discharge
was investigated on thirteen responsive units from twelve arthritic joints (25 ± 5 days
post-adjuvant). In eleven units (ten experiments) BK (1 - 30pg) caused dose-
dependent enhancements in the response to the mechanical stimulus (Figure 7.2). In
the remaining two units (two experiments) there was no dose-dependent increase in
the response to mechanical stimuli.
Although no statistical difference (P>0.05, Mann-Whitney U-test) was found for
BK-induced sensitisation between normal and arthritic joints, there was a trend for
BK-induced sensitisation (3-30pg) to be of greater magnitude in normal joints than in
arthritic joints (Figure 7.2).
7.3.3.3 Delay and duration of bradykinin-induced sensitisation in normal
and arthritic joints
Since the mechanical stimulus was applied every 2min it was not possible to obtain a
precise measurement of latency or duration of BK-induced enhancements of
mechanically-evoked discharge. Nevertheless, responses to mechanical stimuli in
either normal or arthritic ankle joints were increased (sensitised) at the first, second,
or third mechanical stimulus after the injection of BK. The duration of the BK-
induced sensitisation lasted typically between one and five mechanically-evoked
stimuli. There appeared to be no correlation between the dose of BK and the delay or
duration of the BK-induced sensitisation.
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7.3.4 Reproducibility of bradykinin-induced responses in normal and
arthritic joints
The excitation and sensitisation induced by BK (lOjag) were not significantly
changed upon the subsequent application (10 - 20min after first injection) of
BK (lOpg) in units recorded from either normal or arthritic ankle joints (Figure 7.6).
7.3.5 Correlations between bradykinin-induced excitation and sensitisation
Although most units from normal and arthritic joints were both excited and
sensitised by BK, this was not always found to be the case. Thus, three units in normal
joints which showed BK-induced dose-dependent increases in the responsiveness to
mechanical stimuli were susceptible to a reduced BK-induced excitation at higher
doses of BK (10 - 30pg), and four units which showed no sensitisation following BK,
were excited by BK in a dose-dependent manner. Similarly, in arthritic joints, two
units which showed BK-induced dose-dependent sensitisation to mechanical stimuli
were susceptible to reduced BK-evoked excitation at higher doses of BK (10 - 30pg).
Moreover, three units which showed no change in the responsiveness to mechanical
stimuli following injection of BK were excited by BK in a dose-dependent manner.
There was no apparent correlation between the durations of BK-induced excitation
and sensitisation, as it was possible to have BK-induced sensitisation outlasting the
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Figure 7.6 Reproducibility of bradykinin (lOpg, i.a.)-induced enhancement of
spontaneous and mechanically-evoked discharge in (a) normal and (b) arthritic joints.
Open bars represent the first injection of bradykinin and hatched bars the second
(administered 10 - 20min after the first injection). Each point is the mean ± s.e.mean
recorded from 6units (6 individual experiments). There was no difference in the






































Figure 7.7 Computer generated plots illustrating (a) the longer response duration of
bradykinin-induced enhancement in mechanically-evoked discharge as compared to
the bradykinin-induced increase in spontaneous discharge and (b) the longer duration
of bradykinin-induced enhancement in spontaneous discharge as compared to the
bradykinin-induced enhancement in mechanically-evoked discharge. The plots in (a)
and (b) were obtained from units recorded from different normal joints; conduction
velocity of unit recorded in (a) 0.74ms'1 and in (b) 0.89ms"1. Plots illustrating similar
differences in the duration of bradykinin-induced responses were also observed in
arthritic joints (data not shown). Each bar represents a Is time interval. Arrowheads
indicate the application of the mechanical stimulus. The number of impulses evoked
by the mechanical stimulus is given above each response.
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7.3.6 Effects of indomethacin on bradykinin-induced responses in normal
and arthritic joints
Indomethacin (lOmgkg1, i.a.) decreased spontaneous and mechanically-evoked
discharge (see Section 4) but did not have any significant effect on the BK(l-30pg)-
induced increase in spontaneous or mechanically-evoked discharge in units recorded
from either normal (Figure 7.8) or arthritic (Figure 7.9) joints (P>0.05, Wilcoxon).
7.3.7 Bradykinin Bt receptor studies on articular mechanonociceptors
7.3.7.1 Bj receptor studies in normal joints
The Bi receptor agonist, des-Arg9-BK (l-100pg), had no effect on either
spontaneous (delta x analysis, see Section 2.3.5.2) or mechanically-evoked discharge
in any of the units recorded in normal joints (Figure 7.10). In another analysis, delta
£x (see Section 2.3.5.2), des-Arg9-BK (l-100pg) still had no significant effect on
spontaneous discharge (P>0.05, Mann Whitney U-test, versus saline). All units
recorded in this series of experiments were responsive to BK (1 - lOpg, i.a.). The Bi
receptor antagonist, des-Arg9-Leu8-BK (lmgkg1, i.a.), did not affect either the BK(1-
30pg)-induced excitation nor the BK-evoked enhancement of the responsiveness to
the standard mechanical stimulus in any of the units tested (Figure 7.11).
7.3.7.2 B! receptor studies in acute and chronic arthritic joints
des-Arg9-BK (l-100pg), did not alter spontaneous (delta x analysis, see Section
































































Figure 7.8 Bradykinin-induced enhancement of (a) spontaneous and (b) mechanically-
evoked discharge before ( O ) and after ( • ) indomethacin (lOmgkg1, i.a.) in normal




































































Figure 7.9 Bradykinin-induced enhancement of (a) spontaneous and (b) mechanically-
evoked discharge before ( O ) and after ( • ) indomethacin (lOmgkg*1, i.a.) in
chronically arthritic joints (21-27 days post-adjuvant). Each point is the mean ±

























































Figure 7.10 Comparison of bradykinin ( O ) and des-Arg9-BK ( • ) on
(a) spontaneous and (b) mechanically-evoked discharge from normal joints. Each






































































Figure 7.11 Bradykinin-induced enhancement of (a) spontaneous and
(b) mechanically-evoked discharge before ( O ) and after (• ) des-Arg9-Leu8-BK
(lmgkg"1, i.a.) in normal joints. Each point is the mean ± s.e.mean from 3 - 4 units (3 -
4 individual experiments).
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(3-5 days post adjuvant, Figure 7.12) or chronically-(19-30 days post-adjuvant,
Figure 7.13) inflamed joints. In another analysis, delta Xx (see Section 2.3.5.2), des-
Arg9-BK (l-100pg) still had no significant effect on spontaneous discharge (P>0.05,
Mann Whitney U-test, versus saline). All units recorded in this series of experiments
were responsive to BK (1 - lOpg, i.a.). BK(l-3()pg)-induced enhancements in
spontaneous and mechanically-evoked discharge were unaffected in the presence of
des-Arg9-Leu8-BK (lmgkg"1, i.a.) in any of the units recorded from arthritic joints at
either 3-5 days (Figure 7.14) or 15-26 days (Figure 7.15) post-injection of adjuvant.
7.3.7.3 Lack of effects of des-Arg9-Leu8-bradykinin on spontaneous and
mechanically-evoked discharge in normal and arthritic joints.
In units recorded from normal joints, des-Arg9-Leu8-BK (lmgkg"1, i.a.) had no
significant effect on either spontaneous (Table 7.1) or mechanically-evoked (Table
7.2) discharge. Similarly, des-Arg9-Leu8-BK (lmgkg"1, i.a.) had no significant effect
on either spontaneous (Table 7.3) or mechanically-evoked (Table 7.4) discharge
recorded in arthritic joints.
7.3.8 Effects of Hoel40 on bradykinin-induced responses
7.3.8.1 Effects of Hoel40 on bradykinin-induced responses in normal joints
In units recorded from normal joints, the B2 receptor antagonist, Hoe 140 (lOOpgkg
', i.a.), caused insurmountable antagonism of the BK(l-100pg)-induced increase in
spontaneous discharge, but caused surmountable antagonism of the BK(l-lOOpg)-


































































Figure 7.12 Comparison of bradykinin ( O ) and des-Arg9-BK ( • ) on
(a) spontaneous and (b) mechanically-evoked discharge from acutely-arthritic joints




















































Figure 7.13 Comparison of bradykinin ( O ) and des-Arg9-BK (• ) on
(a) spontaneous and (b) mechanically-evoked discharge from chronically-arthritic
joints (19-30 days post-adjuvant). Each point is the mean ± s.e.mean from 4-6 units












































































Figure 7.14 Bradykinin-induced enhancement of (a) spontaneous and
(b) mechanically-evoked discharge before (O ) and after ( • ) des-Arg -Leu -BK
(lmgkg'1, i.a.) in acutely-arthritic joints (3 - 5days post-adjuvant). Each point is the































































Figure 7.15 Bradykinin-induced enhancement of (a) spontaneous and
(b) mechanically-evoked discharge before ( O ) and after (• ) des-Arg9-Leu8-BK
(lmgkg"1, i.a.) in chronically-arthritic joints (15 - 26 days post-adjuvant). Each point
is the mean ± s.e.mean from 4 - 5 units (3 - 5 individual experiments).
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Table 7.1 Lack of effect of bradykinin receptor antagonists on spontaneous









9(9) 6±2 - 6 ± 3 -
4(4) 5 ± 2 NS 4 ± 2 NS
6(6) 5 ± 1 NS 6 ± 2 NS
t Statistical comparisons (Mann-Whitney U-test) between saline and the test bradykinin
receptor antagonist. NS = P>0.05. The pre-injection discharge, was 1.2 ± 0.3 i.p.s pre-saline, 1.4 ±
0.5 i.p.s. pre-des-Arg9-Leu8-BK and 1.6 ± 0.5 i.p.s. pre-Hoel40.
Table 7.2 Lack of effect of bradykinin receptor antagonists on mechanically-










8(8) 1.4 ±0.2 - 1.1 ±0.3 -
3(3) 1.0 ±0.2 NS 1.1 ±0.2 NS
5(5) 1.1 ±0.1 NS 1.1 ±0.3 NS
f Statistical comparisons (Mann-Whitney U-test) between saline and the test bradykinin
receptor antagonist. NS = P>0.05. The pre-injection mechanically-evoked discharge, was 54 ± 9
impulses pre-saline, 48 ± 11 impulses pre-des-Arg9-Leu8-BK and 52 ± 12 impulses pre-Hoel40.
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Table 7.3 Lack of effect of bradykinin receptor antagonists on spontaneous





































f Statistical comparisons (Mann-Whitney U-test) between saline and the test bradykinin
receptor antagonist. NS = P>0.05. The pre-injection discharge, was 2.6 ± 0.7 i.p.s pre-saline, 2.8 ±
0.9 i.p.s. pre-des-Arg9-Leu8-BK, 3.3 ± 1.2 i.p.s. pre-Hoel40 (lOpgkg"1) and 3.1 ± 0.7 i.p.s. pre-
Hoel40 (lOOpgkg"1).
Table 7.4 Lack of effect of bradykinin receptor antagonists on mechanically-
evoked discharge from articular mechanonociceptors in arthritic rat ankle
joints.





saline 8(8) 1.3 ±0.3 - 1.1 ±0.2 -
des-Arg9-Leu8-B K 3(3) 0.9 ± 0.2 NS 1.4 ±0.2 NS
lOOpgkg"1, i.a.
Hoel40 lOpgkg"1, i.a. 5(5) 1.2 ±0.2 NS 1.4 ±0.2 NS
Hoel40 lOOpgkg"1, i.a. 5(5) 1.3 ±0.3 NS 1.1± 0.2 NS
f Statistical comparisons (Mann-Whitney U-test) between saline and die test bradykinin
receptor antagonist. NS = P>0.05. The pre-injection mechanically-evoked discharge, was 41 ± 7
impulses pre-saline, 43 ± 10 impulses pre-des-Arg9-Leu8-BK, 32 ± 8 impulses pre-Hoel40 (lOpgkg"







































Figure 7.16 Effects of bradykinin on (a) spontaneous and (b) mechanically-evoked
discharge before ( O ) and after ( • ) Hoel40 (lOOpgkg'1, i.a.) in normal joints. Each
point is the mean ± s.e.mean from 5 - 6 units (4-6 individual experiments).
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7.3.8.2 Effects of Hoel40 on bradykinin-induced responses in arthritic joints
In units recorded from arthritic joints, BK(1 - 30pg)-induced enhancements in
spontaneous discharge were antagonised by Hoe 140 (10 and lOOpgkg"1, i.a.) in an
insurmountable manner, whereas BK(l-30pg)-induced sensitisations of
mechanonociceptors to mechanical stimuli were antagonised by Hoe 140 in a dose-
dependent surmountable manner (Figure 7.17).
7.3.8.3 Lack of effect of Hoel40 on spontaneous and mechanically-evoked
discharge in normal and arthritic joints
In recordings from normal joints, Hoel40 (lOOpgkg1, i.a.) had no significant effect
on spontaneous (Table 7.1) or mechanically-evoked (Table 7.2) discharge. In units
recorded from arthritic joints, Hoel40 (10 & lOOpgkg"1, i.a.) also had no significant
effect on spontaneous discharge (Table 7.3) or on the responsiveness to the standard
mechanical stimulus (Table 7.4).
7.3.9 Blood pressure studies
As well as having effects on afferent neural discharge, BK (l-100pg, i.a.) also
caused a dose-dependent decrease in mean arterial blood pressure in normal and
arthritic rats (Figure 7.18 illustrates typical experiments). These BK-induced falls in
mean blood pressure were antagonised by the B2 receptor antagonist, Hoe 140, but



























































Figure 7.17 Effects of hradykinin on (a) spontaneous and (h) mechanically-evoked
discharge before ( O ) and after Hoe 140 ( • 10 and A lOOpgkg"1, i.a.) in
chronically-arthritic joints (19-31 days post-adjuvant). Each point is the mean ±


















































Figure 7.18 Typical single experiments illustrating (a) Hoel40 (• )-induced
antagonism and (b) lack of effect of des-Arg9-Leu8-BK (■ ) on bradykinin-evoked
hypotension (O ) in the normal rat. The data shown in (a) and (b) was from different
rats. Similar results were also obtained in arthritic rats (data not shown).
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In some of the neural recordings (normal and arthritic joints) which were responsive
to BK, and in which Hoe 140 was not administered, the non-selective adenosine
receptor agonist, 5'-N6-ethylcarboxamidoadenosine (NECA), was injected (10-30pg,
i.a.) at the end of the experiment. NECA, like BK, caused marked decreases in mean
blood pressure (approximately 40-50mmHg), but unlike BK, produced no change in
neural discharge (see Section 5).
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7.4 DISCUSSION
7.4.1 Effects of bradykinin on neural discharge from normal ankle joint
mechanonociceptors
7.4.1.1 Bradykinin-induced excitation
In the present study, BK enhanced spontaneous afferent discharge (excitation
response) from C-fibre fine afferents innervating normal rat ankle joints in 86% of the
units studied. This percentage is similar to the findings by Kanaka et al (1985) in the
cat knee joint, where BK excited 92.5% of C- and A8-fibre afferent units, and with
investigations in various non-articular fine afferents - 86.5% in dog muscle
(Kumazawa & Mizumura, 1977); 80% in cat heart (Baker et al., 1980); 93% in dog
testis (Kumazawa & Mizumura, 1980); 73% of cat visceral (gallbladder and liver)
fibres (Longhurst et al., 1984); 100% in guinea-pig trachea (Fox et al., 1993); 80% in
cat cornea (Belmonte et al., 1994).
The doses of intra-arterially injected BK required to produce excitation in the
present studies were in the l-10pg range. A similar dose-range (intra-arterial
injection) was also required to cause BK-induced excitation of articular (Kanaka et
al., 1985) and visceral (Haupt et al., 1983) afferents in the cat.
The results of the current study show that the delay to the onset of BK-induced
excitation was 3 - 150s. Similar delay times to the onset of BK-induced excitation
have also been reported in afferents innervating cat knee joints (16s; Kanaka et al.,
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1985), dog muscle (28s; Kumazawa & Mizumura, 1977) and rat skin (30s; Lang et
al., 1990). In the present study, the mean delay of BK-induced excitation was
decreased to approximately 10s at higher doses of bradykinin (10 and 30pg)(Figure
7.3). This observation is consistent with the study by Mense & Schmidt (1974) in cat
muscle afferents, where the higher dose of BK (26pg) had a delay to the onset of
excitation of only 8.8s.
The results of the present investigation in normal joints have shown that the mean
duration of BK-induced excitation varied according to the dose of BK used. At the
two lower doses of BK (1 and 3pg) the mean duration was approximately 100s, but at
higher doses (10 and 30pg) was increased by approximately 2 fold (Figure 7.4). Thus,
increasing the dose of BK results in a longer action of the kinin. This is in contrast
with the results obtained in rat skin afferents where increases in BK concentration did
not change the duration of the response (Lang et al., 1990). Although somewhat
variable, duration of BK responses of 12-138s, 14-167s, and 30-300s were observed
from afferents in cat muscle (Mense & Schmidt, 1974), rabbit ear (Szolcsdnyi, 1987)
and rat skin (Lang et al., 1990), respectively. These durations are comparable with the
findings of the present study.
7.4.1.2 Bradykinin-induced mechanonociceptor sensitisation
In the current study, BK increased the responsiveness of mechanonociceptors to
mechanically-evoked stimuli. Similar BK-induced sensitisation of mechanoreceptors
to mechanically-evoked stimuli have also been reported in canine hearts (Uchida &
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Murao, 1974), cat muscle (Mense & Mayer, 1987), and in cat knee (Neugebauer et
al., 1989) or rat ankle (Grubb et al., 1991; Birrell et al., 1993) joints. Using thermal
stimuli, BK-induced sensitisation of mechano-heat-sensitive units has also been
demonstrated in the skin of cats (Beck & Handwerker, 1974) and rats (Koltzenberg et
al., 1992).
In the present experiments, BK-induced enhancement in the responsiveness to
mechanical stimuli was observed in 80% of the C-fibre afferent units recorded. This
percentage compares fairly well with the proportions found in cat muscle afferents
(38% C-fibres and 67% A8-fibres; Mense & Mayer, 1987), and in afferents from cat
knee joints (70%; Neugebauer et al., 1989).
7.4.2 Bradykinin-induced excitation and sensitisation in arthritic joints
The current investigation has shown that BK induced an increase in spontaneous
discharge (excitation), and enhanced the responsiveness to mechanical stimuli
(sensitisation), of articular mechanonociceptors in chronically inflamed (adjuvant-
arthritic) ankle joints. BK induced excitation in 89% of units, and sensitisation of
88%. These percentages were similar to those obtained in units from normal joints
(see 7.4.1.1 & 7.4.1.2).
Various investigators have reported that sensitivities of nociceptors are enhanced
under inflammatory conditions (Coggeshall et al., 1983; Guilbaud et al., 1985;
Schaible & Schmidt, 1985; Grigg et al., 1986; Schaible & Schmidt, 1988). One group
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of mediators that may be responsible for this enhanced sensitivity of nociceptors are
the prostanoids. Indeed, it has been shown that levels of prostanoids are raised in
arthritic joints (Robinson et al., 1975; Trang et al., 1977), and that they can potentiate
BK-induced excitation and sensitisation (Grubb et al., 1991; Schepelmann et al.,
1992; Birrell et al., 1993). From these observations, it would have been expected that
in the present investigation BK-induced excitation and sensitisation in normal joints
would be enhanced in joints with chronic inflammation (adjuvant-arthritis). However,
BK-induced excitation (10 and 30pg) and sensitisation (3, 10 and 30pg) in arthritic
joints were smaller in magnitude (although this difference did not reach statistical
significance) than that obtained from the ankle joints of normal rats. The are several
hypotheses which could explain the smaller responses to BK in arthritic joints. One is
that since BK levels are elevated in inflammatory states (Lewis, 1970; Hargreaves &
Costello, 1990), then BK will have to act on an elevated baseline such that the
increase induced by BK will be apparently reduced. However, this hypothesis is not
supported by the studies which showed that bradykinin receptor (Bi and B2)
antagonists had no effect on basal spontaneous or mechanically-evoked discharge in
arthritic joints (see Section 7.3.7.3 and 7.3.8.3). A desensitisation or down regulation
of BK receptors with the development of chronic arthritis may explain the reduced
responsiveness of BK in arthritic joints. Another possible explanation to account for
the reduced BK responses is the observation that BK can cause the release of opioids
(Kudo et al., 1986). Since opioids have been shown to reduce afferent discharge from
inflamed knee joints (Russell et al., 1987), then it is possible that the reduced
responses to BK observed in the present study are due to the evoked release of
opioids by BK. Therefore, in arthritic joints the responses to BK may be a
242
combination of an excitatory action of BK and an inhibitory action of released
opioids. This hypothesis could be tested by determining the effects of bradykinin
before and after opioid receptor antagonists such as naloxone. Regarding the possible
location of action of peripheral opioids, electrophysiological recordings from fine
afferent fibres from the inflamed (kaolin and carrageenan-induced) cat knee joint have
indicated that opiates act on opioid receptors (mu and kappa) located at peripheral
sites of primary afferent fibres to cause a peripheral analgesic effect (Russell et al.,
1987). The reduction in mechanical hyperalgesia in adjuvant-arthritic rats by the local
(but not the same dose given systemically) injection of the opioid, fentanyl, also
suggests a role for peripherally located opioid receptors (mu subtype) in the
modulation of nociception in inflamed tissue (Stein et al., 1988). The possible sources
of endogenous opioid ligands for the peripheral receptors are the primary afferent
neurone (Weihe, 1989), pituitary-adrenal axis (Vale et al., 1981; Milan and Herz,
1985) or the immune system (Sibinga & Goldstein, 1988).
Recently, in our laboratory we have shown that BK-induced excitation in arthritic
joints was significantly greater following Nc,-nitro-arginine-methyl-ester (L-NAME)
injection (Kelly et al., 1994). This finding suggests that nitric oxide may be
responsible for the reduced responses to BK in the arthritic joint. In support of this is
the study by Dray et al., (1992) in the neonatal spinal cord-tail preparation where
bradykinin-induced depolarisation was reduced in nitroprusside-treated preparations.
In arthritic joints, the mean duration (approximately 100s) and delay (approximately
40s) of BK-evoked excitatory responses were not altered with increasing dose of BK.
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In contrast, increasing the dose of BK caused reductions in the onset of excitation, as
well as increasing response duration in units recorded from normal joints. It is unclear
as to why these differences in duration and delay times ar ose between normal and
arthritic joints, but may have been due to the action of released opioids by BK in
arthritic joints.
7.4.3 Independence of bradykinin-induced excitation and sensitisation
In agreement with the articular afferent neural recordings by Neugebauer et al
(1989) in the cat, most units in the current study were both excited and sensitised by
BK. However, in the present study (normal and arthritic joints) it was possible to have
a BK-induced excitation without altering the responsiveness to mechanically-evoked
stimuli. Furthermore, although BK induced a dose-dependent increase in
mechanically-evoked discharge, there was desensitisation of BK-evoked excitation at
higher doses. Moreover, the duration of BK-induced sensitisation could be greater
than that of BK-induced excitation or vice-versa (Figure 7.7). From these
observations it can be concluded that there is no correlation between BK-induced
excitation and sensitisation, and that these responses are probably independent of each
other. It can be further hypothesised that bradykinin-induced excitation and
sensitisation of ankle joint mechanonociceptors may occur via different mechanisms.
For example, BK-evoked excitation and sensitisation may involve different second
messenger systems. Indeed, in sensory tissues, protein kinase C is involved in BK-
induced excitation (Dray et al., 1988; Burgess et al., 1989), whereas BK can cause
inhibition of a slow after-hyperpolarisation (Weinreich, 1986; Weinreich & Wonderlin,
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1987), an effect mediated by cyclic-AMP, so as to increase neural excitability.
Another possibility to account for the independent occurrence of BK-induced
excitation and sensitisation is that, whereas BK-induced excitation is due to a direct
action of BK on afferent fibres, BK-induced sensitisation could be mediated indirectly
by the release of mediators from leukocytes, mast cells, macrophages or platelets such
as prostanoids, leukotrienes or 5-HT.
7.4.4 Extent of desensitisation of bradykinin-induced excitation and
sensitisation
Desensitisation of BK-induced excitation and sensitisation, in terms of repeat dose
(lOpg) or increasing dose, was generally not observed in units recorded from either
normal or arthritic joints in the present investigation. This is in contrast to the marked
desensitisation of BK-induced enhancements in neural discharge from fine afferent
fibres in the cat knee joint (Kanaka et al., 1985), dog testis (Kumazawa et al., 1987)
or rat skin (Lang et al., 1990). In line with the present results, desensitisation to BK
was not reported in al'ferents innervating dog viscera (Guzman et al., 1962), cat
skeletal muscle (Hiss & Mense, 1976; Mense et al., 1982) and cat cornea (Belmonte
et al., 1994).
7.4.5 Effects of indomethacin on bradykinin-induced excitation and
sensitisation
The results of the present study have shown that BK-evoked excitation or
sensitisation of mechanonociceptors in either nonnal or arthritic joints was not
affected by indomethacin. This then strongly suggests that BK does not release
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prostaglandins to mediate BK-induced responses in ankle joint mechanonociceptors.
In contrast, BK-induced responses in muscle, visceral and cutaneous nociceptors have
been shown to be dependent on prostanoids, as the responses to BK were reduced by
aspirin, paracetamol or indomethacin (Kumazawa & Mizumura, 1980; Mense, 1982;
Dray et al., 1992). Nevertheless, in agreement with the present study, it has been
demonstrated that BK-induced excitation of vagal afferents was not dependent on
prostaglandins (Fox et al., 1993). Although the results of the present investigation
suggest that BK-induced responses do not involve prostanoids, it is possible that they
may still be secondary to release by BK of other mediators such as leukotrienes
(Samuelsson, 1983), calcitonin gene-related peptide (Franco-Cereceda et al., 1989),
nitric oxide (Ignarro et al., 1986) or cytokines (Ferreira et al., 1993).
7.4.6 Afferent neural discharge and blood pressure
Although BK and the non-selective adenosine receptor agonist, NECA, both
decreased mean arterial blood pressure, it was only BK that affected discharge of
articular afferents. This implies that BK-induced alterations in mechanonociceptor
discharge were not a result of the hypotensive action of BK.
7.4.7 Bi receptor studies on ankle joint mechanonociceptors
Normal joints
The results of the present investigation have shown that the Bi receptor agonist,
des-Arg9-BK, did not alter basal spontaneous or mechanically-evoked discharge, and
that the Bi receptor antagonist, des-Arg9-Leu8-BK, had no effect on BK-induced
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excitation or sensitisation. These results, therefore, show that Bi receptors are
unlikely to be involved in affecting discharge from articular mechanonociceptors in
normal joints. Other studies have also shown non-responsiveness to Bi receptor
agonists and antagonists in non-inflamed tissues (Farmer et al., 1991a; Perkins &
Kelly, 1993; Perkins et al., 1993; Davis & Perkins, 1994). However, in contrast to
these studies and to the present investigation, blockade of BK actions was achieved
by des-Arg9-Leu8-BK in 37% of units recorded from articular afferents in normal cat
knee joints, indicating the involvement of Bi receptors in the BK response (Messlinger
et al., 1992).
Arthritic joints
In contrast to the lack of involvement of B! receptors in normal tissues, it has been
shown that under inflammatory situations Bi receptors become involved. For
example, in models of persistent inflammatory Freunds adjuvant-induced mechanical
(Perkins et al., 1993; Davis & Perkins, 1994) or ultra violet light-induced thermal
(Perkins & Kelly, 1993; Perkins et al., 1993) hyperalgesia, des-Arg9-BK produces
significant hyperalgesia which is antagonised by des-Arg9-Leu8-BK. In view of such
evidence supporting the involvement of Bj receptors under persistent inflammatory
situations, it might be expected that, since the present investigation also used a
persistent model of inflammation (Freunds adjuvant-induced arthritis), Bi receptor
agents would influence neural discharge (excitation and / or sensitisation) from
mechanonociceptors in arthritic joints. However, the results obtained in chronically-
arthritic rats (15-30 days post-adjuvant) showed that des-Arg9-BK had no effect on
articular afferent neural discharge, and that BK-induced excitation and sensitisation
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were not affected by des-Arg9-Leu8-BK. Further evidence which indicates that Bt
receptors are not involved in modulating articular afferent discharge in inflamed joints,
is the finding that des-Arg9-Leu8-BK did not affect basal spontaneous or
mechanically-evoked discharge in arthritic joints (Tables 7.3 - 7.4). In agreement it
has been shown that des-Arg9-Leu8-BK also does not affect the ongoing afferent
activity from inflamed (kaolin and carrageenan-induced) cat knee joints (Meblinger et
al„ 1993).
It is unclear as to why B! receptors play a role in the persistent hyperalgesia in the
studies by Perkins & Kelly (1993) and Davis & Perkins (1994) but appear not to be
involved in modulating neural discharge in rats also with a persistent inflammatory
hyperalgesia (adjuvant-arthritis) in the current investigation. Differences between the
times at which Bi receptor agents were examined in the study by Davis & Perkins
(1994) (3-4 days post-adjuvant) and the present investigation (15 - 30 days post-
adjuvant) cannot explain the differences observed since the present study also
demonstrated lack of activity for Bi receptor agonists and antagonists 3-5 days post-
adjuvant. Other possibilities which could explain the difference in the responsiveness
to Bi receptor agonists / antagonists between the present study and those of Perkins
& Kelly (1993) and Davis & Perkins (1994) are the different models (behavioural
versus electrophysiological) used, or the age, sex, and species of rats used.; young
(80-100g) female Sprague-Dawley rats were used by Perkins & Kelly (1993) and
Davis & Perkins (1994), whereas the studies in the present investigation used adult
(350-450g) male Wistar rats.
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7.4.8 Effects of Hoel40
7.4.8.1 Actions of Hoel40 on BK-induced responses in normal and arthritic
joints
The potent (Bao et al., 1991; Lembeck et al., 1991; Wirth et al., 1991) bradykinin
B2 receptor antagonist, Hoel40, antagonised BK-induced excitation and sensitisation
in both normal and arthritic joints. In agreement with these results of the present
investigation, antagonism of BK-induced responses by Hoel40, consistent with the
involvement of B2 receptors, has also been reported in various models of hyperalgesia
and inflammation (Lembeck et al., 1991; Wirth et al., 1991; Damas & Remacle-
Volon, 1992; Messlinger et al., 1992; Heapy et al., 1993; Davis & Perkins, 1994).
In the present study, Hoel40 showed a differing profile of antagonism for BK-
evoked responses; surmountable antagonism of BK-induced sensitisation, and
apparently insurmountable antagonism of BK-induced excitation. This surmountable/
insurmountable nature of Hoe 140 is also observed in the rat vas deferens (see Section
9), and in cultured colonic epithelial cells (Cuthbert et al., 1992). One conclusion that
can be drawn from this differential response of Hoel40 is that the B2 receptors
responsible for BK-induced excitation and sensitisation are not of a homologous
nature. There may be present subtypes of the B2 receptor or different types of BK
receptor such as B3, B4 or B5 receptor. However, caution is required when
interpreting the actions of Hoel40 since, as discussed in detail for the rat vas deferens
in Section 9.3.8, the differential actions of Hoel40 may simply be reflections of tissue
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kinetics, or could be explained by other mechanisms not involving subtypes of the BK
receptor. In order to provide evidence to support the suggestion for the existence of
subtypes of the B2 receptor mediating BK-induced excitation and sensitisation further
work using other potent and stable B2 receptor antagonists (e.g. D-Arg-[Hyp3, Thi5,
D-Tic7, Tic8]-BK, [Arg(Tos)1, Hyp3, Thi5, D-Tic7, Oic8]-BK, NPC 17731 and NPC
1776; Farmer et al., 1991b; Lembeck et al., 1991; Correa & Calixto, 1993) is required
in order to determine whether these also behave in a surmountable / insurmountable
manner.
7.4.8.2 Hoel40 and basal articular mechanonociceptor discharge
As described in Sections 3 and 4 of this thesis, and in electrophysiological studies in
rats and cats (Coggeshall et al., 1983; Guilbaud et al., 1985; Schaible & Schmidt,
1985; Grigg et al., 1986; Meblinger et al., 1993; Schaible & Grubb, 1993), articular
mechanonociceptors show elevated resting (spontaneous) discharge and sensitisation
to mechanical stimuli following inflammation. The present evidence, that normal joint
articular mechanonociceptors were excited and / or sensitised by BK, and that these
responses could be blocked by the B2 receptor antagonist Hoel40, suggested that
endogenous BK acting via B2 receptors could potentially play a role in causing the
enhanced ongoing discharge and sensitisation to mechanical stimuli of
mechanonociceptors in chronically-arthritic ankle joints. However, the results of the
present experiments demonstrated that Hoe 140 did not alter articular afferent
discharge in arthritic (also normal) rat joints. This suggests that B2 receptors are not
likely to be involved in mediating the enhanced neural discharge from
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mechanonociceptors in chronically-inflamed (adjuvant- arthritic) joints. In support of
this conclusion is the study by Meblinger et al. (1993) who found that Hoe 140 did
not affect ongoing discharges from articular afferents innervating inflamed (induced
by kaolin and carrageenan) cat knee joints. In contrast with this study, and the present
electrophysiological investigations, anti-hyperalgesic or anti-nociceptive activities
have been obtained using Hoe 140 in various behavioural models of inflammation and
hyperalgesia (Wirth et al., 1991; Damas & Remacle-Volon, 1992; Correa & Calixto,
1993; Heapy et al., 1993; Sharma et al., 1993; Davis & Perkins 1994). In most of
these behavioural studies the effects of Hoel40 was determined >30min post-injection
of Hoe 140. Therefore, since in the present investigations the effects of Hoel40 were
determined over a 10-15min post-injection period, it is possible that this time period
was insufficient to observe any changes in neural discharge induced by Hoe 140.
However, behavioural studies by Heapy et al. (1993) demonstrated that Hoel40
produced antinociceptive effects in less than 5min, indicating that Hoel40 has a fast
onset of action. The results in the rat vas deferens also support a fast onset of action
of Hoe 140 (see Section 9).
In electrophysiogical studies, it was reported by Messlinger et al (1992) that Hoel40
produced a short-lasting excitation of C- and A5-fibres innervating the cat knee joint.
No such agonistic activity (excitation or sensitisation) of Hoel40 was observed in the
present experiments on articular afferents from rat ankle joints (normal or arthritic).
The results of the current neuropharmacological investigation on C-fibres
innervating chronically-inflamed (adjuvant-arthritic) rat ankle joints do not support a
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therapeutic role for B2 receptor antagonists such as Hoe 140 in the treatment of
chronic pain and hyperalgesia associated with arthritis. However, a therapeutic role
for Hoe 140 is suggested from the results of behavioural studies in rats with adjuvant-
induced arthritis of the knee joint, where Hoel40 reduces swelling, inflammation, and
mechanical hyperalgesia (Sharma, 1993; Davis & Perkins, 1994). Clearly, studies in
humans are required in order to determine the importance of Hoe 140 as an anti¬
inflammatory or analgesic drug in the treatment of disorders such as rheumatoid
arthritis.
7.5 SUMMARY
The results of the present electrophysiological investigation have shown that intra¬
arterial injection of bradykinin (BK) causes an enhancement in spontaneous
(excitation) and mechanically-evoked (sensitisation) discharge from articular
mechanonociceptors in normal and arthritic joints. BK-induced responses in normal
joints were generally of a greater magnitude, with longer durations and shorter delays,
than the responses in arthritic joints. Since indomethacin did not affect BK-induced
responses this strongly suggests that prostanoids are not likely to mediate the effects
of BKin this model.
Bradykinin Bi receptors appear not to be involved in altering C-fibre discharge in
either normal or chronically inflamed joints as 1) the bradykinin Bi receptor agonist,
des-Arg9-BK, had no effect, 2) BK-induced responses were unaffected by the Bi
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receptor antagonist, des-Arg9-Leu8-BK, and 3) des-Arg9-Leu8-BK had no effect on
basal spontaneous or mechanically-evoked discharge.
The B2 receptor antagonist, Hoe 140, antagonised BK-induced excitation and
sensitisation in normal and arthritic joints. Moreover, Hoel40 had a different profile
of antagonism; surmountable antagonism of BK-induced sensitisation, whereas
insurmountable antagonism of BK-induced excitation. One interpretation of this
differential action of Hoe 140 is that it is evidence to support the existence of subtypes
of the B2 receptor.
Hoe 140 had no effect on the elevated spontaneous discharge and the enhanced
responsiveness to mechanical stimuli in chronically-arthritic joints. This suggests that
endogenous bradykinin, acting via B2 receptors, is unlikely to be involved in the
elevated neural discharge associated with adjuvant-arthritic rats.
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SECTION 8
EFFECT OF BRADYKININ ON RAT NERVES IN-VITRO.
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8.1 INTRODUCTION
As shown in the previous section of this thesis, bradykinin (BK) caused excitation,
and sensitisation to mechanical stimuli, of mechanonociceptors in both normal and
chronically inflamed joints. It is particularly interesting that these responses to BK
were blocked differentially by the potent bradykinin B2 receptor antagonist, Hoe 140;
surmountable antagonism of BK-evoked sensitisation was obtained, whereas
insurmountable antagonism of the BK-induced excitation occurred. Since these
neuropharmacological experiments were performed in-vivo, it was difficult to
interpret the results or to perform further detailed studies of the effects of BK
analogues such as Hoe 140. The difficulties associated with in-vivo experimentation
include the problems of clearly establishing the mechanisms of drug action, for
example, because of the possible contribution of blood or tissue borne mediators or
the problems of the complex interactions between body systems. To overcome some
of these problems, it was decided to investigate the effects of BK and its analogues in
a simple in-vitro rat nerve ('grease-gap') preparation. In such a preparation, drug-
induced depolarisations and/or hyperpolarisations (DC potentials) from whole nerve
bundles are recorded extracellularly. The 'grease gap' technique has been used
successfully by various investigators to record capsaicin-induced depolarisation of rat
vagus (Marsh et al., 1987), 5-HT-induced depolarisation of rat (Ireland, 1987; Ireland
& Tyers, 1987;) or rabbit (Elliot et ah, 1990; Elliot & Wallis, 1990) vagus, 5-HT-
induced hyperpolarisation of rat superior cervical ganglion (Ireland, 1987; Ireland &
Jordan, 1987), prostanoid-induced depolarisation of rat or rabbit vagus (Birrell,
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1990), and depolarisation of rat superior cervical ganglion induced by the peptide,
angiotensin (Hawcock et al., 1992).
The aim of the present study was to determine whether BK or the Bj receptor
agonist, des-Arg9-BK, could alter the membrane potential of various rat nerves
(vagus, tibial, tibialis, sciatic and saphenous) in-vitro, using a 'grease-gap' technique.
The rat vagus, tibial, tibialis, sciatic and saphenous nerves were chosen because
approxiamtely 50% of the axons are unmyelinated (see Jenq & Coggeshall, 1984;
Jenq & Coggeshall, 1985; Schmalbruch, 1986) - the primary articulo-cutaneous ramus
nerve, as recorded from in the present neuorpharmacological experiments (see
Sections 3 - 7), could not be used as only a very short length (<3mm) of the nerve
could be dissected out, which was insufficient for 'grease-gap' recordings.
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8.2 MATERIALS & METHODS
In brief, adult male Wistar rats (200-350g) were killed by cervical dislocation and
segments of vagus, tibial, tibialis, sciatic and saphenous nerve, of approximately 10 -
15mm, were dissected out and mounted across two-compartment perspex baths such
that approximately 50% of the nerve lay in the first compartment, while the remainder
projected through a greased slot (Dow-Corning high vacuum grease) into the second.
Each compartment of the bath was perfused continuously with Krebs solution (27°C)
at a rate of 1 - l.Smlmin"1 The potential difference between the two compartments
was recorded via silver-silver chloride electrodes, connected to the tissue preparation
through an agar-saline / filter paper bridge, and displayed on a potentiometric chart
recorder (Rikadenki). Drugs (made up in Krebs solution) were applied at known
concentration into the perfusate of the first compartment only.
An attempt was made to obtain log concentration-response curves to hradykinin and
des-Arg9-bradykinin (0.01- lOOOpM). In order to determine whether or not BK
receptors are induced in the nerves in-vitro, a protocol was devised where a single
concentration of bradykinin or des-Arg9-bradykinin (0.1 pM) was applied (contact
time 3 - 5min) repeatedly over 4 - 5hr. The effects of superfusing a combination of
bradykinin (0.1 pM) and PGE2 (lpM) was also determined. To confirm that the
preparations were bioactive, a depolarising concentration of KC1 (lOmM - lOOmM)
was used either before, but more typically, after perfusion of the test drugs. For
further details of the experimental setup and protocols see Section 2.4.
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8.3 RESULTS
8.3.1 Effect of KC1 on rat isolated nerves
KC1 (lOmM - lOOmM ) evoked depolarisation of all the nerves studied (vagus, 300 -
400pV; tibial, 250 - 350pV; tibialis, 100 - 250|iV; sciatic, 150 - 250pV; saphenous,
100 - 200pV) [see Figure 8.1 for typical response],
8.3.2 Investigation of the effect of bradykinin and des-Arg9-BK on rat
isolated nerves
In none of the isolated nerves (vagus, tibial, tibialis, sciatic and saphenous) examined
(n=4 - 9), did either BK or the Bi receptor agonist, des-Arg9-BK, cause a
depolarisation or a hyperpolarisation across the concentration range (0.01- lOOOpM)
tested (Figure 8.1). There was also no change in the membrane potential of any of the
isolated nerves when a single concentration of BK or des-Arg9-BK (0.1 pM) was
superfused approximately every 25min over a period of 4 - 5hr (n=2 - 5).
8.3.3 Effect of a combination of bradykinin and PGE2 on rat isolated nerves
PGE2 (lpM), alone or in combination with BK (0.1 pM), had no effect on the
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Figure 8.1 Typical chart records from the isolated rat vagus illustrating the
depolarisation to (a) KC1, and the lack of effect on membrane potential of
(b) bradykinin, (c) des-Arg9-bradykinin, (d) PGE2 and (e) a combination of bradykinin
and PGE2. Similar responses were observed using other isolated nerves (tibial, tibialis,
sciatic and saphenous). Downward deflections indicate depolarisation. The contact
time of drugs was 3 - 5min.
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8.4 DISCUSSION
The results of the current study, obtained using the 'grease gap' technique, have
shown that, in none of the isolated nerves (vagus, tibial, tibialis, sciatic and
saphenous) examined, did either of the peptides, BK or the Bi receptor agonist, des-
Arg9-BK, cause any change in membrane potential; however, all the preparations were
capable of responding, as they were depolarised by KC1. These results are in contrast
with the findings of other studies, also using the 'grease gap' technique in rat isolated
nerve preparations (vagus and superior cervical ganglion), which show that changes in
membrane potential (depolarisation and/or hyperpolarisation) do occur to other
peptides such as angiotensin (Hawcock et al., 1992) or to non peptides such as
prostanoids (e.g. PGI2, Birrell, 1990), 5-HT (Ireland, 1987; Ireland & Jordan, 1987;
Ireland & Tyers, 1987) and ATP (Trezise et al., 1993).
It has been reported in the rabbit isolated aorta that contractile responses to BK or
to des-Arg9-BK increase in magnitude (over 3-6hr, via Bi receptors) in a time-
dependent manner (Bouthillier et al., 1987; Farmer et al., 1991a). In contrast, the
results of the present investigation suggest that BK receptors were not induced
because repetitive challenge with BK or des-Arg9-BK over 4 - 5hr did not change the
membrane potential of the isolated nerves.
Although in the current study, BK had no effect on the membrane potential of any of
the isolated nerves studied, it is possible that an effect could be produced by the
combination of BK with inflammatory agents such as PGE2. Indeed, it has been
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shown that although PGE2 causes little or no increase in afferent neural discharge, it
greatly potentiates the response to bradykinin (Grubb et al., 1991; Birrell et al., 1993).
However, in the present study PGE2, either alone or in combination with BK, failed to
cause any change in membrane potential. The possibility that a change in membrane
potential may be produced upon the combination of BK with other prostanoids (e.g.
PGI2) or with other inflammatory mediators (e.g. 5-HT or ATP) requires further
investigation. In the in-vitro study by Marsh et al (1987), the C-fibre excitant,
capsaicin, was found to depolarise electrically-stimulated vagal sensory C-fibres. In
view of this study, it would be interesting to determine the actions of BK and its
analogues in preparations which are electrically-stimulated.
The use of whole nerve segments may explain the lack of effect of BK in the present
study, as it may be that BK receptors are only found on the terminals (nociceptors) of
the nerve fibres. Thus, in order to observe effects to BK the nerve plus the innervating
organ may be required. Indeed, there are many nerve-organ in-vitro preparations
which show responses to BK such as the skin-saphenous (Chahl & Iggo, 1977; Lang
et al., 1990), cornea-ciliary (Belmonte, 1994), testis-superior spermatic (Kumazawa
& Mizumura, 1983) and trachea-vagus (Fox et al., 1993) nerve preparations.
Radioligand binding studies would help establish whether or not BK receptors are
present in segments of whole rat nerve. It is also possible that although BK receptors
are present in rat nerves, they are not functional because they may not be linked to,
for example, second messengers.
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8.5 SUMMARY
In summary, no change in the membrane potential of isolated rat nerves (vagus,
tibial, tibialis, sciatic and saphenous), studied using the 'grease-gap' technique, was
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The exogenous application of the nonapeptide, bradykinin (BK), to preparations of
smooth muscle in-vitro, has been studied extensively, where it causes contraction and
/ or relaxation, depending on the preparation and tissue used (Erdos, 1979; Taylor et
al., 1989; Farmer & Burch, 1992). The responses to BK are mediated by BK
receptors which have been classified into the Bj and B2 subtypes (Regoli & Barab6,
1980). The vast majority of the physiological and pharmacological effects of BK
appear to be mediated via B2 receptors (See Taylor et al., 1989; Bathon &
Proud, 1991; Steranka & Burch, 1991; Bhoola et al., 1992; Burch & Kyle, 1992;
Farmer & Burch, 1992).
Evidence that there may be different subtypes of the B2 receptor has been provided
by the present neuropharmacological experiments (see Section 7), and by various
studies, such as those in rat myometrial membranes (Liebmann, 1991), rat uterus,
guinea-pig ileum and trachea (Plevin & Owen, 1988), murine neuroblastoma cells
(Braas et al., 1988) and, of particular relevance to the present investigation, the
studies by Huidobro-Toro et al. (1986), Llona et al. (1987) and Rifo et al. (1987) in
the electrically-stimulated rat vas deferens (RVD). Application of BK to the
electrically-stimulated RVD enhances the magnitude of the electrically-driven twitches
(pre-junctional or neurogenic response) and increases the basal tension of the muscle
(post-junctional or musculotropic response). Rifo et al. (1987) showed that, in the
field-stimulated RVD, the "first generation" competitive B2 receptor antagonist, D-
Arg-[Hyp3, Thi5,8, D-Phe7]-BK (NPC349) was more potent at blocking the BK
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neurogenic response than the BK musculotropic response. It was then concluded that
these differences in potency observed with NPC349 could be interpreted as evidence
for the notion that the pre- and post-junctional B2 receptors are of a heterogeneous
population (Rifo et al., 1987).
All of the 'first generation' antagonists for the B2 receptor are of weak affinity and
potency (pKB = 5 - 7) in smooth muscle preparations (Burch et al., 1990). However,
more recently, B2 receptor antagonists have been synthesised and shown to have
potencies two or three orders of magnitude greater than the earlier compounds (Hock
et al., 1991; Kyle et al., 1991; Lembeck et al., 1991; Burch & Kyle, 1992). One such
potent B2 receptor antagonist is D-Arg-[Hyp3, Thi5, D-Tic7, Oic8]-BK (Hoel40). In
the present electrophysiological recordings from articular C-fibres (see Section 7),
Hoe 140 caused a mixed profile of antagonism; there was surmountable antagonism of
BK-induced sensitisation of mechanically-evoked discharge, whereas insurmountable
antagonism of BK-induced excitation occurred. These differences in antagonism of
Hoe 140 can be taken as evidence to suggest the existence of subtypes of the B2
receptor.
Since the neuropharmacological experiments studying the effects of BK and BK
analogues on articular mechanonociceptors were performed in-vivo (see Section 7),
difficulties can arise in the interpretation of results; the difficulties associated with in-
vivo experimentation include the problems of clearly establishing the mechanisms of
drug action, for example, because of the possible contribution of blood or tissue borne
mediators. Therefore, it is desirable to investigate the actions of BK and BK
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analogues (in particular Hoe 140) using a nerve preparation, in vitro. One such in vitro
nerve preparation was the 'grease gap' technique as described in Section 8. However,
since this neural preparation had no effects to BK it was not used further. It was
decided to use the in-vitro electrically-stimulated rat vas deferens, a preparation
known to contain neuronal (albeit on sympathetic neurones) BK receptors (Llona et
al., 1987), in order to investigate in detail the actions of BK and its analogues.
The aims of the present study in the electrically-stimulated RVD were threefold.
Firstly, to characterise the BK receptors involved in the BK-induced neurogenic and
musculotropic responses. Secondly, to determine the profile of antagonism on the pre-
and post-junctional effects of BK using a range of BK receptor antagonists. Thirdly,
to examine in detail the effects of Hoel40 on the BK-induced responses.
Two preliminary studies were also performed in the electrically-stimulated RVD. In
the first study, the presynaptic neurotransmitter responsible for the basal electrically-
induced twitches, and that for the BK-induced enhancement in the electrically-induced
twitch was investigated. The second preliminary investigation examined the role of
protein kinase C in the neurogenic and musculotropic responses to BK.
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9.2 MATERIALS & METHODS
9.2.1 Preparation of isolated vas deferens
Adult male Wistar rats (200-350g) were killed by cervical dislocation and the vasa
deferentia immediately removed. The surrounding connective and adipose tissue and
the adjoining blood vessels were removed from the vas deferens. Only the prostatic
segment (1-1.5cm) of the vas deferens was used in the experiments.
Each prostatic segment was immersed in a 5ml organ bath containing Krebs solution
of the following composition (mM): NaCl 118, KCL 5.4, KH2P04 1.2, MgS04 1.2,
NaHC02 25, glucose 11.1 and CaCl2 2.5. The Krebs solution was gassed with
95% 02 and 5% C02 and maintained at 35°C.
Each prostatic segment was suspended between two parallel platinum electrodes
which were used for transmural electrical stimulation. Electrical pulses were delivered
by a multi-stimulator (Digitimer System-D330) at a frequency of 0.33Hz, 1msec pulse
duration and at supramaximal voltage. To record isometric muscular contractions, the
segments were connected to a force transducer (Dynamometer UF1) coupled to a
chart recorder (Lectromed MT8-PX).
Prior to electr ical field-stimulation or the application of drugs, the tissues were
allowed to equilibrate for 60min with 0.5g of basal tension. During this equilibration
period, the tissues were washed with Krebs solution every 15min and the tension re¬
adjusted to ().5g.
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9.2.2 Agonist / antagonist protocols
Agonists were added to the field-stimulated vas deferens in a cumulative manner.
After completion of a cumulative log concentration-response curve, field-stimulation
of the tissues was stopped and the vas deferens washed with Krebs solution every
2min for lOmin. A further 20min equilibration period (no electrical stimulation) was
allowed before constructing the next cumulative concentration-response curve.
To evaluate the potency of the bradykinin (BK) antagonists, cumulative
concentration-response curves to BK were constructed in the absence and presence of
the test antagonist. Antagonists were added to the organ baths, in the absence of
electrical stimulation, 20min prior to the construction of the BK concentration-
response curves. Three successively increasing concentrations of antagonist were
equilibrated with the vas deferens, with each concentration of antagonist being
washed out before the addition of the next higher concentration. In another series of
BK antagonist studies, BK cumulative concentration-response curves were
constructed before and after co-incubation of NPC349 (30 and lOOpM) at varying
time periods with Hoe 140 (30nM).
Antagonist washout experiments were performed by constructing cumulative
concentration-response curves to BK before and after the addition of a high
concentration of the BK antagonist. To investigate the specificity of the BK
antagonists in the vas deferens, neurogenic and musculotropic response curves were
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constructed to noradrenaline, angiotensin II and U46619 before and after the addition
of the BK antagonists.
In preliminary studies, neurogenic and musculotropic cumulative concentration-
response curves to BK, were constructed before and after prazosin, propranolol,
atropine, mepyramine, ranitidine, thioperamide, ondansetron, GR113808, GR82334,
Menl0207, indomethacin and staurosporine (0.3-lpM). These various agents were
also added (lpM) during basal electrically-evoked stimulation of the rat vas deferens.
In another series of preliminary experiments, the P2 purinoceptor was desensitised by
two successive additions of a,P-methylene-ATP (lOpM). The effects on basal
electrically-evoked twitches, and the effects of BK (lpM), ATP (ImM) and U46619
(lpM) were obtained before and after inducing desensitisation to a,P-methylene-
ATP.
9.2.3 Data analysis
Increases in basal muscle tension (musculotropic response) are expressed as a
percentage of the maximal response that was attained by the test agent. The
potentiations in the magnitude of the electrically-driven twitches (neurogenic
response) are quantified as the percentage of the maximal response above the basal
twitch attained by the test agent. The potency of BK and the B2 receptor agonists at
producing the neurogenic and musculotropic responses are expressed as the
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geometric mean (95% confidence limits) of the EC50 (concentration which produces
50% of the maximal response) values.
In the BK antagonist studies, pA2 and slope values were obtained from Schild plots
using a curve fitting program (Baspak, Glaxo Research & Development). Incubation
with Hoe 140 decreased the maximal BK musculotropic response (insurmountable
antagonism) such that conventional Schild analysis could not be used to determine the
potency of the antagonist. Nevertheless, an apparent pKB for Hoe 140 was derived
using a double regression plot (Kenakin, 1984). Essentially, such a plot involves
plotting 1/A vs 1/A' where A and A' are the equieffective concentrations of agonist in
the absence and presence of Hoe 140, respectively. An estimated pKB is then derived
by using the gradient (G) of this plot in the Gaddum Equation (pKB = -log ([B] / G-l),
where B is the antagonist concentration).
9.2.4 Statistical analysis
Experimental values are given as the mean ± s.e.mean. n represents the number of
vas deferens used. For the BK agonist studies, the Student's paired t-test was used to
determine statistical differences between the neurogenic and musculotropic EC50
values of each test agent. The un-paired t-test was used to determine statistical
relevance between BK and B2 receptor agonists at the neurogenic and at the
musculotropic responses. For the B2 receptor antagonist studies, the paired t-test was
used to statistically compare the pA2 and slope values at the neurogenic response with
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those obtained respectively at the musculotropic response. P values less than 0.05
were considered to be statistically significant.
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9.3 RESULTS
9.3.1 Neurogenic and musculotropic effects of bradykinin
Cumulative additions of BK (0.001 - 3pM) to the electrically-stimulated RVD
produces two distinct effects (typical chart record shown in Figure 9.1); a potentiation
in the magnitude of the electrically-driven twitch (neurogenic response) and an
increase in the basal tension of the muscle (musculotropic response). Both the BK-
induced neurogenic and musculotropic cumulative concentration-response curves
were highly reproducible for at least four consecutive cumulative curves (Figure 9.2).
The EC50 values (nM) and 95% confidence limits for the initial BK neurogenic and
musculotropic curves (n=14) were 109.3 (32.5 - 340.5) and 93.4 (28.5 - 345.5),
respectively. These values were not significantly different (P>0.05). EC50 values for
the BK-induced neurogenic and musculotropic effects did not differ significantly
(P>0.05) from their respective EC50 values over three further BK cumulative
concentration-response curves.
9.3.2 Bi receptor studies
The bradykinin Bj receptor agonist, des-Arg9-BK (1 - 3000nM), had no effect on
either the basal electrically-induced twitch response or on the basal muscle tension of
the vas deferens. Even when cumulative additions of des-Arg9-BK (1 - 3000nM) were
repeated up to three times, it still failed to produce either a neurogenic or
musculotropic response. The bradykinin Bi receptor antagonist, des-Arg9-Leu8-BK (3
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Figure 9.1 Typical chart record showing that cumulative additions of bradykinin to
the electrically-stimulated rat vas deferens produces concentration-related increases in
both the magnitude of the electrically-induced twitches (neurogenic response) and in
the basal muscle tension (musculotropic response).
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Figure 9.2 Reproducibility of cumulative log concentration bradykinin neurogenic (a)
and musculotropic (b) response curves (Oinitial, ©second, Dthird and ■fourth
curves). Each point is the mean ± s.e.mean (vertical bars) from eight experiments.
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- 30pM), had no effect on either the neurogenic or musculotropic response curves to
BK (Figure 9.3).
9.3.3 Effects of B2 receptor agonists
Cumulative additions (1 - 3000nM) of BK and the B2 agonists, Met-Lys-BK and
Lys-BK, all produced concentration-related enhancements of the basal electrically-
evoked twitch and the baseline muscle tension. Table 9.1 lists the EC50 values with
95% confidence limits for the neurogenic and musculotropic responses of BK and two
relatively selective B2 agonists. As with BK, for each B2 receptor agonist, the EC50 for
the neurogenic response did not differ significantly (P>0.05) from its respective EC50
value for the musculotropic response. However, a significant difference (P<0.05) was
found between agonists, with Met-Lys-BK being approximately 4.5-fold more potent
at producing the neurogenic response than was BK (Table 9.1). The EC50 values for
the musculotropic responses induced by BK, Met-Lys-BK and Lys-BK were not
significantly different from each other (P>0.05).
9.3.4 Effects of B2 receptor antagonists on the bradykinin-induced
neurogenic and musculotropic responses
All the B2 receptor antagonists (Thi5,8-DPhe7-BK, adamanteacetyl-NPC349, DPhe7-
BK, NPC349, NPC567, Hyp2-DPhe7-BK, DArg-Hyp2-DPhe7-BK and Hoel40) tested
produced concentration (0.01 - 100pM)-dependent rightward shifts of the cumulative
neurogenic and musculotropic response curves to BK. All of the B2 antagonists (1 -
lOOpM), except Hoel40, produced surmountable antagonism of the BK neurogenic
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Figure 9.3 Effects of des-Arg9-Leu8-BK (#3^M, DlOfiM and ■30fiM), incubated
for 20min, on the control (O) bradykinin neurogenic (a) and musculotropic (b)
cumulative log concentration-response curves. Each point is the mean ± s.e.mean





























































































and musculotropic responses (typical example for NPC567 is shown in Figure 9.4). In
contrast, Hoe 140 (10-300nM), caused a concentration-related rightward shift and
suppression of the maximal response of the BK musculotropic response curve, but
surmountable antagonism of the BK neurogenic response curve (Figure 9.5).
Table 9.2 shows the pA2 and slope values obtained with the various B2 antagonists
for both the BK neurogenic and musculotropic responses. Neither the pA2 nor the
slope values for the antagonists, DPhe7-BK, Thi5'8-DPhe7-BK, D-Arg-Hyp2-DPhe7-BK,
adamanteacetyl-NPC349, and NPC567 (1 - lOOpM) at the BK neurogenic response
differed significantly (P>0.05) from their respective values obtained at the BK
musculotropic response. In contrast, Hyp2-DPhe7-BK (3 - 30pM) showed a modest,
but significantly (P<0.05) greater potency for the BK musculotropic response
(pA2 = 5.83 ± 0.11) than it did for the BK neurogenic response (pA2 = 5.54 ± 0.12).
NPC349 (3 - lOOpM) gave a significantly (P<0.05) higher slope against BK
neurogenic responses (slope: 1.26 ± 0.06) than against BK musculotropic responses
(slope: 0.99 ± 0.03). The slope of 1.26 obtained with NPC349 against BK neurogenic
responses was significantly (P<0.05) greater than unity. The slopes of none of the
other surmountable B2 antagonists differed significantly (P>0.05) between those for
the BK neurogenic and musculotropic responses, and neither did they differ
significantly (P>0.05) from unity. Hoel40 (10 - 3000nM) was approximately 2-3
orders of magnitude more potent against both BK neurogenic and musculotropic
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Figure 9.4 Effects of NPC567 ( OlOpM, V30pM and DlOOpM), incubated for
20min, on the control (•) bradykinin neurogenic (a) and musculotropic (b)
cumulative log concentration-response curves. NPC567 = DArg-Hyp3-DPhe7-BK.
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Figure 9.5 Effects of Hoe 140 (O lOnM, V30nM and DlOOnM), incubated for 20min,
on the control (#) bradykinin neurogenic (a) and musculotropic (b) cumulative log
















































































































































































None of the B2 antagonists, in the concentration range tested (O.OOl-lOOpM), had
any direct effect on the basal electrically-induced twitch response, nor did they affect
baseline tension.
9.3.5 Effects of NPC349 on Hoel40-induced insurmountable antagonism of
the bradykinin innsculotropic response
Incubation (20min) with Hoel40 (30nM) caused a rightward shift and
approximately 70% suppression of the maximal response of the BK musculotropic
response curve (Figure 9.5). Increasing the incubation time of Hoel40 (30nM) from
2-180min had no effect on the rightward shift or on the suppression of the maximal
response of the BK musculotropic curve (Figure 9.6). Incubation (20min) with the B2
antagonist, NPC349 (3 - lOOpM), produced surmountable concentration-dependent
antagonism of the cumulative musculotropic response curve to BK (Figure 9.7 and
Table 9.2). Co-incubation of NPC349 (30 and lOOpM) for the final 18min of the
Hoe 140 (30nM) incubation period (20min), produced BK musculotropic response
curves which were displaced upwards ('rectified') in a concentration-related manner,
and shifted to the left (NPC349, 30pM) or to the right (NPC349, lOOpM) as
compared to the BK curve in the presence of Hoel40 (30nM) alone (Figure 9.8). In
another related series of experiments, varying the incubation time (2 and 18min) of a
single concentration of NPC349 (lOOpM) produced no differences in the subsequent
BK musculotropic curves, where there were shifts to the right and upwards




Figure 9.6 Effects of Hoel40 (30nM), incubated for 2 (O), 20 (□), 120 (A) and
180 (v) min, on the bradykinin musculotropic log cumulative concentration-response
curve (•). Each point is the mean ± s.e.mean (vertical bars) from eight experiments.
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Figure 9.7 Effects of NPC349 (03|iM, VIOpM, [I]30pM and AlOO|iM), incubated
for 20min, on the bradykinin musculotropic log cumulative concentration-response
curve (•). Each point is the mean ± s.e.mean (vertical bars) from seven experiments.
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Figure 9.8 The effects of Hoel40 (30nM, 20min incubation) alone (■), or co-
incubated with NPC349 (A30pM and OlOOpM) for the final 18min of the 20min
incubation period, on the control bradykinin musculotropic log cumulaUve
concentration-response curve (•). Each point is the mean ± s.e.mean (vertical bars)
from four to five experiments.
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Figure 9.9 The effects of Hoe 140 (30nM, 20min incubation) alone (■), or co-
incubated with NPC349 (100pM) for the final 2 (A) or 18 (O)min of the 20min
incubation period, on the control bradykinin musculotropic log cumulative
concentration-response curve (•). Each point is the mean ± s.e.mean (vertical bars)
from four to five experiments.
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9.3.6 Specificity and wash-out experiments of B2 receptor antagonists
The specificity of B2 receptor antagonists (0.1 - lpM) was tested against the
neurogenic and musculotropic effects to noradrenaline, U46619 (thromboxane A2
mimetic) and angiotensin II (O.Ol-lOOpM). Neither the neurogenic nor the
musculotropic concentration-response curves obtained to any of these agonists were
affected by any of the B2 receptor antagonists examined in this study (n=3-4, data not
shown). An example of such a specificity study for Hoe 140 is illustrated in
Figure 9.10 using an approximate EC50 concentration of noradrenaline (lpM).
The effects of all the B2 receptor antagonists (lOOnM, 20-180min incubation for
Hoe 140 and lOOpM, 20min incubation for other antagonists) could be fully reversed
on washing, since the BK-induced neurogenic and musculotropic response curves
obtained after antagonist wash-out were similar to the initial curves without
antagonist (n=4-8, data not shown).
9.3.7 Preliminary studies into the identity of the neurotransmitter in the
electrically-stimulated rat vas deferens
Both the BK-induced neurogenic and musculotropic cumulative concentration-
response curves (n-6-1) were unaffected by the following antagonists (lpM, 20min
incubation): prazosin (cti adrenoceptor, Figure 9.11), propranolol (non-selective (3
adrenoceptor), atropine (muscarinic cholinoceptor), 8-phenyltheophylline (non¬












Figure 9.10 Chart records showing the effects of bradykinin (a) and noradrenaline (b)
before and after incubation (20min) with Hoe 140.
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Figure 9.11 Effect of cumulative dosing with bradykinin on neurogenic (a) and
musculotropic (b) responses of the rat vas deferens before (O) and after (#)
incubating (20min) with prazosin (lpM). Each point is the mean ± s.e.mean (vertical
bars) from seven experiments.
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thioperamide (H3 receptor), ondansetron (5-HT3 receptor), GR113808 (5-HT4
receptor), GR82334 (NKi receptor) and Menl0207 (NK2 receptor). The BK response
curves were also unaffected in tissues incubated with the cyclo-oxygenase enzyme
inhibitor, indomethacin (lpM) (Figure 9.12). None of these drugs had any effect on
the basal electrically-induced twitches (lpM, n=6-7).
Basal electrically-evoked twitches, BK-induced enhancements in the magnitude of
the electrically-evoked twitches, and the contraction induced by ATP, were reduced
or abolished in preparations exposed to oc,p-methylene-ATP (lOpM) (Figure 9.13).
The contraction produced by U46619 (lpM) was unaffected in preparations exposed
to a,P-methylene-ATP (lOpM) (Figure 9.13).
9.3.8 Preliminary second messenger studies in the electrically-stimulated rat
vas deferens
The chart records in Figure 9.14 shows that the PKC inhibitor, staurosporine (lpM),
preferentially blocked the BK musculotropic response (complete block) over the BK
neurogenic response (partial block) in an electrically-stimulated RVD. Figure 9.15
shows the pooled data for the effects of staurosporine (lpM) in the RVD; the BK
neurogenic and musculotropic cumulative concentration-response curves were both
shifted to the right (greater shift at the BK musculotropic response) with
approximately 40% and 85% suppressions in the maximal response, respectively.
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Figure 9.12 Bradykinin-induced neurogenic (a) and musculotropic (b) log cumulative
concentration-response curves before (O) and after (•) incubating (20min) with
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(b) Typical desensitisation of a.,P-methylene-ATP-induced contraction
a,P-methylene-ATP (10(iM)
a,P-methylene-ATP (10)iM)
(c) Responses after desensitisation of ot,P-methylene-ATP
ES ATP (ImM) bradykinin (lpM) | U46619 (l(iM)
Figure 9.13 Chart records showing the effects of basal field electrical stimulation
(ES), ATP (ImM), bradykinin (lpM) and U46619 (lpM) before (a) and after (c)
desensitisation to a,P-methylene-ATP (lOpM) (b).
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Figure 9.14 Chart records showing cumulative additions of bradykinin (0.001 -
30pM) before (a) and after (b) incubation (20min) with staurosporine (lpM). Note
that in this preparation, staurosporine completely abolished BK-induced
musculotropic responses but only partially blocked BK-induced neurogenic responses.
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Figure 9.15 Bradykinin neurogenic (a) and musculotropic (b) log cumulative
concentration-response curves before (O) and after (#) incubating (20min) with




9.4.1 Bradykinin neurogenic and musculotropic responses
This study has shown that addition of BK to the electrically-stimulated RVD
produces two responses; an enhancement in the electrically-driven basal twitches and
an increase in the basal muscle tension. The former response has been shown to be
mediated by neuronal pre-junctional BK receptors, and has been termed the BK
neurogenic response, whereas the latter response has been shown to be mediated by
post-junctional BK receptors located on smooth muscle and is referred to as the BK
musculotropic response (Huidobro-Toro et al., 1986).
9.4.2 Mediators of the bradykinin neurogenic and musculotropic responses
The responses to BK in various preparations have been shown to involve the release
of noradrenaline (Llona et al., 1991), histamine (Sharma, 1991), adenosine (Green et
al., 1991), substance P (Lembeck & Holzer, 1979) and prostanoids (Juan et al.,
1984). In contrast, the results of the present investigation have shown that the basal
electrically-evoked twitches, and the BK-induced neurogenic response, does not
involve oci, |3, Hi, H2, H3, adenosine, 5-HT3, 5-HT4, NKi or NK2 receptors nor the
involvement of prostaglandins. Preliminary results using the P2 purinoceptor
tachyphylactic agent, a,p-methylene-ATP (Meldrum & Burnstock, 1983), have
shown that ATP is likely to be the neurotransmitter responsible for both the basal
electrically-evoked twitches and the BK-induced enhancement in the magnitude of
electrically-evoked twitches (Figure 9.13). In contrast, it has been reported in
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biochemical studies by Llona et al. (1991) in the rat vas deferens, that noradrenaline
was the presynaptic neurotransmitter that mediated the BK-induced enhancement of
the electrically-induced twitches. However, in this study by Llona et al. (1991), high
frequency field stimulation (three 10Hz trains) was used to induce the output of 3H-
noradrenaline from the vas deferens after addition of BK, whereas in the present
functional study, a much lower frequency stimulation (0.33Hz) was used. Therefore,
it appears that, in the present study and in other similar studies (Huidobro-Toro et al.,
1986; Llona et al., 1987; Rifo et al., 1987), the neurotransmitter released pre-
junctionally in the field-stimulated RVD at low stimulation frequencies in response to
BK (neurogenic response) is ATP rather than noradrenaline. Furthermore, since a,(3-
methylene-ATP-induced desensitisation is a recognised identification criterion for the
P2x purinoceptor subtype (Burnstock & Kennedy, 1985; O' Conner, 1992), it can
be further deduced that in the electrically-stimulated RVD, ATP acts on post¬
junctional P2x purinoceptors. In the light of an extensive literature in the vas deferens
(for review see Campbell, 1987) which shows that ATP and noradrenaline are
involved in co-transmission, it would be of interest to investigate the contribution
made by these neurotransmitters, in response to BK, at different parameters of field-
stimulation.
Since the BK-induced musculotropic response was not affected by a variety of
receptor antagonists (prazosin, propranolol, atropine, 8-phenyltheophylline,
mepyramine, ranitidine, thioperamide, ondansetron, GR113808, GR82334 and
Men 10207) or by indomethacin, it is likely that the post-junctional action of BK in the
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RVD is mediated directly, and does not involve the release of other mediators as was
observed to be the case for the BK-induced neurogenic response.
9.4.3 Bradykinin-induced neurogenic and musculotropic responses:
preliminary second messenger studies
The protein kinase C (PKC) inhibitor, staurosporine, was found to inhibit both the
BK-induced neurogenic and musculotropic responses. These results, therefore,
implicate a role for PKC in the pre-and post-junctional transduction pathways
activated by BK receptor stimulation. In agreement with the present study,
involvement of PKC has been implicated in the transduction pathways activated by
BK in various preparations, such as sensory neurones (Burgess et al., 1989), dorsal
root ganglion neurones (Boland et al., 1991) and in the neonatal rat spinal cord-tail
preparation (Dray et al., 1992). The present preliminary findings also indicate that
PKC may not be the only second messenger mediator involved at the BK neurogenic
and musculotropic responses because staurosporine only caused partial blocks of
these BK effects. It has been shown that BK in various preparations can affect levels
of inositol phosphates, arachidonic acid and cyclic AMP (for reviews see Taylor et al.,
1989; Bathon & Proud, 1991; Farmer & Burch, 1992) and, therefore, it is possible
that these mediators, alone or in combination, may play a role, along with PKC, in the
transduction pathway of the BK-induced neurogenic and musculotropic responses. In
the present investigation, staurosporine inhibited to a much larger extent the BK
musculotropic effect than the BK neurogenic response (Figure 9.14 - 9.15). This
differential sensitivity to staurosporine indicates that PKC is likely to be more
important at mediating BK responses in muscle tissue than in neural tissue.
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9.4.4 Bradykinin cumulative concentration-response curves
In the present study, BK was added in a cumulative manner. Preliminary
experiments (data not shown) demonstrated that the BK neurogenic and
musculotropic cumulative concentration-response curves were similar to their
respective curves obtained by single additions of BK. The method of cumulative
additions of BK has advantages over single concentration additions, as used by other
investigators in the vas deferens (Huidobro-Toro et al., 1986; Rifo et al., 1987;
Tousignant et al., 1987), in terms of the speed of construction of the concentration-
response curves (<5min). Furthermore, by using cumulative additions of BK, it was
possible to obtain three further cumulative concentration-response curves which were
not significantly different from the first curve. As a result of this reproducibility,
advantages were gained in the protocols for the antagonist experiments, in that it was
possible to add three increasing concentrations of BK antagonist between cumulative
curves (all antagonists used could be washed out), thus allowing easier and more
accurate determination of antagonist potency.
The increases in the neurogenic and musculotropic responses to BK were generally
similar to those observed by Rifo et al. (1987), who also used the electrically-
stimulated RVD. However, in the study by Rifo et al. (1987), BK was 3-fold more
potent at enhancing the neurogenic response than at increasing the musculotropic
response, whereas in the present studies, BK was equipotent at both responses. A
difference in strain of rat and in the segments of vas deferens used could explain the
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different potencies observed with BK between the two studies. In the present
investigation, Wistar rats were used, whereas Rifo et at. (1987) used Sprague-Dawley
rats. Furthermore, Rifo et al. (1987) used the prostatic segment to determine the BK
neurogenic response and the epididymal segment to determine the BK musculotropic
response (neurogenic response greater at prostatic end, whereas musculotropic
response greater at epididymal end), whereas in the present study the prostatic
segment was used to determine both responses (similar tension changes for
neurogenic and musculotropic responses). The prostatic segment from the Wistar rat
is, therefore, a more suitable tissue on which to investigate comparisons between
neurogenic and musculotropic responses.
9.4.5 Bi receptors in the electrically-stimulated rat vas deferens
Classically, BK receptors are classified into the Bi and B2 subtypes (Regoli and
Barabe, 1980). In the current investigation, the population of BK receptors in the
electrically-stimulated RVD were not of the Bi subtype, since the Bi receptor agonist,
des-Arg9-BK, was inactive at producing either a neurogenic or a musculotropic
response, and the Bi receptor antagonist, des-Arg9-Leu8-BK, failed to antagonise
neurogenic and musculotropic responses to BK. It has been shown that Bi receptors
can be induced, as shown by the increased responsiveness to des-Arg9-BK, in the
isolated rabbit aorta (Bouthillier et al., 1987). In contrast, as there was no response to
des-Arg9-BK (applied repeatedly with time) in the electrically-stimulated RVD, it is
unlikely that Bi receptors were induced in this preparation.
299
9.4.6 Effects of B2 receptor agonists
BK, and the relatively selective B2 receptor agonists, Met-Lys-BK and Lys-BK, all
produced concentration-related enhancements of both neurogenic and musculotropic
responses. No significant difference was found between the neurogenic and
musculotropic EC50 values for any of these agonists. This is in contrast to the study by
Llona et al. (1987), which used whole vas deferens from Sprague-Dawley rats, where
Met-Lys-BK and BK were more potent (26 and 3.5 fold, respectively) at enhancing
the neurogenic response than at increasing the musculotropic response, although in
agreement with the present study, Llona et al. (1987) demonstrated that Lys-BK was
equipotent at both responses. Why such activity differences with Met-Lys-BK and BK
arose between the two studies is not clear, but it may be attributable to segmental
and/or species differences. However, such segmental or species differences do not
explain why Lys-BK produced similar effects in the current study and that of Llona et
al. (1987). In agreement with the findings of Llona et al. (1987), Met-Lys-BK was
found to be more potent (approximately 4-fold) than BK at enhancing the neurogenic
response, whereas no difference in activities was found between the agonists to
increase baseline muscle tension (musculotropic effect). One hypothesis to explain
these orders of activity observed with Met-Lys-BK, Lys-BK and BK is that the pre-
and post-junctional B2 receptors may not be of a homogeneous nature, and thus the
data could suggest the existence of subtypes of the B2 receptor in the RVD.
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9.4.7 Effects of B2 receptor antagonists
A range of B2 receptor antagonists was used to determine their profile of
antagonism for the BK neurogenic and musculotropic responses. All the B2 receptor
antagonists studied, with the exception of Hoe 140 on the musculotropic response,
caused concentration-dependent surmountable shifts of both the neurogenic and
musculotropic concentration-response curves to BK (Table 9.2). The B2 receptor
antagonists, Thi5,8-DPhe7-BK and NPC349, had differing actions on the RVD between
the present study using Wistar rats, and in the studies by Rifo et al. (1987) and Llona
et al. (1987) using Sprague-Dawley rats. Whereas Thi5 8-DPhe7-BK was found to be a
weak surmountable antagonist for both the BK-induced neurogenic and
musculotropic responses in the present investigation, Llona et al. (1987) showed that
Thi5,8-DPhe7-BK behaved as a competitive antagonist on the musculotropic response,
but acted as a full agonist to enhance the basal twitch response. NPC349 was a more
potent antagonist of the BK neurogenic response than of the BK musculotropic
response in the study by Rifo et al (1987), whereas in the current investigation this
antagonist behaved in the reverse manner (Table 9.2). These differences in the
responses of Thi5,8-DPhe7-BK and NPC349 in the RVD of Wistar and Sprague-
Dawley rats could reflect a heterogeneous population of the B2 receptor between rat
species.
The B2 receptor antagonist, Hyp2-DPhe7-BK, gave an interesting result in the RVD
in that, although it caused concentration-dependent competitive shifts of both the BK
neurogenic and musculotropic response curves, it was more potent at antagonising the
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BK musculotropic response than the BK neurogenic response. Although these
potency differences observed with Hyp2-DPhe7-BK are not large, it could be taken as
evidence to suggest that the pre- and post-junctional B2 receptors are different.
The most interesting of the B2 receptor antagonists studied in the electrically-
stimulated RVD was Hoe 140, which was approximately 2-3 orders of magnitude
more potent than any of the other B2 receptor antagonists tested at both the BK-
neurogenic and musculotropic responses (Table 9.2). A similar difference in potency
between Hoe 140 and other B2 receptor antagonists has also been reported in a variety
of other in-vitro smooth muscle preparations (Hock et al., 1991). The most striking
difference between Hoe 140 and the other B2 receptor antagonists tested in the present
study was in the differences in profile of antagonism observed between the BK
neurogenic and musculotropic responses. Whereas all the other B2 receptor
antagonists studied showed competitive antagonism for both the BK neurogenic and
musculotropic responses, Hoe 140 displayed surmountable antagonism at the
neurogenic response but insurmountable antagonism at the musculotropic response.
Such insurmountable antagonism with Hoe 140 has previously been shown in other
preparations, such as the guinea-pig ileum (Griesbacher & Lembeck, 1992), rabbit
jugular vein (Fdldtou et ah, 1994), sheep femoral artery (Fdldtou et ah, 1994) and in
cultured colonic epithelial cells (Cuthbert et ah, 1992). In the study by Cuthbert et ah
(1992), the action of the BK analogue, Lys-BK, to raise intracellular calcium was
blocked in an insurmountable fashion by Hoe 140, although the action on electrogenic
chloride secretion was competitively blocked.
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9.4.8 Mechanisms of insurmountable antagonism of Hoel 40 at the
bradykinin musculotropic response
There are several mechanisms which could be responsible for the insurmountable
action of Hoe 140 on the BK-induced musculotropic response curve in the rat vas
deferens. Hoel40 may act as 1) a 'non-specific' antagonist, 2) an irreversible
antagonist, 3) a pseudo-irreversible antagonist, or 4) an allosteric antagonist, of BK.
These various possible mechanisms are discussed in further detail below.
The possibility that the peptide, Hoe 140, is a 'non-specific' antagonist such that it
could block the chain of events that lead to the production of a response, or that it
blocks a receptor unrelated to BK, is unlikely, because Hoe 140 (O.lpM) was found
not to affect the neurogenic and musculotropic responses induced by the peptide,
angiotensin II, nor those by the non-peptides, noradrenaline and U46619. Thus, it is
more likely that Hoel40 acts at the B2 receptor, or at a site closely related to it.
Insurmountable antagonism can occur when covalent bonds are formed between the
antagonist-receptor complex such that the number of receptors is reduced to an extent
where it is no longer possible to obtain a full agonist response, and hence a
suppression of the maximal response results. This explanation is unlikely to account
for the insurmountable antagonism of Hoel40, since the antagonist could be washed
out from the vas deferens following a 20-180min incubation period, and increasing the
incubation time from 2 to 180min did not produce any change in the suppression of
the maximal response (Figure 9.6). From these two results it is clear that Hoel40
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does not form irreversible contacts with the BK receptor, and also that Hoel40
reaches equilibrium quickly (<2min). The finding that the suppression in the maximal
response induced by Hoel40 could be reversed (Figure 9.8) by co-incubation with the
B2 competitive antagonist, NPC349, gives further evidence in favour of Hoel40 not
being an irreversible antagonist, since if Hoe 140 had bound in a covalent manner to
the B2 receptor, then no effect on the BK maximum would have of been expected if
co-incubated with a competitive antagonist.
A more probable explanation to account for the insurmountable antagonism
observed is that Hoe 140 is acting as a slowly reversible (pseudo-irreversible)
antagonist. The hypothesis of pseudo-irreversible antagonism is that receptor-bound
antagonist dissociates so slowly such that the agonist cannot reach equilibrium with
the antagonist-receptor complex within the time constraints of the experiment
(problems of desensitisation, degradation of agonist etc.) and thus gives the apparent
appearance that the antagonist has bound irreversibly (pseudo-irreversible
antagonism). This hypothesis of pseudo-irreversible antagonism can be used to
explain the results described above for the co-incubation experiments with Hoel40
and NPC349. Thus, Hoe 140 dissociates slowly from the B2 receptor, but as it does,
the vacated receptor becomes occupied by NPC349. The subsequent addition of BK
then competes for receptors occupied by NPC349 as well as those occupied by
Hoel40. On increasing the concentration of NPC349 a greater number of receptors
become occupied by NPC349 than Hoel40. Since BK can surmount the antagonism
by NPC349 (Figure 9.7), the maximal response attainable by BK increases in relation
to the number of receptors occupied by NPC349. If it had been the case that Hoel40
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did not dissociate from the receptor, then co-incubation with NPC349 would have
had the effect of displacing further rightwards an already suppressed BK curve.
Results similar to those in the present study, where reversal of the suppression in the
maximal response, induced by an apparently insurmountable antagonist, by use of a
competitive antagonist has been observed in the 5-HT (Bond et al., 1989) and
angiotensin (Robertson et al., 1992) fields.
In order for this explanation of Hoe 140 being a slowly-reversible antagonist, to be
fully convincing, it is necessary for NPC349 to reach equilibrium with the B2 receptor
much more quickly than Hoe 140. Although no experiments were conducted to
determine whether NPC349 had reached equilibrium within the 20min incubation
period, results from the study by Rifo et al (1987) in the vas deferens showed that
using a lower incubation period of 5min a musculotropic pA2 value of 6.4 is obtained
for NPC349, which compares well with the pA2 of 6.3 in the present study. Therefore,
it is probably the case that NPC349 reaches equilibrium rapidly. However, since
Hoel40 seems to reach equilibration within 2min (Figure 9.6) it would have to be
postulated that for the explanations of the interactions of NPC349 and Hoe 140
discussed above to be valid, NPC349 would have to reach equilibration even more
rapidly, and certainly within 2min. Evidence that NPC349 had reached equilibration
within 2min is provided in Figure 9.9, where a single concentration of NPC349 co-
incubated for 2 or for 18min with Hoel40 produced similar rightwards shifts of the
BK musculotropic curve.
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Also for pseudo-irreversibility to explain the current findings, it would have been
expected that shorter co-incubation times of NPC349 would have resulted in
correspondingly greater suppression in the maximal response to BK, induced by
Hoel40. Such incubation time-related reversal of Hoe 140-induced response
suppression with NPC349 could then be used to give an indication of the slow rate of
dissociation of Hoel40 from the B2 receptor. However, incubation of NPC349 for
2min or 18min produced similar reversals in the suppression of the maximal response
induced by Hoel40 (Figure 9.9) suggesting that Hoel40 dissociates very rapidly from
the BK receptor. Further evidence which suggests that the mechanism of action of
Hoe 140 may not be fully attributed to it being a slowly reversible antagonist, is the
observation that since only a 2min incubation with NPC349 is required to reverse the
suppression seen with Hoel40, then it becomes unclear as to why BK itself cannot
reverse this suppression, assuming that BK, Hoe 140 and NPC349 all act at the B2
receptor. In conclusion, the data from the Hoel40 / NPC349 interaction experiments
provide evidence (Figure 9.8) for Hoel40 being a pseudo-irreversible antagonist at
the musculotropic B2 receptor, although this evidence is not fully supported by the
NPC349 time course experiments (Figure 9.9).
Allosteric modulation of the B2 receptor by Hoe 140 may be another explanation of
why this antagonist operates to cause insurmountable antagonism of the BK
musculotropic response. Essentially, allosteric antagonists act at a site close to
(allosteric effector site), but not at, the agonist binding site, and have the action of
diminishing (by changes in receptor affinity) the capability of the agonist-receptor
complex to generate a response. Thus, in relation to the present results, it can be
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hypothesised that Hoel40 causes insurmountable antagonism of the
BK musculotropic response by acting at an allosteric effector site which then
produces a change in the state of the BK receptor such that the action of BK becomes
impaired. Furthermore, it can be postulated that NPC349 can also act at the allosteric
site to reverse the effects of Hoe 140. Therefore allosteric modulation of the B2
receptor can be used, as an alternative to pseudo-irreversible antagonism, to explain
the Hoel40 / NPC349 interaction experiments described above. From the present
functional studies it is not possible to determine whether Hoe 140 behaves as an
allosteric antagonist or not. Studies using radioligand binding in the vas deferens, in
order to determine whether BK binding to the B2 receptor is affected by Hoel40,
would aid in determining an allosteric modulatory role for Hoel40. Allosteric
modulation has been proposed by Kaumann & Frenken (1985) to explain the
insurmountable action of methysergide on the 5-HT vasoconstrictor responses in calf
coronary arteries.
An alternative to the above possible mechanisms to explain the insurmountable
nature of Hoel40 may be simply that Hoel40 acts on subtypes of the B2 receptor, or
on other types of BK receptor. The existence of subtypes of the B2 receptor have
been suggested in various preparations (e.g. in rat myometrial membranes, Liebmann
et al., 1991; mouse neuroblastoma cells, Braas et al., 1988). In view of studies
reporting the existence of novel types of BK receptor (B3, B4 and B5 types: Farmer et
al., 1989; Sahaet al., 1990; Farmer et al., 1991c; Saha et al., 1991; Farmer &
DeSiato, 1994) it is also conceivable that Hoe 140 produces differing profdes of
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antagonism at the pre- and postjunctional BK responses in the vas deferens by acting
on different types of the BK receptor.
9.5 SUMMARY
In summary, the bradykinin receptors mediating bradykinin-induced neurogenic and
musculotropic responses in the electrically-stimulated rat vas deferens are of the B2
subtype - Bi receptor agonists and antagonists were without effects. The differing
profiles of action observed for some bradykinin B2 receptor agonists and antagonists
at the neurogenic and musculotropic responses (particularly Hoe 140) may suggest
that the B2 receptors located pre- and post-junctionally in the rat vas deferens are not
of a homogeneous nature.
Preliminary experiments have shown that the prejunctional neurotransmitter
mediating the basal electrically-induced twitches, and the bradykinin-induced
neurogenic response, is likely to be ATP. Pilot experiments have provided evidence
that protein kinase C is involved in the signal-transduction pathway for both the
bradykinin-induced musculolropic (predominantly) and neurogenic responses,






The present study has investigated the role of various mediators (purines,
catecholamines and bradykinin) and their receptors in modulating C-fibre afferent
mechanonociceptor discharge (spontaneous and mechanically-evoked) in normal rat
ankle joints and in those with a chronic unilateral adjuvant-induced arthritis. The
results from these investigations provide some insight into the relative importance of
these mediators in contributing to the sensitisation of nociceptors that is associated
with arthritis.
10.1 FCA-induced arthritis in the rat
In the current investigation, a single local subdermal injection of low dose FCA
around the rat ankle joint induced an arthritis that remained confined to the injected
joint. The limited pathology associated with monoarthritis has considerable
advantages over the widespread and systemic nature of adjuvant-induced polyarthritis
because any observed changes (e.g. in mechanonociceptor discharge or behavioural
parameters) are more likely to be directly attributable to the inflammatory process
itself and not a consequence of severe pain and stress.
The mechanisms (e.g. immunological, biochemical) underlying the various phases of
FCA-induced monoarthritis (see Section 3) have not been investigated in the present
work. Thus, studies are required to correlate the various phases with, for example,
changes in the involvement of macrophages, neutrophils, T-cells and serum albumin
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or acute phase proteins levels (see Burnstein & Wakeman, 1964; Billingham, 1983;
Schaible & Grubb, 1993).
The advantage of locally injecting FCA in the rat is that the extent of inflammation
induced is simply determined by the dose of FCA injected. For example, as in the
present experiments, a low dose of FCA (150pg) induced a monoarthritis, whereas
other investigators, by increasing the dose of FCA (250pg), can obtain more severe
forms such as bilateral arthritis (Donaldson et al., 1993). It would be of interest to
perform studies which correlate articular C-fibre discharge or changes in behavioural
parameters with inflammation induced by varying doses of FCA.
10.2 Articular mechanonociceptor discharge from normal and
monoarthritic joints
A particular difficulty in the current neuropharmacological experiments was that it
was not possible to record from the same afferent unit before and after induction of
chronic FCA-induced arthritis. As a result, analysis of neural data is reduced to the
less satisfactory procedure of comparing samples of mechanonociceptor activity from
normal and arthritic joints. It has been shown that the same initially
mechanoinsensitive afferent units in normal cat knee joints (identified by electrical
stimulation of axons) become responsive to mechanical stimuli following acute
inflammation of the joint induced by kaolin / carrageenan (Grigg et al., 1986 and
Schaible & Schmidt 1988). Such receptors have been termed 'silent or sleeping
nociceptors' or, more appropriately by Iggo (1988), 'inflammation receptors'. In view
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of the findings of Grigg et al. (1986) and Schaible & Schmidt (1988), it would be of
value to perform similar studies where neural activity is recorded from the same
afferent unit before and after induction of acute arthritis in the rat ankle joint so as to
determine the role of 'inflammation' receptors in this preparation.
In the present experiments, it was only possible to record action potentials in the
nerve trunk by means of extracellular electrodes located several millimetres (50-150)
from the nerve terminals. It is not possible to determine from such recordings the
mechanisms responsible for action potential generation, nor to study the effects of
drugs directly on the terminals of C-fibres. Thus, drug effects could be primary, on the
nerve terminals, or secondary to actions on other cells (e.g. mast cells and
macrophages), nerves (sympathetic neurones) or blood vessels. It would be of
immense value to record changes in membrane potential from the terminals of C-ftbres
by using the patch-clamp technique. Unfortunately, it is not possible to make such
recordings with the currently available technology. However, it may soon be possible
to patch onto the terminal endings that sprout following a nerve resection (neuroma).
Even if this proves possible, it will then be debatable whether the results obtained
from such neuromas are relevant to the terminals of normal C-fibre afferents.
It has been shown that primary afferents are involved in 'cross over' (inflammation
in the uninjected contralateral limb following inflammation in ipsilateral limb) of FCA-
induced arthritis (Donaldson et al., 1993). In view of this finding, it would be
interesting to perform studies which record alterations in C-fibre neural discharge in
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the contralateral (untreated) joint following inflammation (FCA-induced arthritis), or
electrical stimulation of C-fibres, in the ipsilateral joint.
The present experiments investigated neural activity from only high threshold slowly
adapting capsaicin-sensitive C-fibres but did not study in detail neural discharge from
other fibre types such as the low mechanical threshold-rapidly adapting fibres (i.e.
those responding to gentle pulling of the superficial layers of articular connective
tissue). Thus, it would be of value to record neural activity from these fibres in order
to determine in detail whether their sensitivities are altered in inflamed joints. Other
investigators have shown that fibres, other than C-afferents, such as the AfTfibres
(large myelinated primary sensory neurones) show increased sensitivity following
chronic inflammation, such that innocuous stimuli (e.g. touch) cause pain (Woolf &
Doubell, 1994).
Neural recordings from C-fibres showed that articular mechanonociceptor discharge
was elevated in arthritic joints as compared to untreated joints. How such elevations
in neural discharge affect the excitability of neurones in the central nervous system
(CNS) was not addressed in the current investigation. However, there is a large
literature which describes the many changes in the CNS such as the 'wind-up'
phenomenon or changes in the concentration of a large number of various transmitters
and mediators (see Section 1.4.4). Alterations can also occur outwith the CNS. For
example, use of molecular biological techniques have shown that neuropeptide
expression (substance P and calcitonin gene-related peptide) is increased in the dorsal
root ganglia of adjuvant-arthritic rats (Donaldson et al„ 1992; Smith et al., 1992).
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Increases in neural discharge from mechanonociceptors in arthritic joints can also
contribute to joint inflammation by generating axon-reflexes in the terminal
arborisations of C-fibres which gives rise to the release of various inflammatory
neuropeptides including substance P and CGRP (see Section 3.4.3 and
Foreman, 1987). These C-fibre induced alterations can be avoided by early
pharmacological intervention which reduces discharge from these afferents. However,
in some cases of chronic pain and inflammation, alterations in the CNS can persist
even without a C-fibre input (see Dray et al., 1994).
10.3 Neuropharmacological versus functional studies using FCA-induced
monoarthritis
In addition to recording mechanonociceptor discharge from arthritic ankle joints in
anaesthetised animals, functional studies were also performed using conscious
monoarthritic rats. Acute recordings from C-fibres have the advantage that drug
effects are determined in the short-term (seconds - minutes), whereas behavioural
studies allow drug effects to be studied in the longer term and during chronic dosing.
It seems reasonable that the two types of studies involve different measures of the
same events. Thus, for example, the reduction in threshold for mechanical activation
of mechanonociceptors in arthritic joints (neuropharmacological studies) corresponds
to the reduced latency and increased sensitivity in paw withdrawal following
application of mechanical pressure to the arthritic ankle joint (behavioural studies).
Future investigations could clarify the relationship between behavioural changes and
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C-fibre discharge from the same animal at fixed times (post-FCA injection), with and
without treatment with drugs.
10.4 Effects of indomethacin
The results of the present experiments have shown that indomethacin not only
reduced (but did not abolish) the elevated C-fibre discharge from
mechanonociceptors, but also reduced (but did not abolish) the joint swelling,
inflammation and mechanical hyperalgesia associated with monoarthritis (see Section
3). These results strongly suggest an important involvement of prostanoids in both the
neuropharmacological and functional studies, although this does not exclude the
additional involvement of other mediators (see Section 4.4.1 & 10.6).
Activation of cyclo-oxygenase (COX) enzymes catalyse the formation of
prostanoids. It is now well known that there are two types of COX enzyme, termed
COX-1 and COX-2. Of these, COX-1 is constitutive and active in normal conditions,
whereas COX-2 is induced under inflammatory conditions, and the prostanoids
formed may have pathological functions (Xie et al., 1991; Lee et ah, 1992). Since
increased levels of COX-2 have been reported in patients with rheumatoid arthritis
and in adjuvant-arthritic rats (Sano et ah, 1992), it would be of considerable interest
to determine what role COX-2 has in adjuvant-induced monoarthritis. In order to
investigate this, neuropharmacological and behavioural studies could be performed
using NS-398 (N-[2-cyclohexyloxy-4-nitrophenyl]methanesulfonamide), a COX
inhibitor with reported selectivity for the COX-2 form of the enzyme (Arai et ah,
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1993; Futaki et al., 1994), and the results compared with those obtained with the non¬
selective COX inhibitor, indomethacin.
10.5 Role of purinoceptors, ^-adrenoceptors and bradykinin receptors in
FCA-induced arthritis
The current results showed that neither purinoceptors, whether Pi (adenosine
receptors) or P2 (ATP receptors), nor [^-adrenoceptors appear to be involved in
modulating neural discharge recorded from mechanonociceptors in either normal or
adjuvant-arthritic rat ankle joints. It has previously been shown that although PGEi or
PGE2 cause little or no increase in afferent discharge, they do potentiate the excitatory
action of bradykinin (Chahl & Iggo, 1977; Birrell et al., 1993). Therefore, future
studies should examine the possibility that purines or drugs acting at ^-adrenoceptors
could sensitise articular sensory receptors to inflammatory agents such as certain
prostanoids, bradykinin or 5-HT.
It may be the case that purines or drugs selective for (^-adrenoceptors affect neural
excitability not at the periphery, but centrally. This could be investigated by recording
from neurones in the CNS (e.g. spinal dorsal horn, thalamic or cortical neurones)
whilst activating nociceptors in normal and arthritic joints. Another possibility is that
purinoceptors and (^-adrenoceptors are involved only in modulating afferent neural
activity in the acute phase of inflammation or in inflammation induced by other agents
which differs from FCA (e.g. in immune components or time course). Thus, it would
be worthwhile performing neuropharmacological studies to assess the role of
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purinoceptors and P-adrenoceptors using other models of inflammation (e.g. acutely
induced by FCA, carrageenan, kaolin, urate crystals or latex spheres).
Behavioural studies using the adjuvant-induced monoarthritic rat model are required
to determine what effects, if any, drugs affecting purinoceptors have on the
inflammation and hyperalgesia associated with this preparation. These results could
then be related to the current electrophysiological results to ascertain if there are any
differences. Regarding P-adrenoceptors, the present behavioural studies showed, in
agreement with the neuropharmacological investigations, that neither selective p-
adrenoceptor agonists nor antagonists have any effect on FCA-induced monoarthritis.
Although both adrenaline and noradrenaline failed to affect neural discharge from
mechanonociceptors in normal joints, they did enhance both spontaneous and
mechanically-evoked activity in approximately 50% of C-fibre units studied in
chronically-inflamed (adjuvant-arthritic) joints. The question of why these
catecholamines did not affect neural activity recorded from some C-fibres in inflamed
joints is not clear, but it may simply be due to some C-fibres not expressing or
containing functional adrenoceptors, although why this should be so requires study - it
may be the case that it is only a specific subpopulation of C-fibres which has the
ability to respond to catecholamines following chronic inflammation. Since the effects
of adrenaline or noradrenaline were not modified by propranolol, this strongly
suggests that these catecholamines are not acting at P-adrenoceptors, but possibly at
a-adrenoceptors. The question of whether a-adrenoceptors (ar and/or the a2-
subtype) are indeed responsible for enhancing neural discharge evoked by adrenaline
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or noradrenaline in arthritic joints was not addressed in the present work, and
investigation would require the use of selective oq and a2-adrenoceptor agonists and
antagonists. In addition, future studies could also determine the effects that selective
oq or a2-adrenoceptor antagonists have on the elevated neural discharge from
mechanonociceptors in adjuvant-arthritic joints.
Neuropharmacological experiments are required to establish the precise site(s) of
action of adrenaline and noradrenaline. Possible locations are the terminals of C-fibre
afferents and the sympathetic nervous system (see Section 6.4.2.1). To investigate
this, articular C-fibre neural discharge could be recorded from arthritic rats that have
been sympathectomised either surgically or chemically, by treatment with
guanethidine.
A particularly interesting finding of the present work was that the selective
bradykinin B2 receptor antagonist, Hoe 140, caused insurmountable antagonism of
bradykinin-induced excitation, but surmountable antagonism of bradykinin-evoked
sensitisation. From these results one can speculate that subtypes of the B2 receptor
may exist. Whether these differential effects are common to all bradykinin B2 receptor
antagonists or are peculiar to Hoe 140 requires further neuropharmacological
investigations using other potent and stable B2 receptor antagonists such as D-
Arg[Hyp3-Thi5-D-Tic7-Tic8]-bradykinin, Arg(Tos)'-Hyp3 -Thi5-D-Tic7-Oic8-
bradykinin, NPC17731 and NPC17761 (Fanner et al„ 1991b; Lembeck et al„ 1991;
Correa & Calixto, 1993). The possible existence of B2 receptor subtypes was
supported by studies which investigated the actions of Hoe 140 in the electrically-
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stimulated rat vas deferens (see Section 9). The main reason for choosing the
electrically-stimulated rat vas deferens preparation was not to use it as a replacement
for investigating the actions of bradykinin and Hoe 140 on articular C-fibres, but as a
preparation for investigating further the surmountable and insurmountable actions of
Hoe 140 (see Section 9). Studies in the vas deferens also suggested that mechanisms
such as pseudo-irreversibility could account for the differential actions of Hoel40.
The question of whether or not the bradykinin B2 receptors responsible for BK-
induced excitation and sensitisation of articular sensory C-fibres are indeed equivalent
to the B2 receptors located on sympathetic neurones (causing BK-induced neurogenic
responses) and smooth muscle (causing BK-induced musculotropic responses) of the
vas deferens remains to be established. In such studies it will be necessary to consider
the similarities and differences between C-fibres and sympathetic neurones such as, for
example, the fact that both are unmyelinated but that while C-fibres have a mainly
afferent role, sympathetics have an efferent one.
Although the present results showed that agonists and antagonists selective for
bradykinin Bi receptors had no effect on articular neural discharge recorded from C-
fibres in arthritic joints, it is possible that effects can be observed using other models
of joint inflammation. Pilot recordings from a novel preparation in this laboratory, the
medial articular nerve - knee joint preparation into which IL-ip is injected intra-
articularly, have indicated that Bi receptors may play a role in inflammation. In this
model, des-Arg9-bradykinin induced an excitation which was antagonised by the
bradykinin Bi receptor antagonist, des-Arg9-Leu8-bradykinin.
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The present studies showed that bradykinin receptor antagonists (Bi or B2 selective)
did not affect C-fibre neural discharge recorded from arthritic ankle joints. However,
this does not mean that bradykinin receptor antagonists will be of no value in the
treatment of joint inflammation, as it has been demonstrated that Bi and/or B2
receptor antagonists reduce the swelling, oedema or mechanical hyperalgesia (this
hyperalgesia may be via other fibre types such as A (Tfibres) associated with arthritis
(Sharma, 1993; Davis & Perkins, 1994).
It remains to be established which second messengers are involved in bradykinin-
induced enhancements of articular C-fibre neural discharge. Preliminary studies w-
vitro using the electrically-stimulated rat vas deferens indicate the involvement of
protein kinase C in the responses to bradykinin (see Section 9). Studies are also
needed to examine the role of G-proteins in the bradykinin-induced responses. Such
studies will need to be performed in-vitro, using neural preparations such as the
electrically-stimulated vas deferens, or more appropriately, the isolated medial
articular nerve - knee joint preparation.
10.6 Other inflammatory mediators
This thesis was concerned with the role of bradykinin, purines, and
catecholamines (acting at (3-adrenoceptors) in sensitising mechanonociceptors during
chronic inflammation. The vast literature relating to inflammatory mediators makes it
clear that there is an increasing number of putative inflammatory mediators /
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transmitters with the potential for altering neural discharge recorded from articular C-
fibre afferents. Some examples include: nitric oxide (from endothelial cells,
macrophages and leukocytes), endothelin, cytokines (from macrophages), nerve
growth factor (from fibroblasts and endothelium), platelet activating factor (from
most inflammatory cells including platelets, macrophages, polymorphs and basophils),
leukotrienes (see Section 4.4.1) and various neuropeptides (from mast cells,
sympathetic neurones, and primary afferent neurones) such as substance P,
secretoneurin, galanin, calcitonin gene-related peptide, dynorphin, enkephalin and
neuropeptide Y (Foreman, 1987; Ferreira et al., 1989; Maggi, 1991; Rang et al.,
1991; Dray & Bevan, 1993; Lewin & Mendell, 1993; Schaible & Grubb, 1993; Dray
et al., 1994; Kelly et al., 1994). It is unlikely that any one mediator can be the sole
'pain' mediator, but instead it is more likely that inflammation involves the complex
interactions between many mediators. Much further work is needed to characterise
the actions and interactions of inflammatory mediators on the discharge of articular
sensory afferent nerves. Once a detailed understanding has been obtained concerning
the effects of individual inflammatory mediators, particularly those responsible for the
sensitisation of nociceptors during chronic inflammation, the knowledge gained will
be valuable in the development of new potent analgesic and anti-inflammatory
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APPENDIX I
DETAILS AND SOURCES OF DRUGS USED
Drug vehicle for stock Source
solution
1) 5v-N-ethylcarboxamidoadenosine saline (0.9% w/v) Sigma
(NECA)
2) 8-phenyltheophylline (8-PT) 99.95% saline (0.9% Sigma
w/v); 0.05% 0.1M
NaOH
3) Adenosine saline (0.9% w/v) Sigma
4) Adrenaline saline (0.9% w/v) Sigma
5) a,P-methylene-ATP saline (0.9% w/v) Sigma
6) ATP saline (0.9% w/v) Sigma
7) Angiotensin II (human sequence) saline (0.9% w/v) NOVA biochem, UK
8) Atropine saline (0.9% w/v) Sigma
9) Bradykinin (BK), acetate salt saline (0.9% w/v) Sigma
10) Capsaicin (8-melhyl-N-vanillyl-6- 80% saline (0.9% Sigma
nonenamide) w/v); 10% ethanol;
10% Tween 80
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20) Freunds Complete Adjuvant
(FCA)
solution



























Drug vehicle for stock Source
solution
21) GR113808 saline (0.9% w/v) Glaxo, U.K.
22) GR82334 saline (0.9% w/v) Glaxo, U.K.
23) Hyp2-DPhe7-BK saline (0.9% w/v) NOVA biochem,
24) ICI 118551 (erthro-DL-1 (7- saline (0.9% w/v) Sigma
methyllindan-4-yloxy)-3-
isopropylamino-butan-2-ol)
25) Indomethacin NaHC03 (5% w/v) Sigma
26) Men 10207 saline (0.9% w/v) Glaxo, U.K.
27) mepyramine saline (0.9% w/v) Glaxo, U.K.
28) Metrifudil saline (0.9% w/v) Glaxo, U.K.
29) L-noradrenaline bitartrate saline (0.9% w/v) Sigma
30) N-adamanteacetyl-DArg-Hyp3- saline (0.9% w/v) Sigma
Thi5,8-DPhe7-BK
31) N6-cyclopentyladenosine (CPA) saline (0.9% w/v) Sigma
32) Ondansetron saline (0.9% w/v) Glaxo, U.K.
33) Prazosin ethanol Sigma
34) Propranolol saline (0.9% w/v) Sigma
35) Ranitidine saline (0.9% w/v) Glaxo, U.K.
36) Salbutamol saline (0.9% w/v) Sigma
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The chemicals for the physiological salt solution (Krebs) were of Analar grade and
obtained from BDH Ltd. Dilutions of stock solutions were made in saline (0.9% w/v).
The doses stated in the text are those of the salt where applicable.
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